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Whilst antidepressants are widely prescribed, there is a large degree of variation between patients in terms 
of treatment outcomes. Furthermore, the mechanisms by which these drugs exert their effects remain 
unclear. In this thesis, genetic biomarkers of antidepressant outcomes have been explored, in order to better 
understand the molecular mechanisms underpinning effective antidepressant treatment. The research 
presented here use data from the GENDEP project, which is a large pharmacogenetic study of depressed 
patients receiving antidepressant treatment.  
 
Firstly, the pharmacological underpinnings of antidepressant-associated side effects were used to categorise 
these side effects and conduct a candidate gene analysis. Whilst a significant association between variation 
within the HTR2C gene and serotonergic side effects was found, the observation was not replicated in a 
second sample. 
 
Secondly, the role of variability in drug metabolism rates in treatment outcomes was investigated. Examining 
genotypic information on the cytochrome P450 enzymes, no associations with treatment response, side 
effects or study discontinuation were observed. Furthermore, serum concentrations of antidepressant were 
unrelated to treatment response or overall burden of side effects, predicting only a minority of specific side 
effects.  
 
Thirdly, transcriptomic changes with drug administration were explored in relation to treatment efficacy. Two 
genes were identified where changes in expression levels were significantly associated with treatment 
response amongst patients taking nortriptyline. Furthermore, using a network-based approach, changes in 
gene expression across one module of coexpressed genes showed significant correlation with symptom 




Finally, genomic and transcriptomic data were combined, in an examination of the genetic control of gene 
expression. This analysis then was used to gain an insight into the molecular processes that link genotype to 
phenotype.  
 
The evidence presented within this thesis, when considered in combination with existing literature, highlights 
that antidepressant efficacy is a complex trait, influenced by many genes of small effect. Nevertheless, by 
layering together different levels of information, we can begin to dissect the molecular mechanisms involved 
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1.1 Major Depressive Disorder 
Major depressive disorder (MDD) is a common and disabling illness; the World Health Organisation has 
projected that by 2030, it will be the world’s number one cause of burden of disease, with the disability 
burden being 50% higher for females than males (World Health Organisation, 2008). Estimates from the 
USA suggest that the lifetime prevalence of the disease is 16.6%  (Kessler et al, 2005).  
 
MDD is characterised by persistent low mood and loss of interest in activities. In order for a patient to fulfil 
the DSM-IV diagnostic criteria for MDD (American Psychiatric Association, 2000)1, they should display five 
(or more) of the symptoms shown in Table 1-1 within the same two-week period, and at least one symptom 
should be either depressed mood or loss of interest or pleasure.  
 
DSM-IV criteria outline that symptoms should represent a change from previous functioning, and cause 
significant distress or impairment in social, occupational or other important areas of functioning. Additionally, 
symptoms should not be due to physiological effects of a substance, a general medical condition or be better 
accounted for by bereavement.  
Table 1-1 Diagnostic symptoms of MDD 
Diagnostic symptoms 
Depressed mood most of the day or nearly every day 
Markedly diminished interest or pleasure in all, or almost all, activities most of the day, nearly every day 
Significant weight loss when not dieting or weight gain, 
 or decrease or increase in appetite 
Insomnia or hypersomnia nearly every day 
Psychomotor agitation or retardation nearly every day 
Fatigue or loss of energy nearly every day 
Feelings of worthlessness or excessive or inappropriate guilt nearly every day 
Diminished ability to think or concentrate, or indecisiveness, nearly every day 
Recurrent thoughts of death, suicidal ideation without a specific plan, or a suicide 
attempt or a specific plan for committing suicide 
 
                                                     
1
 Whilst DSM-V was released in May 2013, the new criteria do not represent a major change from the existing criteria with regards to 
defining MDD, with the exception of the removal of the “bereavement exclusion”. As all studies referred to within this thesis have used 
DSM-IV criteria, reference is made to this edition of the manual. 
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Whilst MDD is a single diagnostic entity, patients can differ greatly in their symptomatology, as well as the 
course and treatment responsiveness of their illness (Rush, 2007). It may be that this symptomatic 
heterogeneity reflects aetiological and pathophysiological differences between patients.  
 
1.1.1 Aetiology 
Genetic factors are known to be important in MDD (Hodgson and McGuffin, 2013),as indicated by evidence 
from both family studies (Sullivan et al, 2000) and newer, molecular genetic methods (Lee et al, 2013; Lubke 
et al, 2012). Estimates generally indicate that genetics accounts for somewhere between 30 and 40% of the 
variability in liability to depression, although there is evidence that more severe forms have higher heritability 
(McGuffin et al, 2007). This genetic risk is thought to comprise of a large number of genetic variants each 
exerting a small effect, however no specific variants linked to the disorder have yet been identified (Ripke et 
al, 2013). A number of environmental risk factors have been linked to MDD; these include childhood 
maltreatment (Moskvina et al, 2007; Nanni et al, 2012), stressful life events (Kendler et al, 1999) and 
neonatal complications (Jablensky et al, 2005). Taking the environmental and genetic evidence together, it 
seems that there is not a single factor which drives the presence or absence of depression. Instead, the 
disease is best characterised as a complex disorder, where there are likely to be many genes of small effect 
which act to influence an individual’s liability to the illness, as well as a number of environmental factors.  
 
1.1.2 Pathophysiology 
In terms of the pathological processes underlying MDD, it has long been considered that dysfunctions in 
serotonergic signalling play an important role in the disorder (Sharp and Cowen, 2011). But a number of 
other abnormalities have also been linked to the disorder, including hyperactivity within the hypothalamic-
pituitary-adrenal (HPA) axis (Pariante and Lightman, 2008), alterations in neuroplasticity (Pittenger and 
Duman, 2008) and elevation of proinflammatory cytokines (Dowlati et al, 2010). It would seem that as with 
the disease symptomatology and aetiology, the pathophysiological processes underlying MDD are 




Despite the limitations in current understanding of the aetiology and pathophysiology underlying MDD, there 
are a number of treatment options available for depressed patients including pharmacotherapy, 
psychological treatments, and in more severe cases, electroconvulsive therapy. Antidepressant medications 
are generally used in moderate to severe cases of depression; there are a number of different drugs 
available with proven efficacy (Undurraga and Baldessarini, 2012) and these are widely prescribed. For 
example, in England alone, over 50 million prescriptions were written for antidepressants in 2012 (HSCIC, 
2013). 
 
The serendipitous discovery that iproniazid (a monoamine oxidase inhibitor, originally used as a tuberculosis 
treatment) and imipramine (a tricyclic compound) displayed antidepressant effects led to the development of 
the first antidepressant treatments during the 1950s. These compounds are thought to exert their effects via 
the monoaminergic systems, and despite much development and refinement, nearly all of the 
antidepressants that are currently in use continue to target monoaminergic systems.  
Table 1-2: Pharmacology of available antidepressant medications 
Drug type Mode of action Examples 
Tricyclic antidepressants 
Inhibition of both noradrenergic and 
serotonergic uptake (additional action 
at muscarinic, histaminergic and 
adrenergic postsynaptic receptors) 
Imipramine 
Nortriptyline 
Serotonin reuptake inhibitors Inhibition of serotonergic reuptake Escitalopram Fluoxetine 
Noradrenaline reuptake inhibitors Inhibition of noradrenergic reuptake Reboxetine 
Serotonin and noradrenaline 
reuptake inhibitors 
Non-tricyclic compounds which inhibit 





Various. All show some 
monoaminergic actions, but not known 








However, despite rapid effects on monoaminergic receptors, there is a significant delay before symptom 
improvement is observed (Uher et al, 2011). This is despite evidence of immediate effects of antidepressants 
on attention and memory, from both cognitive and imaging studies (Harmer and Cowen, 2013). The 
evidence indicates that processes occurring downstream from receptor inhibition may be required for clinical 
efficacy. These mechanisms are yet to be fully elucidated, although many of the systems in which 
dysfunction is observed in MDD patients appears to be “normalised” with successful antidepressant 
treatment. For example, it has been noted that whilst patients with MDD are often observed to have low 
levels of the neurotrophic factor BDNF, antidepressants are observed to increase BDNF levels in MDD 
patients (Castrén et al, 2007). Similarly, abnormalities in the stress-response HPA axis that are seen in MDD 
are attenuated with antidepressant treatment (Horstmann et al, 2009b) and the excess of proinflammatory 
cytokines often observed in MDD patients are reduced with treatment (Kim et al, 2007). Many of these 
different pathways are being explored for their potential to yield novel-acting antidepressant medications 
(Berton and Nestler, 2006), but as yet, no single pathway appears to be both necessary and sufficient for 
therapeutic efficacy.  
 
1.2.1 Efficacy 
Indeed, determining the efficacy of these medications in patients has proved a contentious issue. Reports of 
significant publication bias and small effect sizes relative to placebo amongst patients with milder depression 
(Khan et al, 2002; Kirsch et al, 2008) have further complicated the picture (although see Horder et al, 2011 
for debate surrounding these findings).  
 
Large meta-analyses have attempted to assess the average efficacy of a number of different treatments 
(Cipriani et al, 2009; Gartlehner et al, 2011); Gartlehner et al. concluded that there is limited evidence of 
clinically significant differences between medications in terms of response outcomes when looking across a 
population. Nevertheless, measures of efficacy across a population of depressed patients failed to capture 




This variability was demonstrated within the Sequenced Treatment Alternatives to Relieve Depression 
(STAR*D) study. STAR*D is the largest study of treatment efficacy for MDD to date, including data from over 
4,000 patients in the USA. The first line of treatment for patients enrolled in this study was the SSRI 
citalopram, received for up to 14 weeks; around 30% of patients achieved remission whilst just under 50% of 
patients showed response to treatment.  
 
Similar findings were also observed in the Genome Based Therapeutic Drugs for Depression study 
(GENDEP), on which this thesis focuses. GENDEP is a large European pharmacogenetic study, exploring 
outcomes in patients treated with either the SSRI escitalopram or the tricyclic antidepressant nortriptyline, 
and for both of these drugs, response and remission rates broadly matched those reported in STAR*D (Uher 
et al, 2009c) 
 
These large studies highlight that antidepressants do work, but only for some. For those that do not respond 
to the first treatment selected, clinicians must use a trial and error method by which to explore whether other 
options might be efficacious. With the delay often observed in the onset of treatment response (Uher et al, 
2011), this can take some time. Inadequate antidepressant treatment results in increased levels of relapse 
(Kennedy et al, 2002) as well as increased health costs (Masand, 2003). Therefore, the development of a 
rational approach to tailor treatment options to each patient using response-predictive biomarkers would be 
of significant clinical value. Furthermore, if the biological processes that underlie treatment response can be 
identified, then it may be possible to use these to guide the development of novel antidepressant 
medications with improved efficacy. 
 
1.2.2 Tolerability 
Antidepressant medications are associated with a number of common side effects, including dry mouth, 
sexual dysfunction and gastrointestinal symptoms. Given that poor treatment adherence and discontinuation 
is strongly associated with the experience of side effects (Bull et al, 2002; Mitchell, 2006), the tolerability of 
antidepressant medications is also an important treatment outcome for clinicians to consider. SSRIs are 
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generally safer in overdose than tricyclic medications (Whyte et al, 2003), but side effects are still prevalent 
with these drugs. Gartlehner et al (2011) estimated that in the trials of efficacy amongst second generation 
antidepressants included in their meta-analysis, 63% of patients experienced at least one antidepressant 
related side effect. However the side effect profiles do appear to vary between drugs; for example 
mirtazapine is associated with greater weight gain and paroxetine is associated with more reports of sexual 
dysfunction that other antidepressants. Similarly, SSRIs are associated with a greater prevalence of 
diarrhoea and insomnia, whilst tricyclic antidepressants confer a higher risk for dry mouth and constipation 
(Uher et al, 2009a). The observed differences in side effect profiles have generally been observed to vary 
between drugs in relation to the known receptor actions of the drugs (Stahl, 1998).  
 
Therefore, in addition to the value of identifying treatment response predictors, biomarkers of medication 
tolerability are also clinically useful. Not only would they indicate which patients may require closer 
monitoring, but given the differences between drugs in terms of their side effect profiles, if markers of specific 
ADRs could be identified, then this could be used as an aid to treatment selection.  
 
1.3 Genetics and antidepressant treatment 
1.3.1 Pharmacogenetics of treatment response 
One approach to identify biomarkers that predict treatment outcomes is to consider the role of genetic factors 
(Hodgson et al, 2012). Clinical observation suggests that response to treatment is a familial trait. Although 
previously research was constrained by the logistic difficulties in collecting appropriate samples of family 
members taking the same medications, the sparse familial evidence supported the idea that response to 
antidepressants was  partially genetic in nature (Franchini et al, 1998; O'Reilly et al, 1994).   
 
But technological advancements mean that it is now possible to use microarray technology to assay genetic 
variation at upwards of half a million common single nucleotide polymorphisms (SNPs), with relative ease. 
Using this genomic data, it is possible to directly estimate the proportion of variability observed in a 
phenotype that is explained by the genetic variability captured by all of the SNPs included on a genomic 
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microarray (Yang et al, 2010). This genome wide complex trait analysis (GCTA) can be done using unrelated 
individuals, circumventing the requirement to collect twin or family samples in order to estimate the 
heritability of a trait. Using these methods in antidepressant treatment response, it has been estimated that 
in a large sample, including subjects from STAR*D and GENDEP, common genetic variants account for 42% 
of the variation seen between patients in terms of treatment response (Tansey et al, 2013). However, GCTA 
in general may estimate total heritability, and so the overall role of genes in antidepressant response may be 
even higher.   
 
This genomic data has also been used in genome-wide association studies to try and identify which genetic 
variants are involved in treatment response. These studies have been able to rule out the presence of single 
common SNP variants with clinically significant effects of the response outcome (Uher et al, 2012), but no 
replicated association with response has yet been identified. In the largest mega-analysis of antidepressant 
response to date (n=2,256), no variants reaching genome-wide significance were identified (GENDEP 
Investigators; MARS Investigators; STAR*D Investigators, 2013), reflecting the limitations in statistical power 
when conducting analyses to identify small genetic effects on a genome-wide scale (incurring a large 
multiple hypothesis testing burden) (Pe'er et al, 2008). The evidence suggests that whilst response may be 
under genetic control, it is a complex trait, involving many genes, each with small effects, as well as 
environmental factors (Tansey et al, 2013; Tansey et al, 2012). The collection of larger sample sizes is 
needed to gain sufficient power to reach the threshold for genome-wide significance, but pharmacogenetic 
cohorts are very expensive to collect (given the need for clinical monitoring across the course of treatment). 
 
Aiming to avoid this multiple hypothesis testing burden, candidate gene studies preselect appropriate genes 
of interest. These candidates may be either pharmacokinetic (considering “what the body does to the drug”) 
or pharmacodynamic (addressing “what the drug does to the body”). Although hypothesis-driven methods 
cannot reveal novel treatment pathways, the approach is better powered to detect genes with smaller effect 
sizes. However, candidate gene studies have been criticised for poor replicability (Hirschhorn et al, 2002; 
Ioannidis et al, 2001). Furthermore, many candidate gene findings suffer from overestimation of effect sizes 
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in initial studies (known as “winners curse”) (Xiao and Boehnke, 2009). These factors are more likely when 
sample and effect sizes are small (Ioannidis, 2005), which is frequently the case in candidate gene literature. 
 
Therefore, when interpreting results, key considerations are replication and sample size. There is some 
evidence from candidate gene work that genes such as the monoaminergic SLC6A4 and HTR2A may 
predict treatment response, as might the stress-response linked FKBP5 (Hodgson et al, 2012; Horstmann 
and Binder, 2009a; Kato and Serretti, 2010). However, it should be noted that in genome-wide analyses, 
these candidates did not show association with treatment outcomes at levels above what would be expected 
by chance (Garriock et al, 2010; Uher et al, 2010). 
 
1.3.2 Pharmacogenetics of antidepressant side effects 
Genetic predictors of antidepressant side effects have also been explored, although fewer genome-wide 
studies have been published to date. The largest study comes from STAR*D, where 1,762 patients taking 
citalopram were considered. The researchers considered a total of five different outcomes; general side 
effect burden, overall tolerability of treatment, sexual side effects, dizziness and hearing/vision side effects 
(Adkins et al, 2012). In their analysis they found two SNPs reaching significance (defined as an FDR<0.1); 
hearing/vision side effects were associated with a SNP within EMID2, whilst general side effect burden was 
linked to a gene desert region on chromosome 13. However, these results should be interpreted cautiously, 
given the number of different outcomes that were considered. Also from the STAR*D sample, but focussing 
on patients taking drugs other than citalopram, Clark et al (2012) performed a genome-wide analysis of four 
different measures of antidepressant side effects; general side effect burden, sexual side effects, dizziness 
and vision/hearing side effects. They did not replicate the findings in the larger citalopram-only sample, 
instead highlighting one association of interest in the subsample of patients taking buproprion (n=128), 
where SNPs within the SACM1L gene were associated with sexual side effects with an FDR<0.05. The final 
genome-wide study of antidepressant side effects was performed in the GenPod (GENetic and clinical 
Predictors Of treatment response in Depression) sample of patients taking reboxetine or citalopram, and 
focussed on sexual dysfunction amongst males (Crawford et al, in prep). However, no associations reached 




As in the treatment response literature, these studies of antidepressant side effects require further replication 
and are limited by constraints of sample size. However, an additional barrier to identifying genetic 
associations with antidepressant side effects is the number of different side effect outcomes that can be 
considered.  
 
This can also be seen when considering the candidate gene research into genetic predictors of side effects 
(for review, see Kato et al, 2010). A wide range of different outcomes are defined, with some reports 
considering overall side effect burden (Hu et al, 2007; Murphy et al, 2004), whilst others focus on specific 
adverse drug reactions (ADRs) such as sexual dysfunction (Perlis et al, 2009; Strohmaier et al, 2011) or 
nausea (Sugai et al, 2006; Tanaka et al, 2008). But a diffuse literature with frequently small sample sizes 
and poor coverage of so many different outcomes means that no variants have been robustly associated 
with adverse reactions.  
 
The outcome that has been most frequently reported on is that of overall side effect burden. Prediction of this 
may be clinically useful, identifying patients who require closer monitoring and careful dosing. However, this 
approach cannot be used to direct decisions as to which antidepressant might be most appropriate for a 
patient. Given the different side effect profiles of different antidepressants, information of risk for specific 
ADRs may be more helpful in this respect.  
 
There are a large number of different side effects to consider, but these ADRs often share a common 
pharmacological basis. For example, dry mouth, blurred vision, constipation and problems with urination are 
all classic anticholinergic side effects, found with many drugs that have an antagonistic action at muscarinic 
acetyl choline receptors. Whilst tricyclic antidepressants show anticholinergic action, SSRIs do not. Thus 
identifiers of risk for specific ADRs which can be tied to the pharmacological actions of specific medications 




1.3.3 Chapter 3 aims; identification of genetic predictors of antidepressant side effects 
Given the large number of different side effects reported with antidepressant treatment, in Chapter 3 of this 
thesis the shared pharmacological basis of ADRs will be used to rationally reduce the number of different 
side effect outcomes. Then a candidate gene analysis will be performed to identify predictors of 
antidepressant side effects in a manner that aims to be useful in guiding treatment recommendations. 
 
1.4 Cytochrome P450 enzymes and antidepressant treatment 
As noted above, one of the constraints when using genome-wide approaches is the limitation in statistical 
power, due to a large multiple hypothesis testing burden. In addition, these approaches consider only 
individual SNP effects in an independent fashion. This means that other forms of genetic variation such as 
gene duplications will not be captured. Furthermore, variants with common effects (for example three 
different SNPs all resulting in a non-functional protein) will be tested separately. This is of particular 
importance when considering the genetic variation seen in the cytochrome P450 enzymes.  
 
1.4.1 Genetic variation in cytochrome P450 enzymes 
The cytochrome P450 (CYP450) enzymes are members of an isoenzyme superfamily that catalyse the 
oxidation of a large number of different chemicals, including the majority of prescribed drugs. Therefore, they 
are central in the pharmacokinetics of many medications. Many of the CYP450 enzymes are highly 
polymorphic, for example, over 100 allelic variants have been described for CYP2D6, and more than 30 
allelic variants have been identified within CYP2C19. Variants including splicing defects, missense 
mutations, frameshifts and duplications have been observed, with functional effects on levels of enzyme 
activity. Duplications and variants increasing expression levels have been linked to increased enzymatic 
activity whilst other variants decrease function, or in the case of a null allele lead to the enzyme not being 
encoded. The different variants that have been described are catalogued by the Human CYP450 Allele 




Given the number of different polymorphisms observed, scoring systems have been devised to translate 
these variants into categories with common functional effects. Whilst the definitions vary, in general, 
individuals who carry two null alleles are designated as poor metabolisers. Intermediate metabolisers are 
those who carry one null allele with one functional allele, or who carry alleles with reduced function. 
Extensive metabolisers have two functional alleles; individuals in this category are considered to have 
normal enzyme activity. Finally, individuals who carry gene duplications are designated as ultra-
metabolisers, with higher rates of drug metabolism.  
 
Whilst GWAS microarray chips only directly capture a small number of the SNPs observed in the CYP450 
enzymes, microarrays have been developed which specifically test the known functional variants (including 
gene duplications) that are reported in these genes (for example the Affymetrix Drug Metabolising Enzymes 
and Transporters Panel, and the Roche AmpliChip CYP450 Test). Algorithms to derive appropriate 
functional groupings to this genetic data are then applied.  
 
In 2004, FDA approval was granted for the Roche Amplichip CYP450 test for use by physicians (de Leon et 
al, 2006). This has sparked a growing interest in the potential role CYP450 genes might play in informing 
clinical practice for a number of different conditions. Indeed, the majority of health insurers in the USA 
currently cover provision of the test. However, as Matchar and Thankur highlight, FDA approval is linked to 
the accuracy of the technology in providing genotypic information, not the demonstration of its impact on 
clinical outcomes (Matchar and Thakur, 2007a). Nevertheless, CYP450 enzymes are of interest when 
considering outcomes with antidepressant treatment, given their role in the metabolism of these drugs. The 
particular CYP450 enzymes and metabolic pathways involved vary between the drugs, and thus must be 
considered in a drug-specific manner.  
 
1.4.2 Metabolism of escitalopram 
Escitalopram is rapidly absorbed following oral administration, with maximum plasma concentration typically 
reached after 4 hours. The drug is predominantly metabolised in the liver, with an elimination half-life of 27-
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32 hours (Gutierrez and Mengel, 2002). The drug is demethylated to its primary metabolite des-
methylcitalopram. CYP2C19 is the key enzyme involved in this demethylation pathway, but CYP3A4 and 
CYP2D6 also play a role. Escitalopram is a weak inhibitor of CYP450 enzymes, so conferring minimal risk of 
drug interactions (Gutierrez et al; von Moltke et al, 2001). Des-methylcitalopram is present in much lower 
concentrations, and displays only weak inhibition of the serotonergic transporter in comparison to the parent 
drug (von Moltke et al, 2001).   
 
In terms of genetic variability impacting on the function of the CYP450 enzymes involved in the metabolism 
of escitalopram, functional effects of common polymorphisms have been observed for both CYP2C19 and 
CYP2D6 (de Morais et al, 1994; Eichelbaum et al, 1979; Ferguson et al, 1998). However, genetic variation in 
the CYP3A4 gene has been reported to be rare, with little impact on enzymatic activity (Lamba et al, 2002).  
 
1.4.3 Metabolism of nortriptyline 
For nortriptyline, peak plasma concentrations occur around 7-8.5 hours after oral administration. It is also 
metabolised in the liver, and has an elimination half-life of around 32 hours. CYP2D6 is the key enzyme 
involved in the metabolism of nortriptyline; it is responsible for around 90% of metabolism (Olesen and 
Linnet, 1997a). The primary metabolic pathway is via the CYP2D6 mediated hydroxylation to E-10-
hydroxynortriptyline. However, a secondary, minor pathway involves the demethylation of the drug to form 
des-methylnortriptyline. CYP2D6 is also the most important enzyme in this secondary pathway. Nortriptyline 
shows weak inhibition of CYP2D6 and CYP2C19, which has been shown to be clinically insignificant when 
considering drug interactions (Gillman, 2007). The metabolites of nortriptyline show only weak noradrenergic 
action (Nordin and Bertilsson, 1995). 
 
1.4.4 CYP450 genotypes and serum concentration of drug 
Linking together what is known about the functional impact of polymorphisms within CYP2D6 and CYP2C19 
with their importance in the metabolism of antidepressants, it has been shown that the differences observed 
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between patients in serum concentration of antidepressant (Hammer and Sjoqvist, 1967; Reis et al, 2007) 
are partially determined by genetic variability in the CYP450 enzymes (Kirchheiner et al, 2004).  
 
In a large systematic analysis of the relationship between CYP450 genotype and serum concentration of 
psychiatric medications, dose adjustments which would compensate for the observed differences in drug 
metabolism were proposed. For patients taking nortriptyline with PM status for the CYP2D6 gene, a dose 
reduction of 53% of the average dose was suggested. When considering citalopram (data on escitalopram 
was not available), a dose adjustment of 61% was calculated for individuals with poor metaboliser status for 
CYP2C19. Since this report, additional studies addressing the relationship between CYP450 genotype and 
serum levels of antidepressant have been published looking at escitalopram (including one study looking 
within a subset of the GENDEP sample); these observe a similar relationship between CYP2C19 genotype 
and serum concentrations of escitalopram (Huezo-Diaz et al, 2012; Rudberg et al, 2006; Rudberg et al, 
2008).  
 
1.4.5 CYP450 genotypes and treatment outcomes 
Given the observed variability in antidepressant metabolism via the CYP450 enzymes, there has been much 
hope regarding the potential to use genetic variability in these enzymes to predict outcomes and guide 
treatment recommendations (Ingelman-Sundberg, 2004; Kirchheiner and Rodriguez-Antona, 2009). This is 
predicated on the assumption that if individuals who metabolise the drugs very rapidly have lower 
concentrations of drug, this may lead to insufficient levels of antidepressant at the site of drug action, 
causing treatment non-response. Conversely, if individuals with low rates of drug metabolism have high 
levels of antidepressant at the site of drug action, this will cause higher risk of adverse drug reactions.   
 
1.4.5.1 CYP450 genotypes and treatment outcomes for SSRIs 
However, in an Evidence Report from the Evaluation of Genomic Applications in Practice and Prevention 
(EGAPP) Working Group (EGAPP Working Group, 2007; Matchar et al, 2007b),  the researchers concluded 
that the limited existing data exploring the link between SSRIs and either treatment response or treatment 
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tolerability was limited by small sample sizes and heterogeneous study design. They concluded there was no 
evidence of an association between CYP450 genotype and treatment outcomes for these antidepressants.  
 
Several larger studies have been published since the EGAPP Working group evaluation, but these generally 
support the conclusions that CYP450 genotype is not linked to treatment outcomes. The largest of these 
studies is STAR*D; in a two-stage analysis of 1,953 patients taking citalopram, Peters et al found no 
association between any of the pharmacokinetic genes they considered (CYP2D6, ABCB1, CYP2C19, 
CYP3A4, and CYP3A5) and either treatment response or tolerability (Peters et al, 2008). Given the ethnic 
variation in the STAR*D sample, this analysis was conducted separately in Caucasians and African 
American sub-groups.  Whilst a second paper has been published on the same sample, concluding that 
CYP2C19 genotype was associated with both remission and tolerability when the Caucasian analysis was 
limited to non-Hispanics (Mrazek et al, 2011), the associations fail to reach significance when correcting for 
the number of hypotheses tested.  
 
Supporting the conclusions of Peters et al, no association between CYP450 genotype and response was 
observed in a sample of 278 patients taking a range of different antidepressants (Serretti et al, 2009), nor 
between CYP450 genotype and either response or side effects in a sample of 106 patients taking either 
escitalopram or venlafaxine (Ng et al, 2013). In contrast, Tsai et al did observe a link between CYP2D6 and 
treatment response in 100 patients taking escitalopram. However, in this case, genotype was not linked to 
serum levels of drug, and CYP2D6 only plays a minor role in the metabolism of escitalopram. When the 
primary enzyme of CYP2C19 was considered, associations were seen with serum concentrations of drug but 
not response.  
 
Therefore, whilst there are some discrepancies between findings, more recent findings appear to support the 
conclusions of the EGAPP, and there is an absence of strong evidence linking CYP450 genotype to 




1.4.5.2 CYP450 genotypes and treatment outcomes for tricyclic antidepressants 
In contrast, a recent review from the Clinical Pharmacogenetics Implementation Consortium, looking at 
tricyclic antidepressants, gives strong recommendations to avoid prescribing either amitriptyline or 
nortriptyline to individuals identified as CYP2D6 ultra metabolisers or poor metabolisers. Amitriptyline is 
metabolised to nortriptyline via CYP2C19 (Olesen and Linnet, 1997b). The authors of the report suggested 
ultra-metabolisers are at risk of lack of efficacy, whilst poor metabolisers are likely to suffer side effects. 
However, when reviewing the evidence that is presented as part of their systematic literature review, the 
guidelines reference only three studies which observe an association between drug metabolising variables 
and side effects to antidepressant treatment, with no association made to treatment response. 
 
In the first study, a small sample of 18 patients taking a range of different antidepressants, side effects were 
noted to be more common amongst patients with alleles conferring low CYP2D6 activity (Chen et al, 1996). 
More convincingly, in a sample of 50 patients taking a fixed dose of amitriptyline, nortriptyline plasma 
concentrations and CYP2D6 genotype were found to be associated with side effects, but not treatment 
response (Steimer et al, 2005). Similarly in the Rotterdam study (Bijl et al, 2008) (with a large total sample 
size of 1,198) there was increased risk of antidepressant switching amongst patients taking tricyclic 
antidepressants with poor metaboliser genotypes. However, no association was seen with treatment 
discontinuation in this sample. The authors also found that amongst patients taking SSRIs, no association 
was observed between CYP2D6 genotype and any of the clinical outcomes considered.  
 
Thus, there is some evidence indicating CYP450 genotype might be linked to the tolerability of tricyclic 




1.4.6 Serum concentrations of antidepressant and treatment outcomes 
Whilst the existing literature suggests CYP450 genotypes do play an important role in antidepressant 
metabolism rates, the difficulty in linking this to treatment outcomes may reflect that drug metabolism is also 
influenced by other, environmental factors. These include diet, comedications and comorbidities (Reis 2009). 
By directly measuring serum concentrations of drug, the influence of both genetics and the environment can 
be considered together. 
 
But the evidence linking serum concentrations to outcomes with antidepressant treatment is also mixed. A 
seminal study in 1971 reported a curvilinear relationship between serum concentrations and treatment 
response amongst patients taking nortriptyline (Asberg et al, 1971), and this relationship was also observed 
more recently (Perry et al, 1994), with therapeutic concentrations estimated to be between 50-150 ng/ml. 
Nevertheless, determining therapeutic ranges for antidepressants can be imprecise due to confounds of 
spontaneous remission, placebo response and the heterogeneity of the disorder (Preskorn and Fast, 1991), 
and other samples have reported no evidence linking serum levels of nortriptyline to response (Steimer et al, 
2005). For SSRIs, therapeutic ranges are less clearly defined (Baumann, 1996) and whilst one study 
suggested that for patients taking citalopram, serum concentrations below 50ng/mL were associated with 
reduced response (Ostad Haji et al, 2011), several other papers indicate there is no link between serum 
levels of antidepressant and response (Dufour et al, 1987; Nikisch et al, 2004; Rasmussen and Brosen, 
2000).  
 
1.4.7 Chapter 4 and 5 aims; the role of drug metabolism variables in treatment outcomes 
Given the interest surrounding the potential role of cytochrome P450 enzymes in determining outcomes with 
antidepressant treatment, but the absence of robust evidence, in Chapters 4 and 5, I aim to assess their 
impact in the GENDEP sample. Using both genotypic, serum concentration and treatment outcome data, the 
interrelationship between genetic variability, drug metabolism rates and antidepressant response, side 




1.5 Gene expression changes and mechanisms of antidepressant action 
As detailed above, the mechanisms by which antidepressants exert their therapeutic effects remain unclear. 
As researchers have looked at the biological processes affected beyond the immediate effects of the drugs 
on neurotransmitter levels and receptors, there has been an increasing focus on gene expression as a 
possible process which may underpin the long term adaptations in neuronal function that appear necessary 
for effective treatment (Duman et al, 1997; Lesch and Schmitt, 2002).  
 
In light of the high inter-individual variability seen in antidepressant treatment response, it is important not to 
simply identify changes that occur as a result of the administration of a drug. To uncover the mechanisms by 
which antidepressants exert their effects, those changes that are specifically associated with response are of 
interest.  
 
1.5.1 Tissue-specificity of gene expression 
The primary tissue of interest when considering antidepressant action is the brain. However, brain samples 
from patients are evidently only obtainable from post-mortem tissue; this means gene expression can only 
be studied at a single time point. Therefore, in order to consider the change in gene expression across time, 
and its association with response, blood samples have been used instead. Blood has been shown to be a 
useful surrogate for investigating gene expression; for example one study reports that blood shares more 
than 80% of the transcriptome with nine tissues including brain (Liew et al, 2006). Furthermore, comparisons 
between prefrontal cortex and blood indicate that those processes identified as potentially important in both 
the pathophysiology of MDD and the mechanisms of antidepressant action (such as neurotransmitter, stress 
mediator and cytokine pathways) are also overlapping between the two tissues (Sullivan et al, 2006).  
 
1.5.2 Changes in expression levels of candidate genes 
When exploring gene expression changes associated with antidepressant response, the majority of studies 
to date have used candidate gene approaches. A number of different associations with response outcomes 
have been reported. Monoaminergic systems have been implicated in a study of 11 MDD patients, where 
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changes in expression levels of SLC6A4 (the gene for the serotonin transporter) were correlated with 
response to a range of different forms of treatment (Belzeaux et al, 2010). Reports highlighting neurotrophic 
gene expression changes include an observed correlation between VEGF (the gene encoding vascular 
endothelial growth factor) and symptom improvement in a sample of 24 patients (Iga et al, 2007a), as well as 
differential expression between responders and non-responders for the genes BDNF and VGF in a subset of 
74 patients from the GENDEP sample (Cattaneo et al, 2013). This study also implicated both the HPA-axis 
linked FBKP5 and the inflammatory gene IL-6 as treatment-correlated genes. In a second study exploring an 
independent set of 46 patients from GENDEP, a second association between response and the 
inflammation-linked gene ABCF1 (ATP-Binding Cassette, Sub-Family F, member 1) was observed (Powell et 
al, 2013).  
 
Whilst these findings are consistent with our growing knowledge regarding the role of monoaminergic, 
neurotrophic, stress response and inflammatory pathways in antidepressant action, it should be noted that 
many of these studies are small in size, and are currently without replication. Exacerbating this issue, several 
of the studies above have selected different subsets of genes within the same putative pathways of interest. 
 
1.5.3 Transcriptomic methodologies 
Tackling this issue, it is now possible to move beyond candidate gene expression studies to transcriptomic 
approaches. These have the advantage of offering systematic assessment of all genes, and as they are 
hypothesis-free, can also highlight novel associations. However, the advantages of this comprehensive 
approach must be balanced against the large multiple hypothesis testing burden, reducing the power to 
detect effects amongst small samples.  
 
Two small studies (n<10) have been published comparing expression levels before and after treatment on a 
transcriptome-wide scale, but without reference to treatment efficacy. Whilst in one report, no significant 
transcriptomic expression changes are associated with antidepressant treatment (Belzeaux et al, 2012), in 
the second study changes within genes related to ionic homeostasis and neuronal plasticity were highlighted 
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(Kálmán et al, 2005). However, as no multiple hypothesis testing correction was applied, these associations 
are likely to be false positives.  
 
The largest study to date exploring transcriptomic changes with antidepressant treatment used data 
collected from 63 MDD patients (Mamdani et al, 2011). These patients were all treated with citalopram, and 
the authors observed that the gene IRF7 showed change in expression levels that was differentially linked to 
treatment response. Furthermore, additional analysis in post-mortem brain tissue also indicated that in 
prefrontal regions expression of this gene was decreased in MDD.  
 
1.5.3.1 Networks of gene coexpression 
The transcriptomic studies detailed above consider each gene and its association with treatment response 
independently. However, the regulation of gene expression acts via co-ordinated networks; structured 
correlation patterns between genes are observed (Lee et al, 2004; Oldham et al, 2008). In order to capture 
the interconnected nature of gene expression, network based approaches to transcriptomic data have been 
developed (Langfelder and Horvath, 2008). Modules of genes which share coexpression patterns are 
identified, and these co-regulated modules are likely to be functionally related. By considering the 
transcriptomic data using this systems-based level of analysis, the interconnected nature of gene expression 
is captured and any trait-associated signals are aggregated over a functionally-related set of genes. 
Furthermore, these network-based approaches have the added benefit of reducing the multiple hypothesis 
testing burden and so increasing statistical power to detect effects. The methodology has been successfully 
applied to a number of phenotypes including schizophrenia (de Jong et al, 2012), cancer (Horvath et al, 
2006) and Alzheimer’s disease (Miller et al, 2008), but has not yet been explored in relation to 
antidepressant treatment response. 
 
1.5.4 Chapter 6 aims; identification of gene expression correlates of treatment response 
In light of the limited literature on transcriptomic correlates of treatment response, in Chapter 6 of this thesis, 
I aim to explore gene expression correlates of antidepressant response on a transcriptomic scale, within a 
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subset of the GENDEP sample. This will not only be the largest sample studied using transcriptomic data to 
date, but also the first example in which network based methodologies have been explored.  
 
1.6 Genetic control of gene expression to understand predictors of 
response 
1.6.1 Discovery of genetic associations and linking these to phenotypes 
Attempts to disentangle the genetics of antidepressant response have been discussed above, and since the 
publication of the human genome sequence in 2001, there has been an ever growing number of genetic 
variants which have been linked to individual differences in a huge variety of different phenotypes (see 
NHGRI GWAS catalogue; http://www.genome.gov/gwastudies/).  However, as the number of phenotype-
associated variants grows, there is an increasing need to understand how these variants are linked to the 
phenotype of interest. Whilst initial expectations were that variants would be within gene-coding regions and 
take the form of non-synonymous or missense mutations, 90% of trait-associated variants are outside of 
protein coding regions of the genome (Hindorff et al, 2009). Therefore the manner in which they exert their 
effects is unclear and increasingly, researchers are looking at subtler mechanisms by which genotype might 
impact on biology.  
 
1.6.2 Expression quantitative trait loci 
Jansen and Nap published an article in 2001 which discussed the potential power of combining genetic and 
transcriptomic data (within a field they termed “genetical genomics”) in order to trace the impact of genetic 
variants on biological pathways (Jansen and Nap, 2001). Since then, a growing number of studies have 
systematically explored the genetics of gene expression. As gene expression levels are measured as a 
quantitative trait, the genetic loci which influence expression levels are referred to as expression quantitative 
trait loci, or eQTLs. Similar approached have also been developed to consider genetic drivers of methylation 
(Gibbs et al, 2010), protein (Lourdusamy et al, 2012) and metabolite levels (Nicholson et al, 2011), each 




Using transcriptome-wide approaches it has been shown that genetic influences on expression levels are 
wide-spread throughout the transcriptome (Lappalainen et al, 2013). These genetic influences are generally 
classified into two groups; those which are cis-acting, where the variant is local to the affected gene, and 
those which are trans-acting, where the variant is distant to the affected gene (potentially located on a 
different chromosome). By building a resource of well characterised eQTL loci, it is possible to gain a handle 
on the impact of genetic variation on expression levels, the relative importance of cis-eQTLs compared with 
trans-eQTLs, and to begin to understand how trait-associated genetic variants may exert their effects.  
 
Studies have more frequently focussed on cis-eQTLs, and these are generally observed to be located near 
to the transcription start site of a gene, or within exonic regions of the gene (Dimas et al, 2009; Stranger et 
al, 2007; Veyrieras et al, 2008). Furthermore, cis-eQTL signals are often observed to be overlapping with 
activating cis-regulatory elements including transcription factor binding sites (Gaffney et al, 2012) and 
DNase-1 hypersensitive sites (Degner et al, 2012) 
 
The effect sizes of trans-eQTLs are generally smaller than those observed for cis-eQTLs (Grundberg et al, 
2012). Nevertheless, trans effects are significant, and thought to be more numerous than cis effects (Schadt 
et al, 2003), with a number of posible “master regulators” identified, where genetic variation controls 
expression levels of many genes (Morley et al, 2004). Trans-eQTLs are of particular interest as they reveal 
information about the connection between physically distant genetic and transcriptomic variants based on 
biological consequences. Nevertheless, eQTL analysis is still a rapidly developing field; as more data is 
collected, understanding of cis and trans effects on gene expression will grow.  
 
1.6.3 eQTLs as a bioinformatic tool 
1.6.3.1 Using eQTLs to interpret genetic and transcriptomic associations 
Once eQTL loci have been identified, they can be utilised as an important bioinformatic annotation. There 
are a growing number of examples where eQTL annotations have been used to aid the interpretation of 
genetic signals by identifying common downstream effects on gene expression (Fehrmann et al, 2011; 
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Mäkinen et al, 2014), or understand transcriptomic associations, where disturbances in expression levels of 
a number of genes are shown to be driven by genetic variation at a single trans-acting SNP (Small et al, 
2011; Westra et al, 2013).  
 
1.6.3.2 Using eQTLs to identify genetic associations 
In addition to their value in interpretation, eQTL annotations may also aid the identification of trait-associated 
genes. Underscoring the importance of the regulation of gene expression, it has been noted that there is an 
enrichment of eQTLs amongst trait-associated GWAS signals (Nicolae et al, 2010). This enrichment can be 
exploited using a Bayesian approach to up-weight known eQTLs (and so prioritise these variants) prior to a 
genome-wide analysis, and so increase the ability to detect true signals within the data (Knight et al, 2011).   
 
In areas such as antidepressant treatment response, where genome-wide associations are yet to be found, 
and the collection of samples is very expensive, this overrepresentation of eQTLs amongst trait-associated 
SNPs may be useful, providing a method by which to recover genomic signal within the noise of GWAS data.  
 
1.6.4 Context specificity of eQTLs 
While many eQTL analyses are performed in blood samples taken from control subjects, due to ease of 
access, one caveat to consider when using eQTL annotations is that the regulation of expression levels by 
genotype may vary depending upon context.  
 
For example, as gene expression profiles are known to vary between tissues, so do patterns of eQTLs. To 
explore the tissue-specificity of eQTLs, both the MuTHER project (Multiple Tissue Human Expression 
Resource; http://www.muther.ac.uk/) and the Genotype-Tissue Expression project (GTEx; 
http://www.gtexportal.org/) have been set up to characterise eQTLs in a range of tissues. Currently available 
estimates of the degree of eQTL overlap between tissues vary according to both the analysis approach used 
and the tissues that are compared. For example, a pilot study from the MuTHER study estimated that 30% of 
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cis-eQTLs were shared between the tissues studied (Nica et al, 2011), but when the sample was expanded, 
60% of identified cis-eQTLs were found to have significant effects in multiple tissues (Grundberg et al, 2012).  
 
The issue of tissue-specificity indicates that ideally, when probing gene-trait relationships, analyses should 
focus on eQTLs that have been identified in the primary tissue of interest for that trait. For example, adipose 
tissue samples were used in the identification of a trans-regulator of gene expression linked to diabetes 
(Small et al, 2011). However, eQTLs identified in blood have been informative as to the downstream effects 
of trait-associated SNPs in non-blood related traits such as breast cancer and ulcerative colitis (Fehrmann et 
al, 2011). Furthermore, in the case of antidepressant treatment response, whilst the brain may be the 
primary tissue of interest, differences in eQTLs have been observed between brain regions (Hernandez et al, 
2012; McKenzie et al, 2014), and the region that would be relevant for treatment response is unclear.  
 
Phenotypic specificity 
There is evidence that genetic control of gene expression varies not only with tissue type, but also with other 
factors. For example sex and age-specific eQTLs have been noted (Dimas et al, 2012; Glass et al, 2013; 
Yao et al, 2014). Context-specific eQTLs have been robustly indicated using an in vitro paradigm of immune-
stimulating cells using interferon-γ or lipopolysaccharide (Fairfax et al, 2014). Over 50% of the cis-eQTLs 
identified were only observed in specific states of immune activation, and a number of context-specific trans-
eQTL hotspots were also noted. Interestingly, these hotspots were within immune-related regions of the 
genome. Thus, the presence of eQTLs within immune-associated pathways is dependent on the immune 
context of the tissue.  
 
The characterisation of context-specific eQTLs is still in its infancy, and further work is needed to establish its 
importance. However, given that gene expression differences have been shown to predict antidepressant 
response in depressed patients (Mamdani et al, 2013; Tansey et al, in prep), it may also be the case that the 
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genetic regulation of gene expression levels varies between patients who are more or less likely to respond 
to antidepressant treatment.  
 
If antidepressant response-specific eQTLs can be identified, this indicates that the mechanism by which a 
genetic variant influences expression levels varies in a manner which is associated with the treatment 
response phenotype, and so gives an insight into the biological differences that may exist between 
responders and non-responders prior to treatment.  
 
1.6.5 Chapter 7 aims; identification and exploration of eQTLs 
In chapter 7 of the thesis, I aim to use both the genetic and transcriptomic data available to characterise the 
eQTLs that can be observed within the GENDEP dataset. Having identified the pattern of eQTLs, I will 
investigate their potential value as bioinformatics annotations in identifying predictors of antidepressant 
treatment response. Finally, I will consider whether the genetic effect of gene expression levels is dependent 
on the phenotype of antidepressant treatment response.  
 
1.7 Conclusions 
Given the widespread use of antidepressants, there is a need to better understand and predict the high 
degree of variability seen in treatment outcomes. Genetics offers one tool by which to approach this issue, 
with the advantage that only a blood sample is required from the patients. However genetic approaches 
often come at the cost of low statistical power, requiring the collaborative collection of very large samples 
within projects such as GENDEP. In this thesis, I will use a range of different genetic-based approaches 
applied to the GENDEP sample, to attempt to disentangle the biological underpinnings of effective 
antidepressant treatment, with the ultimate aims of informing clinical decision making and identifying novel 













2.1 The GENDEP project 
This thesis uses data collected as part of the Genome-based Therapeutic Drugs for Depression (GENDEP) 
project. The project includes in vitro and animal components, but the work here comes solely from the 
human pharmacogenetic portion of the project. GENDEP was approved by ethics boards in each of the 
participating centres and all participants provided written consent after the procedures were explained. 
GENDEP is registered at EudraCT (No.2004-001723-38, http://eudract.emea.europa.eu) and ISRCTN (No. 
03693000, http://www.controlled-trials.com). The project was designed to identify clinical, genetic and 
environmental predictors of antidepressant treatment response. Below, the measures that were used within 
this thesis are described.  
 
2.2 Participants 
Participants were recruited into the study across nine centres within eight European countries (detailed in 
Table 2-1), using generalist and specialist referrals as well as advertisements. For inclusion in the study 
participants must have been diagnosed with at least moderate severity of depression, as defined by ICD-10 
(World Health Organisation, 1992) and DSM-IV (American Psychiatric Association, 2000). Diagnosis was 
established using the semi-structured SCAN interview (Wing et al, 1998), and the computerised classification 
system CATEGO5 (Grayson et al, 1990). Exclusion criteria included; a first-degree relative with bipolar 
disorder or schizophrenia, a history of hypomanic or manic episodes, mood incongruent psychotic 
symptoms, and current dependence on drugs or alcohol. Patients who had contraindications (including 
previous history of lack of efficacy or side effects) to both of the study medications were also excluded, as 
well as those who were either pregnant or lactating. All patients were of White European descent, in order to 
control for population stratification within genetic analyses, and over 18 years of age. The complete sample 
totalled 868 patients; 547 were female and 321 were male. The age range of the sample was 19 to 72 years 





Table 2-1: Number of patients recruited into GENDEP per centre 












Two antidepressant drugs were used in GENDEP; escitalopram and nortriptyline. These drugs were selected 
because they differentially target the two most common mechanisms of antidepressant action. Whilst 
escitalopram is an SSRI which acts via inhibition of serotonin reuptake, nortriptyline is a tricyclic 
antidepressant which predominantly influences noradrenaline reuptake action. More specifically, 
escitalopram has a very high affinity for the serotonin transporter and negligible affinity for other receptors in 
the brain (Sanchez, Bergqvist et al. 2003). In contrast, nortriptyline shows preferential action at the 
noradrenergic transporter, although the drug displays some affinity for the serotonin transporter (Sanchez 
and Hyttel 1999). However, nortriptyline also demonstrates antagonistic action at several postsynaptic 
receptors; the H1 histamine receptor, the adrenergic α-1 receptor, serotonergic 5HT-2A and -2C receptors 
and muscarinic cholinergic receptors (Sanchez and Hyttel 1999). Whilst reboxetine may be more selective in 
its action at noradrenergic receptors (Wong et al, 2000), there are questions regarding its efficacy (Eyding et 





Patients were randomly allocated to receive one of these two antidepressants, unless prior contraindications 
indicated one of the drugs was not suitable. On this basis, 374 patients were non-randomly allocated to 
treatment (67.65% of these individuals were prescribed escitalopram). Any participants who were 
antidepressant-free (or on low doses of other antidepressants) at the first assessment were started on the 
study medication immediately. A wash out period of two weeks was required for participants taking fluoxetine 
or monoamine oxidase inhibitors. 
 
Drugs were prescribed using a flexible-dosage protocol (50-150mg/day of nortriptyline or 10-30mg/day of 
escitalopram). This, together with the option for non-random drug allocation, the open-label design of the 
study and the absence of a placebo arm were included as pragmatic study design features to make the 
project more inclusive and open to a wider proportion of patients. Self-reported pill counts were obtained and 
98.4% of the sample reported treatment adherence. 
 
2.3.1 Comedications 
Patients were prohibited from using other psychotropic medications during the trial, excepting the occasional 
use of hypnotics. Any other medications taken throughout the study were recorded.  
 
2.4 Clinical measures 
2.4.1 Treatment response 
2.4.1.1 Selection of appropriate measurement tool for treatment response 
Antidepressant treatment response is measured as an improvement (i.e. decrease) in depressive symptoms. 
However, there are a number of different scales that can be used to measure depressive symptoms; no gold 
standard has been identified. It is unclear whether clinician-rated inventories offer a more objective measure 
of symptomatology (Prusoff et al, 1972) or lack sensitivity (Greenberg et al, 1992). Additionally, the 
appropriate weighting for each symptom encompassed within a diagnosis of depression has not been fully 
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established (Bagby et al, 2004), particularly in light of the high levels of heterogeneity between depressed 
patients in terms of symptomatology.  
 
Within this context, three measurement scales were used in GENDEP; the self-report Beck Depression 
Inventory (BDI; Beck et al, 1961), the clinician-rated Hamilton Depression Rating Scale (HDRS-17; Hamilton, 
1960, 1967) and the clinician-rated Montgomery-Asberg Depression Rating Scale (MADRS; Montgomery 
and Asberg, 1979). Each scale was administered weekly from baseline (week zero) to week twelve of 
treatment. At weeks zero, eight and twelve, interviews were given face-to-face by a psychiatrist and a 
research assistant (both trained in administration of the scales). All remaining assessments were done either 
by telephone or with face-to-face interviews by either a trained psychologist or psychiatrist.  
 
Previous work exploring the three scales within the GENDEP data set concluded that MADRS outperforms 
the other two scales for both inter-rater reliability and accuracy of detecting depression symptoms over a 
range of symptom severity (Uher et al, 2008). Thus the MADRS has been used as the primary outcome 
measure throughout this thesis. The MADRS is included in Appendix A.   
 
2.4.1.2 Selection of appropriate model for treatment response 
Depression symptomatology is a continuous trait, and whilst various cut-off points to define response and 
remission in depression have been defined, there is a lack of consensus on which cut-off point is most 
appropriate (Frank et al, 1991; Zimmerman et al, 2004). Additionally, dichotomising a continuous trait results 
in a substantial loss of statistical power (Streiner, 2002), which is a particular concern given the evidence 
indicating genetic and environmental influences on antidepressant treatment response are likely to have 
small effect sizes. Therefore, in this thesis, antidepressant treatment response is always considered as a 




Given the availability of weekly data on treatment response, longitudinal measures of treatment response 
have been employed in this thesis, where possible. By using linear mixed models it was possible to include 
the repeated measures for each individual. Furthermore, these models are robust to missing data, giving 
unbiased estimates without the need for imputation (Lane, 2008; Mallinckrodt et al, 2001).  
 
However, the inclusion of longitudinal data for each participant was not feasible within the context of 
analyses conducted on a genomic scale (Chapters 6 and 7). In these cases, an alternative outcome of 
percentage change in MADRS from baseline to week 12 of the study was used (previously described by 
Uher et al, 2010). Missing data at week 12 was imputed using linear mixed effects regression models, with 
fixed linear and quadratic effects of time and random effects of recruitment centre and individual. Given that 
treatment response was observed to be associated with age and recruitment centre, the final measure of 
percentage change in MADRS score was adjusted for these factors. It has been observed that within 
GENDEP, percentage change in MADRS score is preferable to absolute change, given its high correlation 
with end-of-treatment score (r=0.84), low correlation with baseline severity (r=-0.06) and aligns with clinical 
impressions of improvement (Uher et al, 2010).  
 
2.4.2 Antidepressant side effects 
2.4.2.1 Selection of appropriate measurement tool for side effects 
Two inventories were used to assess antidepressant side effects in GENDEP. The self-report Antidepressant 
Side Effect Checklist (ASEC, Uher et al, 2009a) was developed as part of the GENDEP project. The 
checklist was designed specifically to identify side effects that have been previously identified as associated 
with antidepressants and indexes 21 items. The ASEC was administered weekly from week zero to week 
twelve. In addition, the interviewer-rated UKU (Udvalg for Kliniske Undersoegelser Side Effects Rating Scale, 
Lingjaerde et al, 1987) was administered by a psychiatrist at week zero, eight and twelve. This semi-
structured interview assesses common side effects associated with psychotropic medications, indexing 48 




 The ASEC has previously been shown to correlate well with the UKU (Uher et al, 2009a), and given that the 
ASEC data available was more comprehensive, this measure was used to index adverse drug reactions 
throughout this thesis. The ASEC is included in Appendix B.  
 
2.4.2.2 Selection of appropriate model for side effects 
Each of the 21 items included in the ASEC were rated on a four-point scale (0 absent; 1 mild; 2 moderate; 3 
severe). As moderate and severe ratings were rare in this sample, these values were collapsed to give 
dichotomous presence/absence outcomes per week. In addition to considering each specific side effect, a 
measure of total side effect burden was also constructed.  
 
As described above for response measures, linear or logistic mixed models were used to capture the 
longitudinal measures of side effects, making maximum use of the weekly data available.  
 
2.4.3 Study drop out 
Study end week was recorded for each participant. The proportion of patients exiting the study each week is 
shown in Figure 2-1; 64.05% of participants remained in the study for the full twelve weeks. 
 
2.5 Serum measurements 
To establish circulating concentration of antidepressant and primary metabolite, serum measurements were 
taken using blood samples taken at week eight of the study, when steady state serum concentrations have 
been achieved (Hiemke & Hartter, 2000; Linder & Keck, 1998). Blood samples were taken in the morning, 
and patients were asked to postpone taking their morning dose of antidepressant until after the samples 
were collected. Serum levels of antidepressant were available for 319 patients taking escitalopram and 213 





Figure 2-1: Proportion of sample exiting GENDEP study, per week per drug 
All serum analyses were performed at the Department of Clinical Biochemistry, Kings College Hospital, 
London (UK). Escitalopram, desmethylcitalopram, nortriptyline and total 10-hydroxynortriptyline were 
measured using achiral turbulent flow liquid chromatography (Couchman, 2012) using an Aria Transcend 
TLX-II system (ThermoFisher Scientific, San Jose, USA). Detection was by tandem mass spectrometry 
(MS/MS) (TSQ Vantage, ThermoFisher Scientific, Hemel Hampstead, UK) in positive ionisation mode using 
atmospheric pressure chemical ionisation (APCI), with two selected reaction monitoring (SRM) transitions 
used for each analyte. The cis- and trans-isomers of 10-hydroxynortriptyline were resolved and assay 
calibration was based on the cis-isomer. Sample preparation in both cases was by protein precipitation. 
Samples, calibration standards, and internal quality control solutions (50 µL) were vortexed (5 min) with a 























(5 min, 13,000 rpm), the supernatant was transferred to the well of a 96-well plate and 40 µL injected. The 
method was fully validated according to FDA guidelines (FDA, 2001).  
 
In all cases, detection was by positive mode electrospray ionisation. Selected reaction monitoring was used 
(two m/z transitions per analyte). Each assay was calibrated using 7 calibration solutions over the following 
ranges; escitalopram, desmethylcitalopram, and nortriptyline: 10-500 µg/L, cis-10-hydroxynortriptyline: 10-
1000 µg/L. Internal standards were: LU-10-2020, an escitalopram analogue (for escitalopram and 
desmethylcitalopram) and nortriptyline-D3 (for nortriptyline and cis-10-hydroxynortriptyline). The response for 
trans-10-hydroxynortriptyline was assumed to be the same as that of cis-10-hydroxynortriptyline. Ion 
suppression or ion enhancement were not observed using standard testing procedures. 
 
2.6 Genotypic measures 
Blood sample for genetic analysis were taken at baseline. DNA was extracted from these samples and 
buffered in ethylenediaminetetraacetic acid (Freeman et al, 2003). 
 
2.6.1 CYP450 enzymes genotyping 
For CYP450 genotyping, blood samples were available for 846 participants. Genotyping was performed 
using the Roche AmpliChip CYP450 (Roche Molecular Diagnostics, Alameda, CA, USA), a micro-array that 
measures 33 variants in CYP2D6 and two variants in CYP2C19. In addition, the common *17 allele observed 
within CYP2C19 (Sim et al, 2006) was also genotyped, using a TaqMan SNP genotyping assay on the 
7900HT sequence detection system (Applied Biosystems, CA, USA). Genotypes were determined using 
SDS software (Applied Biosystems). The nomenclature of alleles within the CYP450 enzymes is defined as 




2.6.2 Genome-wide genotyping 
For genome-wide genotyping, a total of 795 samples were available in sufficient quantity and quality. These 
were sent to the Centre National de Genotypage (Evry Cedex, France) and genotyped using the Illumina 
Human610-quad bead chip (Illumina, Inc., San Diego). This chip assays more than 610,000 single 
nucleotide polymorphisms (SNPs) and copy number variant markers selected to provide a comprehensive 
coverage across populations.  
 
2.6.2.1 Quality control for GWAS data 
Using PLINK (Purcell et al, 2007), standard quality control procedures were performed on the genome-wide 
data. Firstly, SNPs were removed if the minor allele frequency (MAF) was <0.01 or if SNP completeness was 
<99%. However, given GENDEP is a case-only sample, Hardy Weinberg Equilibrium was not used as a 
quality control filter (Wittke-Thompson et al, 2005).  Secondly, individuals were removed if genotypic sex did 
not align with phenotypic sex data, or if they were identified as outliers on autosomal heterozygozity 
(potential indicators of sample contamination). Thirdly, using a linkage disequilibrium (LD)-pruned dataset 
(containing 39,658 SNPs in low LD), estimation of identity by descent was performed in PLINK to identify 
related individuals; in first- or second-degree relatives, the individual with less complete data was removed 
from the sample. Finally, individuals with genotypic completeness <95% were removed.  
 
2.6.2.2 Population stratification 
In order to account for the genetic variation that is seen across European populations (Seldin et al, 2006; 
Tian et al, 2008), principal component analysis was applied to the LD-pruned dataset described above, using 
EIGENSTRAT (Price et al, 2006).  The first five principal components identified reach significance (p<0.05). 
The first principal component corresponded to north-south geographic locations, whilst the second 
corresponded to east-west locations. The third and fourth principal components jointly distinguished UK 
samples from the remainder of the sample. The fifth principal component showed no relationship with 
recruitment centre, and so the first four principal components were used as covariates to capture population 
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The Illumina Human 610-quad bead chip (Illumina, Inc., San Diego) surveys over 610,000 SNPs across the 
genome. However, it is possible to use imputation to estimate the values for unobserved genotypes within 
the study data, using data from references panels, such as the 1,000 Genomes Project (Abecasis et al, 
2010). Patterns of linkage disequilibrium within the reference panel data can be used to extrapolate likely 
genotypic values within the study data (Howie et al, 2009). This additional imputed data increases power to 
detect genetic associations; this has been demonstrated for genome-wide association studies of gene 
expression traits (Liang et al, 2013). In order to impute the genotypic data within this sample, IMPUTE 2 
software was used (Howie et al, 2011). 1000 Genomes Phase 1 integrated haplotypes (NCBI build 37) were 
downloaded from the IMPUTE2 website as the reference panel for the imputation 
(https://mathgen.stats.ox.ac.uk/impute/impute_v2.html). The study panel was the quality-controlled 
genotypes from the Illumina Human 610-quad bead chip. Genomic positions of variants within the study 
panel were converted from NCBI build 36 to build 37 coordinates with UCSC LiftOver 
(http://genome.ucsc.edu/cgi-bin/hgLiftOver). Any ambiguous A/T or C/G SNPs were removed, to enable 
automatic strand alignment options within IMPUTE2. After imputation in IMPUTE2, any genotypes with INFO 
scores <0.5 or MAF<0.1 were removed. The tool fcGENE was used to convert genotype probabilities into 
allelic dosages (http://www.imise.uni-leipzig.de/en/Groups/GenStat/Tools/index.jsp). The total number of 
imputed SNPs after quality control was 8,317,505 SNPs.  
 
2.7 Transcriptomic measures 
Blood samples for RNA measurement were taken at two time-points during the study; week zero and week 
eight. Data was available from a total of 227 participants at week zero; of these 136 participants also had 
data available from samples taken at week eight. The samples used for the transcriptomic analysis were 
taken at the same point as those used for the serum measurements (outlined in 2.5); all samples were taken 
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in the morning, prior to taking the morning dose of antidepressant. Typically, samples were taken at around 
10am.  
 
2.7.1 Whole blood RNA extraction and microarray expression measurement 
Ten mL of blood was collected in PAXgene tubes (PreAnalytiX, Switzerland) and stored at -80 
degrees.  Prior to RNA extraction, PAXgene tubes were allowed to thaw for 12 hours at room temperature. 
RNA extraction was subsequently performed using the Qiagen PAXgene Blood miRNA Kit (PreAnalytiX) 
following the standard manufacturer’s protocol. The purity and quantity of RNA was measured using the 
Nanodrop, ND1000 (Thermoscientific, Wilmington, DE), and RNA integrity numbers (RINs) were furthermore 
assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies, Berkshire, UK). RNA samples were 
then sent to the University of California Los Angeles, where genome-wide RNA expression profiling was 
performed using HumanHT-12 v4 Expression BeadChip microarrays (Illumina, Inc., San Diego). This 
microarray contains over 47,000 gene-specific probes measuring gene expression levels. Raw data was 
extracted using BeadStudio©. Samples were sent in four batches; assignment to batch was random.  
 
2.7.2 Transcriptomic quality control 
Two datasets were created; the first contained all week zero samples (227 samples) and the second 
contained samples from all individuals where data was available at both week zero and week eight (272 
samples from 136 participants). These datasets were considered separately, but the same quality control 
metrics were used in each case. Quality control and analysis was undertaken in R (version 3.0.2). All gene 
expression values were log transformed. Samples with sex-incongruent expression of the XIST gene were 
removed, as were samples where inter-array correlations were more than 2 standard deviations from the 
mean. Detection p-values were used for probe filtering (p<0.05 in at least one sample), and probes 
displaying little variation were also removed (where the standard deviation was within the lowest quartile).   





After quality control, data was normalised using quantile normalisation, and ComBat (Johnson et al, 2007) 
was used to control for batch effects. As measurements of cell type proportions were unable for these data, 
deconvolution methods were used. The R package CellMix (Gaujoux and Seoighe, 2013) was used to 
estimate proportions of lymphocytes, neutrophils and monocytes per sample, employing previously identified 
cell-specific markers (Abbas et al, 2009).   
Week zero data 
227 individuals, 47,231 probes 
3 individuals removed 
7,774 probes removed 
6 individuals removed 
9,881 probes removed 
213 individuals, 29,576 probes 
Transcriptomic datasets 
Sex incongruent XIST expression 
Inter-array correlations greater than 
2 standard deviations from mean 
Detection score p-values <0.05 
Invariant probes (standard 
deviation in lowest quartile) 
Final dataset 
121 individuals, 29,765 probes 
2 individuals removed 
7,549 probes removed 
13 individuals removed 
9,917 probes removed 
Paired data 
(week zero and eight) 
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Patients taking antidepressants report a range of different medication-linked side effects. Estimates vary, but 
the frequency of these adverse drug reactions (ADRs) has been observed to be as high as 75% (Meijer et al, 
2002). Given the link between ADRs and treatment non-adherence and discontinuation (Bull et al, 2002; 
Mitchell, 2006), it is important to understand the causes of these side effects. An individual’s risk of ADRs is 
thought to be partially determined by genetic factors; identifying the genes that predict particular ADRs would 
enable clinicians to determine the side effect risk profile of each patient and tailor prescriptions accordingly. 
Despite the clinical relevance of this approach, given the number of different ADRs that are reported with 
antidepressants, the literature is this area is diffuse, with poor coverage of a large number of outcomes. 
 
As noted in the Introduction, there are differences between antidepressants in terms of commonly reported 
ADRs, which are echoed by differences in drug receptor affinities. The majority of common antidepressant 
side effects are associated with one of four receptor classes; adrenergic, cholinergic, histaminergic and 
serotonergic. Orthostatic hypotension and dizziness are associated with antagonism of adrenergic receptors 
(Carruthers, 1994), whilst dry mouth, blurred vision, constipation and problems with urination result from 
antagonism of cholinergic receptors. Drowsiness, increased appetite and weight gain are linked to 
histaminergic antagonism (Lecklin et al, 1998; Monti et al, 1990) and insomnia, reduced appetite, sexual 
dysfunction, nausea and diarrhoea are associated with serotonergic receptors (Kennedy et al, 2000; Nutt, 
2002; San and Arranz, 2008; Stahl, 1998). These proposed groupings are supported by the observed 
patterns seen between the side effect profiles and receptor affinities of various antidepressants (Hamon and 
Bourgoin, 2006). Tricyclic antidepressants act at cholinergic, histaminergic, serotonergic and adrenergic 
receptors, whilst selective serotonin reuptake inhibitors (SSRIs) target the serotonin transporter more 
specifically (Hamon et al, 2006). Consequently, one novel approach to identifying genetic predictors of ADRs 





Using these four receptor-defined categories of ADRs, this chapter aimed to investigate whether the 







The details of the GENDEP sample are described in Chapter 2. Those patients from the study with genetic 
information, as well as data on the experiences of ADRs (both prior to medication and for at least one week 
post-baseline) were selected for inclusion. Additionally, only randomly allocated patients were included in 
this analysis.  
 
This is because the GENDEP study design involved partial-random allocation to antidepressant medication; 
individuals with previous contra-indications were non-randomly allocated to the alternative antidepressant 
(36% of the sample). Non-random allocation to treatment is based on the assumption that patients are likely 
to experience the side effect again if given the same medication, and less likely to experience the side effect 
when taking the alternative medication. If these assumptions are true, the ability to detect genetic 
associations with ADRs is reduced in non-randomly allocated patients.  
 
Figure 3-1 shows the patients from GENDEP that were included in the analyses presented in this chapter.  
 
As described in Chapter 2.3, two antidepressants with divergent actions were used in GENDEP: 
escitalopram and nortriptyline. Briefly, escitalopram is an SSRI with a very high affinity for the serotonin 
transporter and negligible affinity for other receptors in the brain (Sanchez et al, 2003). In contrast, 
nortriptyline is a tricyclic antidepressant, with preferential action at the noradrenergic transporter, but also 






Side effects were measured weekly, using the self-report Antidepressant Side Effect Checklist (ASEC), as 
described in Chapter 2.4.2. The ASEC measures 21 side effects. From these, four categories were derived, 
based on the putative pharmacological basis of the side effects; serotonergic, adrenergic, histaminergic or 
cholinergic, as shown in Table 3-1. Adverse reactions where the pharmacological basis is unclear were 
excluded, as there may be several interacting processes involved. These included palpitations, headache, 
sweating, increased temperature, tremor, disorientation, yawning. 
 
Although each item on the ASEC is rated on a four-point scale (0 absent; 1 mild; 2 moderate; 3 severe), 
moderate and severe ratings were uncommon (Uher et al, 2009a). Thus, for each outcome group 
(adrenergic, cholinergic, histaminergic or serotonergic) and for each week of the study where ratings were 






Side effect data available (and baseline and 
for at least 1 week of the study) 
N=701 
Randomised to treatment 
N=431 
Genetic data available 
N=676 
Figure 3-1: Sample included in Chapter 3 
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available, ADRs were coded as present if the patient scored any of the side effects in the grouping at one or 
above.  
Table 3-1: ASEC items grouped according to physiological pathway 
Serotonergic Adrenergic Cholinergic Histaminergic 
Nausea or vomiting Feeling light-headed on 
standing Problems with urination Drowsiness 
Diarrhoea Feeling like the room is 
spinning Blurred vision Increased appetite 
Decreased appetite  Constipation Weight gain 
Insomnia  Dry mouth  
Sexual problems    
 
3.2.3 Genotyping 
Using the quality-controlled genome-wide data described in Chapter 2.6.2, genotypic information was 
extracted for twenty-four candidate genes. The candidate genes were selected across the four receptor 
systems proposed to underlie each side effect group. For each gene, 1000bp up and downstream of the 
coding sequence was included, to capture proximal promoter sequences (Solovyev and Shahmuradov, 
2003). Only variants with a minor allele frequency greater than 5% were included.  
 
Additional variants within genes of particular interest in depression were also genotyped in the sample (as 
described in Uher et al, 2009b). Four of these genes had been selected as candidates in this study and this 
additional genotypic information supplemented the genome-wide data. In the serotonin transporter gene 
(SLC6A4), the serotonin-transporter-gene-linked polymorphic region (5-HTTLPR), and the putative functional 
marker rs25531 that lies within this region were both genotyped in a two-stage method. Two further 
polymorphic microsatellite markers (STin2 and STin4) within the SLC6A4 gene were also genotyped, and 
after examination of the distribution of repeats, both STin2 and STin4 were categorised as either “long” 
(STin2: 12 repeats, STin4: 8-9 repeats) or “short” (STin2: 9-10 repeats, STin4: 5-7 repeats). All other 
additional SNPs were genotyped using the SNPlex method (Applied Biosystems, Inc., Foster City, CA) with 
genotype discrimination achieved using the Applied Biosystems ABI 3130 sequencer. Data was exported 
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and analysed with GENEMAPPER software (Applied Biosystems, version 4.0), see Huezo-Diaz et al (2009) 
for further details and quality control thresholds applied. 
 
In total, genotypic data was available for 436 markers from twenty candidate genes (see Table 3-2 for further 
details).  
Table 3-2: Candidate genes selected for ADR analysis in GENDEP sample. (Meff: effective number of comparisons, as 
calculated using SNPSpD) 
 Candidate gene Associated side 
effects 




SLC6A2 Adrenergic 47 0.00117 
ADRA1A Adrenergic 53 0.00103 
ADRA1B Adrenergic 14 0.00415 
ADRA1D Adrenergic 7 0.00810 
SCL6A4 Serotonergic 21 0.00320 
HTR1A Serotonergic 3 0.04808 
HTR1B Serotonergic 0  
HTR1D Serotonergic 0  
HTR1E Serotonergic 9 0.00668 
HTR1F Serotonergic 0  
HTR2A Serotonergic 51 0.00110 
HTR2B Serotonergic 2 0.02666 
HTR2C Serotonergic 14 0.00520 
HTR3A Serotonergic 9 0.00922 
HTR3B Serotonergic 5 0.01228 
HTR3C Serotonergic 2 0.03182 
HTR3D Serotonergic 5 0.01313 
HTR3E Serotonergic 2 0.02582 
CHRM1 Cholinergic 3 0.01730 
CHMR2 Cholinergic 32 0.00191 
CHRM3 Cholinergic 119 0.00044 
CHRM4 Cholinergic 0  
CHRM5 Cholinergic 16 0.00449 




3.2.4 Statistical Analysis 
3.2.4.1 Regression model 
For each of the four groupings (serotonergic, adrenergic, histaminergic and cholinergic), logistic regression 
was used to test the effect of genotype on the presence or absence of side effects under an additive genetic 
model. For genes located on the X chromosome, males were treated as homozygotes. Data on ADRs from 
all 12 weeks of the study were included in the analyses; therefore a Huber-White sandwich estimator of 
variance was used to account for the use of repeated measurements (Kuzman et al, 2008). This estimator 
relaxes the assumption of independent observations by providing standard errors that are robust to intra-
individual correlations (Kent, 1982). 
 
To examine only those side effects that emerged as a result of antidepressant treatment, baseline ADR 
ratings (prior to treatment initiation) were controlled for. Additionally, given the effect of depression severity 
on ADR endorsement (Uher et al, 2009a), current and baseline ratings on the Montgomery-Asberg 
Depression Rating Scale (Montgomery et al, 1979) were entered as covariates in all analyses. Other 
covariates included age, sex, study week, dose (standardised to allow comparison between drugs), and drug 
(when applicable). 
 
3.2.5 Subgroup analyses 
Escitalopram and nortriptyline have different receptor affinities, and it was hypothesized that the association 
between genotype and side effect may be specific to patients taking medications with direct action at the 
relevant receptors. Thus, for each of the four ADR outcomes, associations between genotype and ADR 
ratings were examined for the following groups: A) all patients randomly allocated to their medication; B) 
patients randomly allocated to escitalopram; C) patients randomly allocated to nortriptyline. All statistical 




3.2.6 Correction for multiple testing 
In order to control for multiple tests, the effective number of comparisons was calculated based on the 
procedure described by Li and Ji (2005), using SNPSpD software (Nyholt, 2004). This takes into account the 
linkage disequilibrium that exists between SNPs. For each ADR outcome, 436 SNPs were tested for 
association, equivalent to 427.13 effective comparisons. This effective number of comparisons (Meff) was 
used to calculate an outcome-wide significance level (0.05/Meff) of p=1.17 x 10-4. 
 
In order to identify any SNPs that may not reach outcome-wide significance, but do reach significance on a 
gene-wide scale, the effective number of comparisons per gene was also calculated (as shown in Table 3-2). 
 
To estimate the posterior probability of true positive findings in the context of multiple non-independent tests, 
false discovery rate q-values were calculated using the Benjamini and Hochberg step-up procedure (Theisen 
et al, 2004) and QVALUE software (Risselada et al, 2010). These q-values indicate the proportion of false 
positives amongst those tests that reach significance.  
 
3.2.7 Replication in GenPod 
The GenPod study was used as a replication sample to follow up significant associations that were observed 
in the GENDEP sample. GenPod is a UK-based multi-centre trial where depressed patients are randomised 
to receive either citalopram (of which escitalopram is the (S)-stereo-isomer) or reboxetine (a specific 
noradrenergic reuptake inhibitor, which unlike nortriptyline, has a weak affinity for muscarinic, H1 
histaminergic or adrenergic α-1 receptors (Boothman et al, 2006). Patients were followed over a period of 12 
weeks, with assessments taken at baseline, week 6 and 12 of treatment. Side effects were measured using 
a modified version of the Toronto Side Effects Scale (TSES; Lesch et al, 1994), included in Appendix C, and 
depression severity was measured with the self-report Beck Depression Inventory (BDI). Samples were 
genotyped at the University of Geneva Medical School (Geneva, Switzerland) using the Illumina 
Human660W-Quad BeadChip (Illumina Inc., San Diego, CA). Further details are published elsewhere 
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(Cremers et al, 2004). From a sample of 601 patients, 474 had both genetic and ADR data available (50.2% 







3.3.1 Adverse drug reaction profiles in GENDEP 
Figure 3-2 demonstrates the pattern of side effects in GENDEP across the 12-week trial, split by medication 
taken. The expected relationships are observed, with adrenergic, histaminergic and cholinergic outcomes 
more frequent amongst patients taking nortriptyline, and serotonergic adverse effects more common 
amongst those on escitalopram. However, this difference is relative; all groups of side effects are reported 
with both antidepressants. Further, there are notably high rates of side effect endorsement at baseline (study 
week zero), when all patients were unmedicated.  
 
3.3.2 Genetic associations in GENDEP 
All associations reaching gene-wide significance are shown in Table 3-3 and Table 3-4.  
 
3.3.2.1 Cholinergic adverse reactions 
No SNPs reached outcome-wide significance when considering cholinergic adverse reactions. A gene-wide 
significant association was observed with a SNP in HTR2B in the whole sample, whilst for individuals taking 
escitalopram, there was a gene-wide significant association with a SNP in cholinergic receptor CHRM3. In 
patients taking nortriptyline, there were associations in both CHRM3 and HTR2B at gene-wide levels, 
however at different variants to those identified in the escitalopram-specific (CHRM3) or randomised 
(HTR2B) analyses. The linkage disequilibrium between the implicated SNPs in each of these genes was low.  
 
3.3.2.2 Adrenergic adverse reactions 
No outcome-wide significant associations were observed with adrenergic side effects. In the whole sample 
analysis, one SNP in HTR3E reached gene-wide significance. This same SNP (rs7432211) was also 
associated at a gene-wide level in the nortriptyline-specific analysis. While escitalopram has no adrenergic 
action, three SNPs in three different genes were associated at a gene-wide threshold (CHRM3, ADRA1A 

















































































































Table 3-3: Genetic associations with cholinergic, adrenergic and histaminergic adverse drug reactions in GENDEP sample.  
Analysis: A=whole sample; B=patients taking escitalopram; C=patients taking nortriptyline. SNPs that are present in more than one analysis are marked in superscript 
(1=also in analysis A, 2=also in analysis B, 3=also in analysis C). MAF= minor allele frequency, n=number of individuals, Obs=total number of observations across all 12 










A HTR2B 0.02666 2 rs10194776 231980019 T/C 0.40 362 3290 0.0245 0.4357 1.37 1.04 1.81 
B CHRM3 0.00044 1 rs1431718 239879553 T/C 0.41 184 1764 2.92E-04 0.0479 1.87 1.33 2.62 
C 
CHRM3 0.00044 1 rs11578320 239906616 C/T 0.07 178 1526 1.95E-04 0.0826 5.41 2.23 13.17 
HTR2B 0.02666 2 rs4973377 231981992 A/G 0.17 178 1526 0.0091 0.6502 0.43 0.23 0.81 
Adrenergic 
A HTR3E 0.02582 6 rs7432211(3) 183819155 C/T 0.41 361 3276 0.0200 0.4634 1.38 1.05 1.81 
B 
CHRM3 0.00044 1 rs685548 239994906 T/G 0.39 183 1752 3.38E-04 0.1006 0.48 0.32 0.72 
ADRA1D 0.00810 20 rs6084670 4222509 C/A 0.24 183 1752 0.0044 0.3115 0.48 0.29 0.80 
HTR3C 0.03182 3 rs6808122 183772821 G/A 0.37 183 1752 0.0093 0.3892 0.58 0.39 0.88 
C HTR3E 0.02582 3 rs7432211 (1) 183819155 C/T 0.41 178 1524 0.0032 0.3920 1.72 1.20 2.46 
Histaminergic 
A HTR3D 0.01313 3 rs6792482 183754029 C/T 0.44 362 3289 0.0078 0.7847 1.37 1.09 1.73 
B 
              
C 






Table 3-4: Genetic associations with serotonergic  adverse drug reactions in GENDEP sample.  
Analysis: A=whole sample; B=patients taking escitalopram; C=patients taking nortriptyline. SNPs that are present in more than one analysis are marked in superscript 
(1=also in analysis A, 2=also in analysis B, 3=also in analysis C). MAF=minor allele frequency, n=number of individuals, Obs=total number of observations across all 12 











HTR2C 0.00520 X 
rs6644093(2) 114064023 T/G 0.15 362 3288 7.43E-05 0.0252 1.72 1.31 2.25 
rs4911871(2) 113997140 G/A 0.21 362 3288 0.0016 0.1074 1.49 1.16 1.91 
rs12846241 113854086 G/T 0.18 362 3288 0.0021 0.1074 1.52 1.17 1.99 
rs12690355 113910850 G/A 0.18 361 3280 0.0022 0.1074 1.53 1.64 2.01 
rs2428700 114010664 A/G 0.14 361 3284 0.0031 0.1074 0.63 0.46 0.86 
rs4332303 114047867 T/C 0.14 362 3288 0.0031 0.1074 0.63 0.46 0.86 
rs5946005 114082535 G/A 0.14 362 3288 0.0031 0.1074 0.63 0.46 0.86 
rs5988087 113934856 T/C 0.16 362 3288 0.0032 0.1074 0.64 0.48 0.86 
rs11167436 113944060 A/C 0.16 362 3288 0.0032 0.1074 0.64 0.48 0.86 
CHRM2 0.00191 7 rs1364403 136588827 T/C 0.30 362 3288 0.0020 0.1074 0.65 0.49 0.85 
B 
HTR2C 0.00520 X 
rs6644093(1) 114064023 T/G 0.15 184 1763 6.07E-04 0.2642 2.02 1.35 3.01 
rs4911871(1) 113997140 G/A 0.21 184 1763 0.0032 0.4062 1.70 1.19 2.42 
CHRM1 0.01730 11 
rs2067477 62678306 T/G 0.09 184 1763 0.0030 0.4062 0.55 0.33 0.89 
rs2075748 62688269 T/C 0.21 184 1763 0.0115 0.5204 1.74 1.13 2.68 








3.4.1.1 Histaminergic adverse reactions 
In the whole sample analysis, one SNP in HTR3D was associated at gene-wide significance. No 
associations were seen, even at gene-wide significance thresholds, in the drug-specific 
analyses.  
 
3.4.1.2 Serotonergic adverse reactions 
In the whole sample analysis of serotonergic side effects, one SNP in HTR2C (rs6644093) 
achieved outcome-wide significance (OR=1.72, 95% CI=1.13-2.25, p=7.43 x 10-5). The 
occurrence of serotonergic side effects for each genotype at this SNP is shown in Figure 3-3.  
 
Given the significance of this association, the analysis was repeated, restricted to those patients 
where drug adherence could be confirmed using plasma concentrations (n=204, see Chapter 
2.5 for further details). The association between rs6644093 and serotonergic ADRs was verified 
in this restricted analysis (OR=1.54, 95% CI=1.10-2.17, p=1.15 x 10-2). Eight further SNPs in 
HTR2C reached gene-wide significance in the whole sample analysis, along with one variant 
within CHRM2.  
 
In the escitalopram-specific analysis, two HTR2C SNPs, two CHRM1 SNPs and one SNP in 
HTR2B reached gene-wide significance with serotonergic ADRs. Amongst patients taking 







































3.4.2 Replication analysis in GenPod 
Serotonergic ADRs identified in GENDEP using the ASEC were matched to items included in 
the TSES used in GenPod (Table 3-5). However, data on sexual problems was not available for 
the whole sample in GenPod. In the two samples, a similar longitudinal profile of decreasing 
prevalence with time was observed for the serotonergic ADRs, although in GenPod, these 
ADRs were not more common amongst patients taking an SSRI. Furthermore serotonergic 
ADRs were more frequently reported in the GenPod sample than in GENDEP (see Figure 3-4).  
 
Figure 3-4: Comparison of frequency of serotonergic ADRs in GENDEP and GenPod. 
 
Side effect scoring, genetic models and analysis framework mirrored those used in the analysis 
of data from GENDEP. Given that reboxetine does not display direct serotonergic activity, the 























Escitalopram Citalopram Nortriptyline Reboxetine
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GenPod, 13 SNPs were available within the HTR2C gene (8 of which were also genotyped in 
the GENDEP sample). For the most significant association in the GENDEP sample 
(rs6644093), the association in the GenPod sample was not significant (OR=0.91, 95% 
CI=0.55-1.52, p=0.723). Furthermore, no other variants in the HTR2C gene showed association 
with the occurrence of serotonergic side effects, when corrected for the effective number of 
SNPs tested within HTR2C (0.05/Meff; p<6.50 x 10-3), or when using a nominal significance 
(p<0.05). These results are shown in Table 3-6. The analyses of the whole GenPod sample and 
the reboxetine-specific analysis are shown in Table 3-7 and Table 3-8, again no significant 
associations were found. 
Table 3-5: Serotonergic adverse drug reactions as indexed in GENDEP and GenPod 
GENDEP 
(measured using the ASEC) 
GenPod 
(measured using the modified TSES) 
Nausea or vomiting Felt sick or nauseous 
Diarrhoea Diarrhoea 
Decreased appetite Noticed changes in the way food tastes 
Insomnia Difficulty sleeping 






Table 3-6: Genetic association with serotonergic adverse drug reactions in GenPod patients taking citalopram.  
MAF= minor allele frequency, n=number of individuals, Obs=total number of observations across 2 timepoints. Odds Ratios are per minor allele. Significance threshold 
=p<6.50 x 10-3, corrected for the effective number of SNPs tested within HTR2C. 





rs5988087 113841112 A/G 0.18 237 459 0.713 0.93 0.63 1.37 
rs11167436 113850316 A/G 0.18 237 459 0.713 0.93 0.63 1.37 
rs4911871 113903396 G/A 0.21 237 459 0.347 1.29 0.76 2.2 
rs4332303 113954123 A/G 0.18 237 459 0.497 0.87 0.59 1.29 
rs6644093 113970279 A/G 0.16 237 459 0.723 0.91 0.55 1.52 
rs5946005 113988791 G/A 0.18 237 459 0.497 1.14 0.78 1.68 
rs10875535 114033435 G/A 0.05 235 455 0.735 0.86 0.35 2.08 
rs1801412 114048960 C/T 0.05 237 459 0.729 0.85 0.35 2.08 
rs1414324 114054754 A/G 0.19 237 459 0.611 0.91 0.62 1.33 
rs1335617 114084871 G/A 0.19 237 459 0.611 1.1 0.75 1.62 
rs5987834 114092371 A/G 0.19 237 459 0.611 0.91 0.62 1.33 
rs6579571 114122419 G/A 0.13 237 459 0.197 1.42 0.83 2.44 






Table 3-7: Genetic association with serotonergic adverse drug reactions in GenPod (whole sample analysis).MAF= minor allele frequency, n=number of individuals, 
Obs=total number of observations across 2 timepoints. Odds Ratios are per minor allele. Significance threshold =p<6.50 x 10-3, corrected for the effective number of 
SNPs tested within HTR2C. 




rs5988087 113841112 A/G 0.18 473 900 0.914 0.98 0.72 1.34 
rs11167436 113850316 A/G 0.18 473 900 0.914 0.98 0.72 1.34 
rs4911871 113903396 G/A 0.20 473 900 0.188 1.28 0.89 1.84 
rs4332303 113954123 A/G 0.17 473 900 0.709 0.94 0.69 1.29 
rs6644093 113970279 A/G 0.15 473 900 0.553 0.89 0.61 1.30 
rs5946005 113988791 G/A 0.17 473 900 0.709 1.06 0.78 1.45 
rs10875535 114033435 G/A 0.06 470 895 0.158 0.70 0.42 1.15 
rs1801412 114048960 C/T 0.06 472 898 0.149 0.69 0.42 1.14 
rs1414324 114054754 A/G 0.17 473 900 0.867 0.97 0.71 1.33 
rs1335617 114084871 G/A 0.17 473 900 0.867 1.03 0.75 1.40 
rs5987834 114092371 A/G 0.17 473 900 0.867 0.97 0.71 1.33 
rs6579571 114122419 G/A 0.13 473 900 0.656 1.09 0.74 1.61 






Table 3-8: Genetic association with serotonergic adverse drug reactions in GenPod (reboxetine-specific analysis).  
MAF= minor allele frequency, n=number of individuals, Obs=total number of observations across 2 timepoints. Odds Ratios are per minor allele. Significance threshold 
=p<6.50 x 10-3, corrected for the effective number of SNPs tested within HTR2C. 




rs5988087 113841112 A/G 0.165 236 441 0.532 1.18 0.7 1.98 
rs11167436 113850316 A/G 0.165 236 441 0.532 1.18 0.7 1.98 
rs4911871 113903396 G/A 0.183 236 441 0.416 1.22 0.75 2 
rs4332303 113954123 A/G 0.156 236 441 0.599 1.16 0.67 2 
rs6644093 113970279 A/G 0.143 236 441 0.636 0.87 0.49 1.55 
rs5946005 113988791 G/A 0.156 236 441 0.599 0.86 0.5 1.49 
rs10875535 114033435 G/A 0.062 235 440 0.129 0.61 0.32 1.16 
rs1801412 114048960 C/T 0.06 234 439 0.121 0.6 0.31 1.15 
rs1414324 114054754 A/G 0.153 236 441 0.516 1.2 0.69 2.07 
rs1335617 114084871 G/A 0.153 236 441 0.516 0.83 0.48 1.44 
rs5987834 114092371 A/G 0.153 236 441 0.516 1.2 0.69 2.07 
rs6579571 114122419 G/A 0.119 236 441 0.24 0.69 0.38 1.28 







Identifying predictors of antidepressant side effects is an important aim with clear clinical utility, 
given both the prevalence of ADRs and their impact on treatment adherence. Here, a novel 
approach was used to classify ADRs using the wealth of evidence linking drug action at specific 
receptors with the emergence of particular side effects. ADRs were grouped into four receptor-
defined categories, adrenergic, cholinergic, histaminergic and serotonergic, and their 
relationship to genetic markers within relevant receptors was studied.  
 
No clear evidence of genetic association with adrenergic, cholinergic or histaminergic side 
effects were seen in the GENDEP sample, even when only considering those patients taking 
medication with stronger affinity for these receptors (nortriptyline). Nonetheless, there was 
evidence that an individual’s risk of experiencing antidepressant side effects with a serotonergic 
basis may be influenced, in part, by HTR2C, with a significant relationship observed looking in 
the whole sample, and suggestive gene-wide associations in the escitalopram-specific analysis. 
However, this finding was not replicated in the GenPod sample.  
 
3.5.1 Adrenergic, cholinergic and histaminergic outcomes 
Assuming genetic factors do play a role in determining an individual’s liability to these side 
effects, there are several possible reasons why genetic associations were not observed with 
adrenergic, histaminergic or cholinergic outcomes. Firstly, individual differences in the 
occurrence of the ADRs considered may not be determined by those genetic variants tested in 
this study. Whilst our knowledge of the pharmacology underlying side effects allows us to make 
rational choices when selecting candidate genes, this study focused only on the receptors 
themselves; it may be that the genes involved may be those that encode downstream effectors 
such as G-proteins.  
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Secondly, the study may have failed to demonstrate genetic associations with adrenergic, 
cholinergic or histaminergic side effects because the pharmacologically defined groupings used 
can only be a simplified model of the complex biological interactions leading to ADRs.  
 
Finally, the study may have lacked sufficient power to detect genetic effects for adrenergic, 
cholinergic or histaminergic effects. If the association between genotype and ADRs is only 
robust when the patient is taking medication with drug action at the relevant receptor, as only 
nortriptyline displays adrenergic, cholinergic or histaminergic action, genetic associations might 
be limited to the nortriptyline-only sample for these three outcomes. Given the reduced sample 
sizes available when performing drug-specific analyses, these may have been underpowered.  
 
3.5.2 HTR2C and serotonergic side effects 
Considering serotonergic side effects, in addition to the outcome-wide significant association 
with a SNP within HTR2C (rs6644093) in the whole GENDEP sample, supportive evidence of 
association was also observed with further SNPs in HTR2C at a gene-wide level across the 
escitalopram-specific analysis. Escitalopram acts exclusively at the serotonin transporter, 
altering serotonin levels at the synapse and so indirectly impacting upon the postsynaptic 5HT-
2C receptor. In contrast, nortriptyline not only displays modest affinity for the serotonin 
transporter, but also has an antagonistic action at the 5HT-2C receptor. It is unclear what the 
net effect of these two actions of nortriptyline would be, particularly given that there is likely to 
be an interaction between these two processes (Bostwick, 2010). Nonetheless, the association 
with genetic variation in HTR2C was seen most convincingly in the whole of the GENDEP 
sample, which included patients on both medications. This may reflect the increased power of 
this analysis due to the larger sample size. 
 
A relationship between HTR2C polymorphisms and serotonergic ADRs is consistent with what 
is known about the physiology of the side effects included in this grouping. Not only has 
experimental manipulation at the 5HT-2C receptor been connected to gut motility (Fujitsuka et 
al, 2009), sleep regulation (Uhr et al, 2000), sexual dysfunction (Heils et al, 1996) and feeding 
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behaviour (San et al, 2008), but antidepressants with prominent antagonistic effects at 5HT-2C 
are associated with reduced levels of serotonergic side effects, relative to other antidepressants 
(Hu et al, 2006; Lesch et al, 1996). Indeed, in one study, nausea, insomnia and diarrhoea were 
reported at higher levels by those taking placebo than by patients on agomelatine (Kennedy et 
al, 2002).  
 
However, when considering the GenPod sample, no association was found between 
serotonergic ADRs and variation in the HTR2C gene, in either the whole sample, nor in drug-
specific samples. Whilst the two studies were similar in design, this failure to replicate may have 
been due to differences that can be seen in the rates of reporting ADRs between the two 
samples; in GenPod, serotonergic ADRs are not only more frequently reported, but also do not 
show differences in reporting frequencies between patients taking serotonergic versus 
noradrenergic antidepressants. Another difference between the two studies is the frequency 
with which ADRs were measured after baseline (in GENDEP, twelve weekly measurements 
were taken, whilst in GenPod measurements were only taken at week six and week twelve). 
However, in a supplementary analysis of the GENDEP data, using only the information collected 
on week six and week twelve of the study, the positive association between serotonergic ADRs 
and genetic variation in the HTR2C was still observed (see Appendix D). This indicates that the 
non-replication in the GenPod sample cannot be attributed to the differences in the frequency of 
data collection. 
 
Other sources of variation between the studies include; differences in terms of the type of 
noradrenergic antidepressants administered (nortriptyline versus reboxetine) and the different 
scales used to index the ADRs (the ASEC versus the TSES). Nonetheless, it remains that the 
finding could not be replicated in GenPod and thus, may be a false positive association.  
 
3.5.3 Limitations 
The region surrounding each gene was tightly defined as 100bp up and downstream from the 
coding sequence, as described by Solovyev and Shahmuradov (2003). However, it may be that 
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more distant variants could play a role in determining individual risk to antidepressant side 
effects. To address this, a supplementary analysis was undertaken, where the region 
surrounding each candidate gene was expanded to cover 50KB up and downstream. This 
expanded approach was only possible within the GENDEP sample. The details of this analysis 
are included in Appendix D.  
 
The association of rs6644093 with serotonergic ADRs remained significant in this expanded 
analysis. Only one of the additional variants showed significant association with any of the four 
phenotypes (serotonergic, cholinergic, adrenergic and histaminergic ADRs) tested, when 
performing whole sample and drug-specific analyses. This variant (rs6467694) is 7318bp 
downstream from the CHRM2 gene transcript (this includes the UTR), and showed significant 
association with cholinergic outcomes in the whole sample analysis (OR=3.09, 95% CI=1.81-
5.29, p=3.75 x 10-5), but no significant association was seen in the drug-specific analysis. This 
indicates that the cholinergic side effects observed with antidepressants are linked to genetic 
variation in the muscarinic cholinergic receptor 2, which aligns with the known role of cholinergic 
receptors in these side effects. However, no other SNPs within this gene showed evidence of 
association (using the gene-wide suggestive threshold of p<0.00107), and the variant did not 
reach gene-wide significance in either of the drug-specific analyses. This is surprising given the 
highly drug-specific profile of cholinergic side effects, but may reflect limitations in statistical 
power due to sample size in these subset analyses. As it was not possible to replicate this 
analysis within the GenPod dataset, and the lack of suggestive signal from other SNPs included 
in this gene, the association between CHRM2 and cholinergic side effects should be treated 
with caution until further evidence of association is found.  
 
A fundamental issue when addressing drug-induced adverse reactions is the frequency with 
which depressed patients report complaints considered as ADRs prior to receiving any 
antidepressant medication. This blurs the line between depressive symptoms themselves and 
unwanted side effects that result from treatment of depression, and represents a complex issue 
to disentangle. However entering baseline reports of ADRs and depression symptom scores as 
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covariates into the analysis helps to ensure the associations between genotype and side effects 
that are seen here are not driven by some factor linked to illness severity.  
 
Arguably, the most important limitation in terms of detecting genetic associations with 
antidepressant side effects is treatment discontinuation. As has been highlighted, 
antidepressant discontinuation is strongly associated with the experience of side effects (Bull et 
al, 2002; Mitchell, 2006). Therefore, it is likely that those experiencing more severe side effects 
were more likely to drop out of research projects early. The general pattern of side effect ratings 
in GENDEP support this proposal, as ratings were consistently higher in the week prior to drop 
out in those discontinuing treatment than in those who remained in the study. This non-
randomly missing data may bias the findings presented here; however this bias is towards the 
null, and may result in an underestimate of genotype-ADR associations. 
 
3.5.4 Conclusions 
In this chapter, antidepressant ADRs were categorised using knowledge about their shared 
underlying pharmacological basis. However, when relating the variability seen in the 
appearance of these pharmacologically-defined side effect groups to genetic polymorphisms 
within those receptors, predictors of ADRs could not be identified for adrenergic, cholinergic or 
histaminergic side effects. Significant associations were observed between the occurrence of 
serotonergic side effects and variability within the HTR2C gene in the GENDEP sample, 
however this finding could not be confirmed using GenPod as a replication dataset.  
 
On expansion of the regions considered surrounding the candidate genes, the HTR2C 
association with serotonergic side effects remained significant. An additional association 
observed between a single variant in CHRM2 and cholinergic side effects were seen in the 




 If robust predictors of specific sub-types of antidepressant side effects could be identified 
(genetic, or otherwise), patients with a high risk of suffering from particular subtypes of side 
effects could be identified prior to treatment commencement, and treatment options guided 
accordingly. Whilst the results presented here provide evidence of potential genetic 
underpinnings of antidepressant ADRs, the absence of replication indicates caution in 
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4.1.1 Role of CYP450 enzymes in the metabolism of antidepressants 
CYP450 enzymes are involved in the metabolism of 75% of marketed drugs (Guengerich, 
2008). As outlined in the Introduction, a number of common polymorphisms in the genes 
encoding the CYP450 enzymes are associated with differences in enzyme activity. Given that 
variability in the rate of drug metabolism could alter the concentrations of active compound, it 
has been suggested that genotyping the CYP450 enzymes may allow many drug therapies to 
be “personalised” by matching drug doses to an individual’s genetically predicted drug 
metabolism rate (Ingelman-Sundberg, 2004).  
 
Antidepressants are amongst those drugs that are metabolised by CYP450 enzymes. With 
reference to those antidepressants studied in GENDEP, the tricyclic antidepressant nortriptyline 
is metabolised to both cis- and trans- forms of 10-hydroxynortriptyline via the CYP2D6 enzyme 
(Olesen et al, 1997a). In contrast, three CYP450 enzymes are involved in the metabolism of 
escitalopram to its primary metabolite desmethylescitalopram; CYP3A4, CYP2C19 and, to a 
lesser extent, CYP2D6 (Olesen and Linnet, 1999). 
 
4.1.2 Impact of genetic variability in CYP450 enzymes 
Genetic variation in the CYP3A4 gene has been reported to be rare and have little impact on 
enzymatic activity (Lamba et al, 2002). However, genetic differences in CYP2C19 and CYP2D6 
do have functional consequences on enzymatic activity (De Morais et al, 1994; Eichelbaum et 
al, 1979; Ferguson et al, 1998; Mahgoub et al, 1977; Tucker et al, 1977).  
 
Previous reports have found that the genetic variation in CYP2C19 is related to serum 
concentrations of escitalopram in patients being treated with the antidepressant; this has been 
found both within a subset of the GENDEP sample (Huezo-Diaz et al, 2012) and in other 
datasets (Rudberg et al, 2006; Rudberg et al, 2008). Similarly nortriptyline concentrations have 
been associated with polymorphisms in CYP2D6, albeit in smaller sample sizes (Dahl et al, 
1996; Murphy et al, 2001). 
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Whilst previous literature indicates there is a relationship between CYP450 genotypes and 
antidepressant serum concentrations, this has not been translated robustly into clinically 
important differences in treatment response. Kirchheiner and colleagues reviewed the 
relationship between CYP450 genotypes in CYP2D6 and CYP2C19 and serum concentration of 
drug, attempting to establish genotype-specific dose adjustments for a range of 
antidepressants, but they did not examine the effect on treatment outcome (Kirchheiner et al, 
2001; Kirchheiner et al, 2004). More recent studies into the role of CYP450 genetic variation on 
antidepressant treatment response report discrepant findings (Mrazek et al, 2011; Peters et al, 
2008; Tsai et al, 2010). The results of a pilot study (Hall-Flavin et al, 2012) suggested outcomes 
could be improved amongst depressed patients when treatment is directed by a 
pharmacogenomics algorithm which included information on cytochrome P450 genotypes. 
However the sample size in this pilot study was small, and the information contained within the 
algorithm is not limited to drug metabolising genes, but also encompasses genes involved in the 
serotonergic system. To date, there remains a lack of direct evidence for a relationship between 
CYP450 genotype and differences in antidepressant treatment outcomes. 
 
4.1.3 Serum concentrations of antidepressant 
Whilst CYP450 genotype is observed to play a role in determining serum concentration of 
antidepressant, other factors such as diet, comedication and comorbidities are also known to 
contribute to the large inter-individual variability observed in serum concentrations (Reis et al, 
2009).  Therefore, measuring serum levels of antidepressant allows us to consider both genetic 
and environmental influences together in order to understand the role that drug metabolism 
differences may have on treatment response.  
 
Previous work reporting a curvilinear relationship between peripheral concentrations of 
circulating nortriptyline and treatment response may indicate a complex relationship between 
serum drug levels and treatment response (Asberg et al, 1971; Perry et al, 1994). But when 
investigating citalopram (the racemic form of escitalopram), evidence indicates there is not a link 
between serum concentrations of antidepressant and likelihood of treatment response (Dufour 
et al, 1987; Nikisch et al, 2004; Rasmussen et al, 2000). Nevertheless, a recent study observed 
that patients with citalopram levels above 50µg/L had improved scores of depression severity 
than those with levels below this concentration (Ostad Haji et al, 2011).  
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The Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP) 
Consensus Guidelines for 2011 (Hiemke et al, 2011) recommend therapeutic dose monitoring 
for both nortriptyline and citalopram. However, particularly in the case of citalopram, this is 
based on evidence predominantly related to the observed variability in the pharmacokinetics of 
the drug, rather than direct tests of the relationship with serum levels of the drug and treatment 
outcomes.  
 
4.1.4 Aims  
This chapter aims to directly test the relationship between genetic variation in CYP450 
enzymes, serum concentration of antidepressants and response to treatment. Using the data 
available in GENDEP, the three objectives of this chapter were to: (1) to replicate previous work 
showing that CYP450 genotype influences serum concentrations of antidepressant; (2) to 
examine whether CYP450 genotype predicted antidepressant treatment response; and (3) to 





Participants included in this chapter are drawn from the GENDEP sample, as described in detail 
in Chapter  2.2. Figure 4-1 shows the patients included in analyses presented in this chapter.  
 
4.2.2 CYP450 Genotypic information 
As described in Chapter 2.6.1, genotyping of the CYP450 enzymes CYP2C19 and CYP2D6 
was achieved using the Roche AmpliChip CYP450 (Roche Molecular Diagnostics, Alameda, 
CA, USA). Functional annotations were made for each of the alleles contained on the 
microarray using information as described by the Human Cytochrome P450 (CYP) Allele 
Nomenclature Database (http://www.cypalleles.ki.se/). Allele frequencies across the entire 
GENDEP sample are reported in Table 4-1 and Table 4-2.  
 
After annotations were assigned to each allele, genotypic classification was performed. We 
used four categories to classify CYP2D6 genotypes; poor (PM), intermediate (IM), extensive 
(EM) or ultrarapid (UM) metabolisers (Rebsamen et al, 2009). For CYP2C19, we used six 
categories; poor (PM), intermediate (IM), intermediate plus (IM+), extensive (EM), extensive 
plus (EM+) or ultrarapid (UM) metabolisers (Mrazek et al, 2011). The allele frequencies in each 












CYP2C19 & CYP2D6 
N=443 
Serum measurements  








available for week 8 
N=279 
Dose information 





Treatment response data available 
N=839 
Figure 4-1: Sample included in Chapter 4 
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Table 4-1: Functional annotations for alleles identified in CYP2D6 






















*10 x N - 
*17 x N - 






*1 x N 13 
*2 x N 17 








Table 4-2: Functional annotations for alleles identified in CYP2C19 
Functional consequence Allele name (CYP nomenclature) Frequency in GENDEP sample 
Decreased *2 249 
Normal *1 999 




Table 4-3: Frequencies of genotypic categories for CYP2D6 amongst patients taking nortriptyline. (Total 
N=334)
 Genotypic group Classification criteria 
Frequency in GENDEP sample 
N % 
PM 2 non-functional alleles 23 6.89 
IM 1 non-functional, 1 decreased / 2 decreased alleles 23 6.89 
EM At least 1 wild type allele 281 84.13 
UM At least 3 copies of a wild type allele 7 2.10 
 
Table 4-4: Frequency of genotypic categories for CYP2C19 and CYP2D6 amongst patients taking 
escitalopram. (Total N=443) 
Genotypic group Classification criteria 
Frequency in GENDEP sample 
N % 
CYP2C19 
PM *2/*2 6 1.35 
IM *1/*2 85 19.19 
IM+ *17/*2 34 7.67 
EM *1/*1 176 39.73 
EM+ *17/*1 115 25.96 
UM *17/*17 27 6.09 
CYP2D6 
PM 2 non-functional alleles 34 7.67 
IM 1 non-functional, 1 decreased / 2 decreased alleles 37 8.35 
EM At least 1 wild type allele 354 79.91 
UM At least 3 copies of a wild type 
allele 18 4.06 
 
4.2.3 Serum concentrations of antidepressant 
As described in Chapter  2.5, concentrations of antidepressant (escitalopram/nortriptyline) and 
primary metabolite (desmethylescitalopram/total 10-hydroxynortriptyline) were measured in 
blood samples taken at week eight of antidepressant treatment. For ease of interpretation, 
standardised serum measurements were calculated, with a mean of 0 and a standard deviation 
of 1. The ratio of metabolite to drug concentration was also calculated.  
 
Daily prescribed dose of antidepressant was recorded. Of those with serum measurements, 
86.84% had information available on the dose of antidepressant taken that week. For additional 




As described in Chapter 2.3.1, patients reported all medications taken throughout the study, in 
addition to the prescribed antidepressant. These comedications were categorised using the 
FDA classification of in vivo inhibitors or inducers (FDA, 
2011)http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInt
eractionsLabeling/ucm093664.htm%23classInhibit. In week eight (the week that blood samples 
were taken for serum concentration measurements), 4.51% of patients with serum 
concentration data reported taking a CYP2C19 and/or CYP2D6 inhibiting drug, but no patients 
reporting taking CYP2C19 and/or CYP2D6 inducing drugs. The specific drugs reported are 
shown in Table 4-5 and Table 4-6.  
Table 4-5: CYP450-inhibiting comedication reported by patients prescribed escitalopram (N=319). 
 Drug taken CYP450 Enzymes Inhibited Number of patients 
Combined Oral Contraceptive Pill CYP2D6 and CYP2C19 11 
Diltiazem CYP2D6 1 
Propafenone CYP2D6 1 
Verapamil CYP2D6 1 
Omeprazole CYP2C19 1 
 
Table 4-6: CYP2D6-inhibiting medication reported by patients prescribed nortriptyline (N=213)
 Drug taken CYP450 Enzymes Inhibited Number of patients 
Combined Oral Contraceptive Pill CYP2D6 and CYP2C19 8 
Amiodarone CYP2D6 1 
Ranitidine CYP2D6 1 
 
4.2.5 Treatment response  
Treatment response was measured using the MADRS, as detailed in Chapter 2.4.1. All weekly 
ratings of depression severity were used within a repeated measures design. 
 
4.2.6 Statistical analysis 
All analyses were performed using STATA 11 (StataCorp., 2009). Given the different metabolic 




For escitalopram, CYP2C19 was examined as the relevant CYP450 genotype and we included 
CYP2D6 genotype as a fixed effect covariate given the smaller reported role of the CYP2D6 
enzyme (Olesen et al, 1999). For nortriptyline, CYP2D6 was used as the relevant CYP450 
genotype in the nortriptyline-specific analysis.  
 
To account for the clustering of individuals around recruitment centres, mixed models were 
used (fitted with maximum likelihood); centre was entered as a random effect. Fixed effects 
included age and sex.  
 
4.2.6.1 CYP450 genotype predicting serum concentrations of antidepressant 
The first stage of the analysis aimed to examine CYP450 genotype as a potential predictor of 
three standardised serum measures; concentrations of the antidepressant, its primary 
metabolite, and the metabolite to drug ratio. Cytochrome P450-inhibiting comedications were 
included as a fixed effect in the model.  
 
4.2.6.2 CYP450 genotype predicting treatment response 
The second stage of the analysis aimed to examine CYP450 genotype as a potential predictor 
of treatment response (using weekly measures as described above). Fixed effects of baseline 
depression severity, cytochrome P450-inhibiting comedications and both linear and quadratic 
effects of time were included. Given the longitudinal analysis of response, individual was 
included as a random effect (in addition to recruitment centre).  
 
4.2.6.3 Serum concentration of antidepressant predicting treatment response 
The final stage of the analysis considered whether serum concentrations of antidepressant were 
predictive of treatment response. Three potential predictors were explored: concentrations of 
drug, primary metabolite and ratio of metabolite to drug. For any significant associations, the 
analysis was repeated, with dose included as a fixed effect. This is particularly important in light 
of the flexible dosing protocol used in GENDEP, where daily drug dose could be altered over 
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the course of the study if necessary (for example, in response to limited improvement in 
depressive symptoms).  
 
Given previous reports of a curvilinear association between serum concentration and response 
to treatment with nortriptyline (Asberg et al., 1971), an additional analysis of the relationship 
between serum concentration of antidepressant and treatment response was also performed, 
where serum measurements were centred and then squared.   
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4.3 Results 
4.3.1 Descriptive statistics 
4.3.1.1 CYP450 genotype 
The observed CYP450 genotypic frequencies match those expected in Caucasian populations, 
with the most common genotypic group being EM (extensive metaboliser) for both CYP450 
enzymes (de Leon et al, 2006; Mrazek et al, 2011; Rebsamen et al, 2009). Genotype was 
unrelated to recruitment centre, baseline depression severity, age, dose or sex, in either those 
taking escitalopram or nortriptyline.  
 
4.3.1.2 Serum concentration of antidepressant 
4.3.1.2.1 Serum concentrations and dose of antidepressant prescribed 
The mean serum concentrations of antidepressant are shown in Table 4-7, along with the 
prescribed daily dose of antidepressant for week eight of the study. Serum levels are 
comparable to those observed in other studies (Foglia et al, 1997; Vandel et al, 1978). 
Table 4-7: Daily prescribed dose and serum concentration of drug 
Drug taken  N Mean SD 
Escitalopram 
Daily dose (mg) 279 15.99 6.40 
Serum escitalopram (µg/L) 319 29.04 18.40 
Serum desmethylescitalopram (µg/L) 230 10.99 5.07 
Nortriptyline 
Daily dose (mg) 183 103.66 32.25 
Serum nortriptyline (µg/L) 213 91.07 57.99 
Serum total 10-hydroxy-nortriptyline (µg/L) 205 65.74 51.54 
 
Concentrations of drugs and primary metabolites were unrelated to age in this sample. Females 
had significant higher concentration of both escitalopram (female; M=31.36, SD=19.30, male; 
M=24.50, SD=19.29; t(317)=-3.20, p=0.0015) and desmethylescitalopram  (female; M=11.46, 
SD=5.28, male; M=9.88, SD=4.34, t(228)=-2.16, p=0.032).  No significant differences were 
observed between males and females for nortriptyline and 10-hydroxynortriptyline 
concentrations. As expected, dose was significantly related to serum levels of antidepressant 
measured at week eight (see Figure 4-2).  
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Figure 4-2: Relationship between dose and serum level of antidepressant.  
All associations are highly significant (p<0.0001). Proportion of variance explained by dose in each of the 
analyses; A) 0.29 B) 0.36 C) 0.08 D) 0.21.   
 
There were also differences between centre of recruitment in terms of serum concentrations of 
antidepressant, daily dose prescribed and also in dose-adjusted serum concentrations of 
antidepressant and metabolite (Table 4-8). This emphasises the importance of including 
recruitment centre as a random effect in all models.  
Table 4-8: Variation between recruitment centres in dose and dose-adjusted serum concentration in 
GENDEP 
Drug taken Analysis F-statistic p-value 
Escitalopram 
Daily dosage (8,270)=14.70 8.00 x 10-18 
Dose-adjusted escitalopram level (8,248)=3.45 0.0009 
Dose-adjusted desmethylescitalopram level (8,188)=2.34 0.0201 
Nortriptyline 
Daily dosage (8,174)=10.67 3.76 x 10-12 
Dose-adjusted nortriptyline level (8,160)=3.04 0.0033 
Dose-adjusted 10-hydroxynortriptyline level (7,158)=6.40 1.23 x 10-6 
 
4.3.1.2.2 CYP450-inhibiting comedication and serum concentrations 
All the CYP450-inhibiting comedications reported (see Table 4-5 and Table 4-6) were classified 
by the FDA as “weak” inhibitors of CYP2D6 or CYP2C19. Amongst patients on escitalopram, 














































































































escitalopram (M=40.41, SD=18.04) than those not taking these medications (M=28.51, 
SD=18.27; t(317)=-2.38, p=0.0178). These comedications did not affect desmethylescitalopram 
concentrations. Patients taking nortriptyline along with CYP2D6-inhibiting comedications had 
higher concentrations of nortriptyline (M=145, SD=45.14) than those without comedications 
(M=88.69, SD=57.42; t(211)=-2.90, p=0.0041). They also had significantly higher levels of total 
10-hydroxnortriptyline (M=102.33, SD=58.82,) than those without comedications (M=64.06, 
SD=50.72; t(203)=-2.20, p=0.0290). All analyses included CYP450-inhibiting comedications as 
a covariate. Additionally, when those individuals taking CYP450-inhibiting comedications are 
excluded from the analysis, the pattern of findings remained unchanged. 
 
4.3.1.2.3 Comparison of participants with and without serum measurement data available 
As can be seen from Figure 4-1, serum measurements were not available for all participants. 
Therefore, differences between those participants where serum measurements were available 
and those where this data was missing were explored.  
 
There were no observed differences between those with and without serum measurements in 
age, sex, baseline depression severity or CYP450 genotype.  
 
However, significant differences were observed in terms of treatment response outcomes. Of 
those without serum measurements, 52% had dropped out of the study prior to week eight of 
the trial. Nevertheless, a comparison of treatment response as measured by adjusted 
percentage change in MADRS scores (Uher et al, 2010) in those cases who had remained in 
the study until at least week eight found significant differences (t(653)=3.13, p=0.0018); those 
with serum measurements available (M=4.40, SD=27.39) were more likely to have responded to 




4.3.2 CYP450 predicting serum concentrations of antidepressant 
4.3.2.1 Escitalopram  
Genetic variation in CYP2C19 significantly predicted serum concentration of escitalopram 
(n=264, ß=-0.232 SE=0.044, p=1.06x10-7); genotypes that encode more active forms of the 
CYP2C19 enzyme were associated with lower levels of escitalopram. CYP2C19 genotype was 
not associated with concentration of desmethylescitalopram (n=196, ß=0.085 SE=0.048, 
p=0.072), but was significantly associated with the ratio of desmethylescitalopram to 
escitalopram (n=195, ß=0.281, SE=0.054, p=2.31x10-7); higher levels of enzyme activity were 
associated with higher metabolite to drug ratios (Figure 4-3). 
 
4.3.2.2 Nortriptyline 
Genetic variation in CYP2D6 significantly predicted dose-adjusted levels of both nortriptyline 
(n=173, ß=-0.562 SE=0.107, p=1.64x10-7) and total 10-hydroxy-nortriptyline (n=168, ß=0.327, 
SE=0.106, p=0.0021). Genotypes encoding more active forms of the CYP2D6 enzyme were 
linked to lower serum concentrations of nortriptyline and higher concentrations of total 10-
hydroxy-nortriptyline. Genetic variation linked to higher levels of CYP2D6 activity were 
associated with higher 10-hydroxy-nortriptyline to nortriptyline ratios (n=167, ß=0.496, 




Figure 4-3: Relationship between CYP2C19 genotype and serum concentration of escitalopram.  
















































































































































































































































































































4.3.3 CYP450 genotype and treatment response 
There was no significant relationship between genetic variation in CYP450 enzymes and 
response to treatment with antidepressants in either of the two medications examined in this 
study (escitalopram, n=443, p=0.478, ß=0.165, SE= 0.233; nortriptyline, n=334, p=0.807, 
ß=0.127, SE=0.524).  
 
4.3.4 Serum concentration of antidepressant and treatment response 
For patients taking escitalopram, there was a significant association between serum 
concentrations of escitalopram and treatment response (n=319, p=0.004, ß=0.932, SE=0.321). 
However, this association was not in the expected direction, with higher serum concentrations 
of escitalopram predicting poorer treatment response. When drug dose was added as a 
covariate, this association no longer reached significance (p=0.207). Neither 
desmethylescitalopram concentrations nor the ratio of desmethylescitalopram to escitalopram 
significantly predicted response.  
 
In those patients taking nortriptyline, higher concentrations of total 10-hydroxy-nortriptyline were 
significantly linked to poorer treatment response (n=205, p=0.006, ß=1.144, SE=0.416). Again, 
this association no longer reached significance when dose was entered as a covariate 
(p=0.183). There was no significant association between treatment response and with 
concentration of nortriptyline or metabolite to drug ratio. 
 
There was no evidence of a curvilinear relationship between treatment response and serum 







4.4.1 Summary of results 
4.4.1.1 CYP450 genotype 
This analysis has shown that CYP450 genotype predicts serum concentration of antidepressant 
for patients taking either escitalopram or nortriptyline. However, there is no relationship between 
CYP450 genotype and treatment response for the patients in GENDEP.  
 
4.4.1.2 Serum concentration of antidepressant  
Contrary to expectations, higher concentrations of drug predicted poorer treatment response for 
patients taking escitalopram, and higher concentrations of metabolite predicted poorer 
treatment response for patients taking nortriptyline. However, controlling for the effects of drug 
dosage removes these effects, indicating that it is likely that the relationship between serum 
concentration and poor response is due to the dosing protocol used in GENDEP. Serum 
samples were taken after eight weeks of treatment, during which time clinicians were able to 
follow a protocol-driven flexible dosing schedule, informed by depressive symptoms and side 
effects. Thus, higher drug doses were prescribed to those patients who were failing to 
adequately respond to treatment. No evidence of a curvilinear association between serum 
concentration and treatment response was observed for either antidepressant.  
 
4.4.2 Comparison to previous literature  
4.4.2.1 CYP450 genotype 
The evidence presented here does not support early hopes that pharmacogenetic examination 
of pharmakinetic processes would prove clinically useful (Ingelman-Sundberg, 2004). Whilst the 
association between CYP450 genotype and serum concentration is as previously reported 
(Dahl et al, 1996; Huezo-Diaz et al, 2012; Kirchheiner et al, 2001; Kirchheiner et al, 2004; 
Murphy et al, 2001; Rudberg et al, 2008), this association cannot be  translated into differences 




This is in line with a report from the US-based antidepressant study STAR*D, where response 
to treatment with citalopram was assessed in relationship to CYP2C19 genotype in a sample of 
nearly 2,000 subjects (Peters et al, 2008). Nevertheless, a second paper on the same sample 
drew contradictory conclusions, reporting some evidence of a link between CYP450 genotype 
and response (Mrazek et al, 2011). In this analysis, we have not only replicated the finding of 
Peters et al, but also extended this to include the tricyclic antidepressant nortriptyline.  
 
4.4.2.2 Serum concentration 
Furthermore, GENDEP is the largest study to date to incorporate measurements of 
antidepressant serum concentrations and together with comprehensive CYP450 genotypic 
information. Our failure to find links between serum concentration and treatment response 
seems to be consistent with the majority of studies looking at citalopram (Dufour et al, 1987; 
Nikisch et al, 2004; Rasmussen et al, 2000), but is in contrast to classical work looking at serum 
levels for nortriptyline (Asberg et al, 1971; Perry et al, 1994), which indicated there may  be a 
curvilinear association between serum concentration and treatment response.  
 
4.4.3 Methodological considerations 
4.4.3.1 Power calculation 
In light of the negative associations reported here, a post-hoc power calculation was undertaken 
to establish the statistical power that this sample has to detect clinically meaningful effects of 
drug metabolism enzymes. Uher et al. (2012) calculated that for studies addressing predictors 
of antidepressant treatment outcomes, continuous biomarkers (such as serum levels in this 
study) should explain at least 6.3% of the variance in treatment response in order to be clinically 
significant.  Using G*Power (http://www.psycho.uni-
duesseldorf.de/abteilungen/aap/gpower3/download-and-register), it was calculated that a 
sample size of n=120 would be needed to detect an effect size of this magnitude with p=0.05, 
and power of 80%. Each analysis presented here exceeds that sample size, so is adequately 
powered to detect clinically significant associations between serum levels of antidepressant and 
treatment response. Thus the failure to observe an association with treatment response cannot 




4.4.3.2 Multiple-hypothesis testing  
No formal multiple-hypothesis testing corrections were applied to control for false positive 
associations, in light of the interdependence of the measures explored here. Nonetheless, the 
key significant findings of CYP450 genotype being associated with antidepressant concentration 
are highly significant (escitalopram; p=1.06x10-7, nortriptyline; p=1.64x10-7), and so are unlikely 
to be false positives. Neither CYP450 genotype nor dose-adjusted serum levels predicted 
treatment response, even at the uncorrected cut-off for statistical significance of p<0.05.  
 
4.4.3.3 CYP450 genotypic categorisation 
There remains some debate over the most appropriate model to use when categorising 
CYP450 genotypes. CYP2C19 genotypic variation has been categorised into  six subgroups 
(Mrazek et al, 2011), four subgroups (Brandl et al, 2014), or two categories (Peters et al, 2008); 
in this study the six category model was used, as by Mrazek et al., because this model utilises 
the full information obtained by genotyping the more recently reported *17 allele (Sim et al, 
2006). Similarly, CYP2D6 can be considered within a model of 4 genotypic categories (Brandl et 
al, 2014; Rebsamen et al, 2009) or two categories (Peters et al, 2008), here the 4 category 
model was used as the more comprehensive option. However, the pattern of results reported 
here, where CYP450 genotype predicts dose-adjusted serum levels of antidepressants but not 
treatment response, remain robust to the use of alternative models of CYP450 genotype 
grouping. 
 
4.4.4 Study limitations 
Despite the robustness of the findings to these methodological considerations, there remain 
limitations to the study. 
4.4.4.1 Treatment response biases 
Whilst there are no significant differences in baseline characteristics and CYP450 genotype 
between patients with and without serum data, in those patients where the relevant data is 
available, treatment response is significantly better amongst those with serum measurements. 
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This may be a source of bias in the study. The reasons for this are not known, but potentially, 
those patients with greater improvement in depression symptoms may be more likely to be fully 
engaged in the study, and so consent to the additional blood sample taken at week eight of the 
study.  
 
4.4.4.2 Recruitment centre variation 
Significant differences in serum concentration are observed between recruitment centres, even 
after dose-adjustments are made. Given that CYP450 genotype shows no association with 
recruitment centre, these variations may be due to environmental differences between 
populations recruited to the different centres across Europe; for example diet is known to affect 
drug metabolism rates (Conney et al, 1980). Whilst recruitment centre is added as a random 
effect in all analyses, these differences add variability to the data. 
 
4.4.4.3 Flexible dosing protocol 
Finally, the flexible dosing protocol used in GENDEP means that dosage was titrated according 
to clinical need (in response to non-response or the occurrence of side effects). Therefore, our 
conclusions indicate the extent to which data on CYP450 genotypes and serum concentrations 
of antidepressants are predictive of treatment response when used in addition to clinical 
observation, but cannot be extended beyond this.  
 
4.4.5 Conclusions 
CYP450 enzymes play a key role in the metabolism of antidepressants, and the efficacy of 
these enzymes varies across the population as a result of genotypic differences. This chapter 
has shown that these genetic factors have a significant impact on serum concentrations of 
antidepressants in this sample. However, CYP450 genotype could not be used as a predictor of 
treatment response and there was no clear relationship between serum concentrations of 
antidepressant and differences in treatment response in this study. Therefore, within the context 
of clinical observation and a flexible dosing protocol, drug metabolism variability appears to be 
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uninformative regarding treatment response.  In the next chapter, the effects of drug metabolism 














5.1.1 The importance of side effects as an antidepressant treatment outcome 
As noted in Chapter 3, antidepressant medications are associated with a number of unwanted 
side effects (or adverse drug reactions) including dry mouth, sexual dysfunction and 
gastrointestinal symptoms. Whilst selective serotonin reuptake inhibitors (SSRIs) were 
developed and marketed as drugs with improved tolerability compared to the older tricyclic 
antidepressants (Whyte et al), and indeed are safer in overdose, side effects with these newer 
drugs are still high. Estimates vary, but the frequency of adverse drug reaction (ADRs) with 
SSRI treatment has been observed to be as high as 75% (Meijer et al, 2002).  
 
Side effects play an important role in clinical decision-making when prescribing antidepressants; 
it is known that the experience of adverse drug reactions is strongly associated with 
discontinuation and poor treatment adherence (Bull et al, 2002; Mitchell, 2006). As would be 
expected, inadequate antidepressant treatment results in increased levels of relapse (Kennedy 
et al, 2002) as well as increased health costs (Masand, 2003). Therefore, the ability to predict 
which individuals are at higher risk of experiencing side effects or discontinuing treatment would 
be useful in a clinical setting.  
 
5.1.2 Role of drug metabolism rates in risk for side effects 
The value of exploring adverse drug reactions in relation to drug metabolism variability is 
underscored by examples within other medical areas. For example, for the anticoagulant 
warfarin, the observed association between drug metabolism rates and adverse drug reactions 
has led to therapeutic dose monitoring being used as standard within NHS treatment guidelines, 
and extensive research into the viability of translating a pharmacogenetic test for clinical use 
(Gage et al, 2008; Kangelaris et al, 2009).  
 
Considering adverse drug reactions to antidepressant treatment, the Clinical Pharmacogenetics 
Implementation Consortium issued guidelines in 2013 regarding dosing of tricyclic 
antidepressants (Hicks et al, 2013). With reference to nortriptyline, the consortium concluding 
103 
 
that there was strong evidence to avoid nortriptyline or amitriptyline (which is metabolised in the 
body to nortriptyline) amongst CYP2D6 poor metabolisers due to potential for side effects. 
However, much of this evidence is based on the observed relationship between CYP450 
genotype and serum concentrations of antidepressant; there is a paucity of evidence evaluating 
whether CYP450 genotype is associated with treatment outcomes in patient samples. 
Nevertheless, the guidelines do reference two studies which observe associations between 
drug metabolising variables and measures of adverse reactions to tricyclic antidepressants (Bijl 
et al, 2008; Steimer et al, 2005).  
 
With reference to SSRIs, a comprehensive review in 2007 found six studies exploring the 
relationship between CYP450 genotype and side effects, four of which reported no association. 
However, the authors of the review highlighted the limited power of these studies and concluded 
that no firm conclusions could be drawn regarding the association between CYP450 genotype 
and SSRI-associated ADRs.  
 
Since this review was published, the role of genetic variation in the CYP450 enzymes for 
patients taking SSRIs has been further explored in the STAR*D study, with two reports 
exploring treatment tolerance alongside response measures (Mrazek et al, 2011; Peters et al, 
2008). Treatment tolerance in STAR*D was assessed using study exit data and patient 
decisions on whether to continue with citalopram treatment. Mirroring the findings in treatment 
response (detailed in Chapter 4), whilst one report found no evidence of association with 
tolerance amongst patients taking citalopram (Peters et al, 2008), a more recent paper based 
on the same data concluded that there was evidence of a link between CYP450 genotype and 
tolerance (Mrazek et al, 2011). 
 
5.1.3 Aims 
In light of the importance of adverse drug reactions in determining outcomes to antidepressant 
treatment, and the lack of clear evidence demonstrating links between drug metabolism rates 
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and ADRs, this chapter aims to extend the work of Chapter 4, examining the potential links 
between rates of drug metabolism and antidepressant side effects.  
 
The in-depth data available in the GENDEP sample allows a detailed analysis of side effects 
reported with antidepressant treatment. Firstly side effect burden was considered as a 
quantitative trait, by totalling the number of side effects reported, per individual, per week. 
Secondly, the relationship between drug metabolism and each specific ADR was explored. This 
approach allows consideration of the differences between side effects in terms of their 
pharmacological basis.  
 
As with the analysis in Chapter 4, drug metabolism rates were considering in two ways; firstly 
using genotypic information from the CYP450 enzymes of relevance, and secondly using serum 
concentrations of drug, which allow us to capture the combined effects of both genetic and 
environmental influences on drug metabolism rates.  
 
Finally, we explored the association between CYP450 genotype and study drop out, to enable 







Participants included in this chapter are drawn from the GENDEP sample, as described in detail 
in Chapter 2.2. Figure 5-1 shows the patients included in analyses presented in this chapter.  
 
5.2.2 CYP450 genotypic information 
The genotyping of CYP2C19 and CYP2D6, using the Roche AmpliChip is described in detail in 
Chapter 2.6.1, with the functional annotations and genotypic frequencies detailed in Chapter 4. 
In brief, four genotypic categories were used to classify CYP2D6 genotypes (PM, IM, EM and 
UM; (Rebsamen et al, 2009), whilst CYP2C19 was classified into 6 genotypic categories (PM, 
IM, IM+, EM, EM+, UM (Mrazek et al, 2011).  
 
5.2.3 Serum concentrations of antidepressant 
Serum concentrations of drug (escitalopram or nortriptyline) and primary metabolite 
(desmethylescitalopram or total 10-hydroxynortriptline) were measured in blood samples taken 
at week eight of treatment, using achiral turbulent flow liquid chromatography as outlined in 
Chapter 2.5. These values were standardised, with a mean of 0 and a standard deviation of 1. 
The ratio of metabolite to drug concentration, and total concentration of drug plus metabolite 
were also calculated.  
 
5.2.4 Comedications 
Reported comedications that may act as CYP450 enzyme inducers or inhibitors were identified 
using FDA guidelines (FDA, 2011). In the week that we took the blood sample for the 
measurement of serum levels, 5.81% of patients with data on both serum concentration of 
antidepressant and side effects reported taking a CYP2C19 and/or CYP2D6 inhibiting drug, but 
no patients reporting taking CYP2C19 and/or CYP2D6 inducing drugs. 
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CYP2C19 & CYP2D6 
N=366 
Serum measurements  








available for week 8 
N=255 
Dose information 





Side effect data available (and baseline and 
for at least 1 week of the study) 
N=701 




5.2.5 Side effects 
Antidepressant side effects were measured weekly using the ASEC (see Chapter 2.4.2). Side 
effect scores were compiled from the ASEC in two ways. Firstly, the total number of ADRs 
experienced each week was calculated, to give a measure of the overall side effect burden for 
the patient. Secondly, the weekly presence or absence of each individual side effect was 
examined separately, to investigate ADR-specific effects.  
 
5.2.5.1 Study drop out 
Study drop out was also considered, using the recorded study end week for each participant 
(detailed in Chapter 2.4.3).  
 
5.2.6 Statistical analysis 
The analysis of side effects followed the same framework as described in Chapter 4, when 
exploring the outcome of treatment response. All analyses were performed using STATA 11 
(StataCorp., 2009). Given the different metabolic pathways of nortriptyline and escitalopram, all 
analyses were performed in a drug-specific manner.  
 
For escitalopram, CYP2C19 was examined as the relevant CYP450 genotype and we included 
CYP2D6 genotype as a fixed effect covariate given the smaller reported role of the CYP2D6 
enzyme (Olesen et al, 1999). For nortriptyline, CYP2D6 was used as the relevant CYP450 
genotype in the nortriptyline-specific analysis.  
 
5.2.6.1 CYP450 genotype predicting side effects 
To assess the relationship between CYP450 genotype and side effects, a longitudinal model 
including weekly ADR scores was used. To account for the clustering of individuals around 
recruitment centres, mixed models were used (fitted with maximum likelihood); centre was 
entered as a random effect along with individual. Fixed effects included age, sex, cytochrome 
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P450-inhibiting comedication, current depression severity, baseline ADR rating and linear and 
quadratic effects of time.  
 
The inclusion of baseline depression severity was to ensure that reports of ADRs were not 
confounded by depressive symptoms (Uher et al, 2009a), whilst the inclusion of baseline ADR 
ratings was necessary to ensure ADRs were in fact associated with the antidepressant being 
taken, in the context of high endorsement of ADRs prior to treatment (see Chapter 3).  
 
Associations with total ADR burden were tested using linear models, whilst the weekly 
presence/absence of each specific ADR was examined using logistic models. When considering 
the specific ADRs, in order to correct for the 21 different outcomes, a Bonferroni correction for 
multiple hypothesis testing was applied; only associations where p<0.002381 were considered 
significant (0.05/21 = 0.002381).  
 
5.2.6.2 Serum concentration of antidepressant predicting side effects 
A longitudinal model was also used to assess the impact of serum concentration of 
antidepressant on side effects. Four standardised serum measures were considered; 
concentrations of the antidepressant, its primary metabolite, the metabolite to drug ratio and 
finally the total concentration of drug plus metabolite. Covariates were as described above, 
when considering CYP450 genotype prediction of side effects, with the exception that 
cytochrome P450-inhibiting comedication was not included in the model.  
 
For any ADRs which showed significant associations with serum concentration of 
antidepressant, secondary analyses were undertaken including dose as a covariate, to probe 




5.2.6.3 Drug metabolising enzymes predicting study drop out 
Finally, CYP450 genotype was considered as a predictor of time to study discontinuation, using 
a survival Cox proportional hazards model. Covariates of age, sex, centre, baseline depression 





5.3.1 Descriptive statistics 
The CYP450 genotype frequencies, serum concentration of antidepressants and relationship 
with dose are described in Chapter 4. Patterns of study drop out are described in Chapter 2. 
With regards to side effects, it was observed that frequencies differed between the two drugs 
(Uher et al, 2009a). The pattern of overall side effect burden is shown in Figure 5-2, with 









































































Figure 5-3: Prevalence of specific ADRs per week, per drug (A) 












































































































































































































Figure 5-4: Prevalence of specific ADRs per week, per drug (B) 
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Figure 5-5: Prevalence of specific ADRs per week, per drug (C) 
  


















































































5.4.1.1 Comparison of side effects in patients with and without serum measurements 
available 
Comparisons of baseline measures between patients with and without serum measurements 
available are also described in Chapter 4. When considering differences in terms of side effects 
(where measurements were available), amongst patients taking escitalopram, total ADR burden 
in week eight (when samples were taken for serum measurements) was unrelated to whether 
serum measurements of antidepressant concentration were available or not. However, total 
ADR burden was associated with whether serum measurements were available amongst 
patients taking nortriptyline (t(236)=-2.13, p=0.005); higher ADR burden was seen in those 
patients without serum measurements (M=4.91, SD=3.57, compared with patients with serum 
measurements; Mean=3.80, SD=3.28).  
 
5.4.2 CYP450 genotype and side effects 
CYP450 genotype predicted neither overall side effect burden nor specific side effects reports, 
for patients taking either escitalopram or nortriptyline.  
 
5.4.3 Serum concentration of antidepressant and side effects 
Furthermore, overall side effect burden was not predicted by any of the four measures of 
antidepressant serum concentration considered, for patients on either escitalopram or 
nortriptyline. 
Table 5-1 shows the results for prediction of overall side effect burden by both CYP450 
genotype and serum concentration of antidepressant.  
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Table 5-1: Prediction of overall side effect burden; all associations not significant 
Antidepressant Predictor n p coeff SE 
Nortriptyline 
CYP2D6 genotype 251 0.5638 -0.133 0.229 
nortriptyline 184 0.8534 -0.029 0.154 
10-hydroxynortriptyline 180 0.7323 0.063 0.183 
ratio (OH-nortriptyline: nortriptyline) 178 0.1895 0.232 0.176 
total (nortriptyline+OH-nortriptyline) 178 0.7975 0.044 0.170 
Escitalopram 
CYP2C19 genotype 340 0.9627 -0.004 0.084 
escitalopram 275 0.0852 0.250 0.145 
desmethylcitalopram 205 0.1587 0.248 0.175 
ratio (desmethylcitalopram:citalopram) 204 0.6945 -0.066 0.167 
total (citalopram+desmethylcitalopram) 204 0.1155 0.260 0.165 
 
For the majority of the 21 specific side effects considered, there was also no significant 
relationship with serum concentrations of antidepressant (details of non-significant associations 
for each individual ADR are in the Appendix E). However, there were three exceptions to this. 
 
Firstly, for all patients (taking nortriptyline or escitalopram), a significant association was seen 
between dry mouth and serum concentrations of both drug, metabolite and total level of drug 
plus metabolite (Table 5-2), although not ratio of metabolite to drug. When the effect of dose 
was removed, dry mouth was significantly associated with metabolite concentrations in patients 
taking nortriptyline (n=164, p=0.0011, OR=1.841, SE=0.345) and total drug plus metabolite 
concentration (n=163, p=0.0016, OR=2.082, SE=0.484). All other associations were no longer 
significant.  
Table 5-2: Relationship between serum concentrations and dry mouth  (significance threshold p<0.00238) 
Antidepressant Serum concentration n p OR SE 
Nortriptyline 
nortriptyline 184 0.0023 1.826 0.362 
OH-nortriptyline 180 1.20x10-4 2.100 0.405 
ratio (OH-nortriptyline: nortriptyline) 178 0.0406 1.406 0.234 
total (nortriptyline+OH-nortriptyline) 178 4.97x10-5 2.284 0.465 
Escitalopram 
escitalopram 275 6.69x10-4 1.480 0.170 
desmethylescitalopram 205 0.0018 1.420 0.159 
ratio (desmethylcitalopram:citalopram) 204 0.6162 0.931 0.133 
total (citalopram+desmethylcitalopram) 204 0.0012 1.496 0.186 
 
Secondly, amongst patients taking escitalopram, significant associations were observed 
between diarrhoea and the ratio of metabolite to drug (n=203, p=4.96x10-4, OR=0.597, 
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SE=0.088), which remained significant when covarying for dose (n=188, p=0.0013, OR=0.632, 
SE=0.090).  
 
Thirdly, for patients taking escitalopram, dizziness was significantly associated with 
concentration of metabolite (n=202, p=3.28x10-5, OR=1.564, SE=0.168). This association also 
remained significant after covarying for dose (n=188, p=1.05x10-6, OR=1.658, SE=0.172).  
 
5.4.4 CYP450 genotype predicting study drop out 
CYP450 genotype was unrelated to study discontinuation, for patients taking either 
escitalopram (n=376, p=0.118, Hazard Ratio=0.870, 95% CI=0.731-1.034), or nortriptyline 
(n=284, p=0.174, Hazard Ratio=1.300, 95% CI=0.891-1.898). The (non-significant) hazard 
ratios given describe the increase in relative risk of discontinuation, moving from less to more 




5.5.1 Summary of results 
Cytochrome P450 genotype did not predict overall side effect burden, any of the 21 specific 
ADRs measured, or study discontinuation in this sample. Further investigation, using serum 
concentration measures indicated that for both overall burden, and the majority of specific 
ADRs, there was also no relationship with circulating levels of antidepressant. Exceptions to this 
general pattern were observed for dry mouth, dizziness and diarrhoea.  
 
In the case of dry mouth, higher serum concentrations of antidepressant were linked to higher 
risk of the side effect for both escitalopram and nortriptyline. After adjusting for the influence of 
dose on serum concentration, the association with both metabolite and total serum 
concentration remained significant for patients taking nortriptyline.  
 
Amongst patients taking escitalopram, associations of diarrhoea with the ratio of metabolite to 
drug, and dizziness with concentration of metabolite were observed; both of these associations 
also remain significant after adjusting serum concentrations for prescribed dose of escitalopram.  
 
5.5.2 Comparison to previous literature 
Whilst the existing literature on the association between drug metabolism rates and ADRs is 
limited (predominantly relying on smaller samples or case study reports), there are three key 
papers exploring the issue in well-powered samples.  
 
The publications on the STAR*D sample represent the largest sample to date in which CYP450 
genotype has been explored in relation to antidepressant ADRs (n=1,953; Mrazek et al, 2011; 
Peters et al, 2008). Both papers used measures of overall tolerance to citalopram treatment 
using study exit data. This could be compared to either the measures of weekly overall side 
effect burden, or study drop out within the GENDEP sample. But using either of these 
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outcomes, no association is observed in GENDEP between CYP450 genotype and ADRs (for 
either escitalopram or nortriptyline), in line with the report from Peters et al. (2008).  
 
The Rotterdam Study (Bijl et al, 2008) also included a large sample size (n=1,198), a range of 
antidepressants were considered and categorised as either tricyclic antidepressants or SSRIs. 
Amongst patients taking SSRIs, no association was observed between CYP2D6 genotype and 
clinical outcomes. Amongst patients taking tricyclic antidepressants, no association was seen 
with treatment discontinuation. However, the findings in the Rotterdam Study contradict those 
presented here, in that there was increased risk of antidepressant switching amongst patients 
taking tricyclic antidepressants with poor metaboliser genotypes.  
 
In GENDEP it is not possible to study antidepressant switching (the data are not available), in 
order to examine how robust this disassociation between antidepressant switching and 
treatment discontinuation is. Nevertheless, by using the detailed measurement of side effects 
available in GENDEP, together with study drop out data, the work presented here provides an 
assessment of a range of methods to assess adverse treatment events. Given the range of 
different ADRs, their varying pharmacological basis, as well as the changing profile of risk to 
ADRs across treatment (Uher et al, 2009a) and their impact of treatment adherence (Mitchell, 
2006), this more in depth look in particularly valuable.  
 
5.5.3 Methodological considerations 
Many of the methodological considerations for these analyses are similar those also detailed in 
Chapter 4.  
 
5.5.3.1 Power calculation 
Despite finding limited evidence that individual variation in drug metabolism rates is linked to 
ADRs, power calculations suggest that the analyses presented here are sufficiently powered to 
detect any effects of a magnitude that would be clinically useful. For example, when considering 
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CYP450 genotype prediction of overall side effect burden, we used G*Power (Faul et al, 2007) 
to estimate that a sample of 250 patients can detect effect sizes explaining 3.1% of the variance 
in total ADR burden with 80% power (at a threshold of p<0.05); this corresponds to a change of 
approximately 0.34 points on the ASEC scale.   
 
Nevertheless, the potential translational impact should also be considered in addition to the 
statistical power available to detect significant associations. Clinical utility of prediction is 
determined in part by the incidence rate of the outcome. In the case of the three specific ADRs 
where associations with serum concentrations were observed, both diarrhoea and dizziness are 
rare side effects (with prevalence below 10% of reports from patients taking escitalopram in this 
sample). This contrasts with dry mouth, which occurs in more than 70% of reports from patients 
taking nortriptyline. Therefore the association between serum concentration of antidepressant 
and dry mouth is likely to be of greater clinical value in terms of the number of patients affected.  
 
5.5.3.2 Multiple-hypothesis testing  
Whilst Bonferroni corrections were applied to consider the 21 specific ADRs tested, no further 
corrections were applied for the number of predictors tested (as these variables are 
interdependent). Thus, the threshold of significance applied within these analyses was lenient. 
Despite this, there was still limited evidence of a link between drug metabolism rates and 
antidepressant side effects.  
 
5.5.3.3 CYP450 genotypic categorisation 
As in Chapter 4, alternative methods of the categorisation of CYP450 genotypes were explored. 
Four or two category models for CYP2C19 (Brandl et al, 2014; Peters et al, 2008) and two 
category models for CYP2D6 (Mrazek et al, 2011) were considered. The results remained 
unchanged; CYP450 genotype was not predictive of overall ADR burden, specific ADRs or 
study drop out for either drug.  
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5.5.4 Study limitations 
5.5.4.1 Biases arising from missing data 
As mentioned in Chapter 4, if missing data (either due to study drop out, or not providing blood 
samples for serum measurements) is not at random, this may be a potential source of bias in 
the study. If data is more likely to be missing from patients who experienced high levels of 
ADRs, then it made lead to an underestimation of the impact of drug metabolism variability on 
side effects. However, the analysis of study drop out goes some way to addressing this issue. 
Given samples were taken at baseline to measure CYP450 genotype, and study drop out data 
is available for all participants, it is possible to accurately assess whether CYP450 genotype is 
linked to study drop out; we find no evidence to support this hypothesis. However, this does not 
exclude the possibility of missing data being linked to other variables of interest. 
 
5.5.4.2 Flexible dosing protocol 
Patients received treatment according to a flexible dosing protocol, where both treatment 
response and side effects could be used by clinicians to inform dose alterations throughout the 
study. Therefore the doses received by patients were adjusted in response to treatment 
outcomes as the study proceeded. This means that the findings presented here indicate the 
extent to which data on CYP450 genotypes and serum concentrations of antidepressants 
predict ADRs when used in addition to clinical observation.  
 
5.5.5 Conclusions 
Where antidepressant dosage is monitored by clinicians and adjusted using their judgement 
during the first eight weeks of treatment, CYP450 genotypes do not explain treatment 
associated side effects, as measured by overall side effect burden, specific ADRs, or study 
discontinuation. However there is some evidence that serum concentration of antidepressants 
may be linked to the occurrence of dizziness and diarrhoea for patients taking escitalopram and 








Chapter 6 Transcriptomics and the mechanisms of 




6.1.1 Molecular mechanisms of antidepressant action 
With antidepressant medications, the blockade of neurotransporters occurs immediately after 
drug administration. But, as discussed in Chapter 1, there is often a significant delay of 2-3 
weeks before symptom improvements can be observed (Frazer and Benmansour, 2002; Uher 
et al, 2011). Therefore, the molecular mechanisms that underlie the therapeutic action of these 
drugs remain unclear. 
 
It seems that the immediate action of antidepressants within the synapse activates a pathway of 
downstream adaptive changes necessary for clinical improvement; the precise nature of these 
changes is unclear but they may occur through transcription pathways altering gene expression 
levels (Duman et al, 1997; Lesch et al, 2002).  
 
6.1.2 Potential involvement of gene expression 
Using candidate gene approaches, gene expression alterations that are associated with 
treatment response have been observed within several key systems linked to antidepressant 
action; including inflammatory (Powell et al, 2013), stress response (Cattaneo et al, 2013) and 
neuroplasticity (Belzeaux et al, 2010; Cattaneo et al, 2010) pathways (see Introduction for 
further details).  
 
By focusing specifically on those changes in gene expression that are associated with treatment 
outcomes, these studies are able to probe the mechanism by which these drugs exert their 
therapeutic effects (Gerhold et al, 2002). This is particularly important in light of the high degree 
of variability seen between patients in terms of efficacy (Trivedi et al, 2006).  
 
6.1.3 Transcriptome-wide approaches 
However, the majority of patient studies have used candidate gene approaches to measuring 
expression levels. By using microarray technology, it is possible to interrogate the entire 
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transcriptome in a systematic and hypothesis-free manner. This enables the detection of novel 
gene expression changes which are associated with antidepressant efficacy, and places 
evidence regarding changes in expression levels for candidate genes within the context of the 
whole transcriptome (albeit it at the cost of a higher multiple-hypothesis testing burden, 
necessitating larger sample sizes).  
 
Indeed transcriptome-wide analyses using animal models indicate that gene expression 
changes associated with antidepressant action are likely to be complex, involving the co-
ordinated change of many different transcripts to produce therapeutic effects (Sillaber et al, 
2008). 
 
Nevertheless, to date there is limited work exploring expression changes linked to treatment 
response in patients on a transcriptomic level. Mamdani et al. (2011) used blood samples from 
63 patients with major depressive disorder to identify 32 probesets that were differentially 
expressed according to response to citalopram, the most significant of which was Interferon 
Regulatory Factor 7 (IRF7). Only two other studies have so far been published looking at 
transcriptome-wide gene expression changes in patients receiving antidepressant treatment, 
and these had very sample sizes (less than 10 patients; Belzeaux et al, 2012; Kálmán et al, 
2005).   
 
Transcriptome-wide information not only allows individual, gene-by-gene analysis, but can also 
be used within a system-based approach, where networks of genes which share expression 
patterns can be investigated (Langfelder et al, 2008). It is known that genes show structured 
correlation in expression levels (Lee et al, 2004); by using coexpression based approaches it is 
possible to organise genes into co-regulated modules which are likely to be functionally related 
and identify alterations in expression at a network level. This has the added benefit of reducing 
the multiple hypothesis testing burden of a gene-by-gene approach and so increases statistical 
power to detect effects.  
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This network-level methodology has not yet been applied to gene expression changes in 
patients receiving antidepressant treatment. 
  
6.1.4 Aims 
In this chapter, the antidepressant effects on gene expression were investigated using both an 
individual gene and a network-based approach. Variability in gene expression changes were 
considered as potential correlates of antidepressant therapeutic effect.  
 
Given the divergent mechanisms of action of the two antidepressants used in GENDEP, 
together with the evidence from animal work that expression profiles may vary between different 
treatments (Palotás et al, 2004), drug-specific analyses were also performed. This allowed 
exploration of whether any significant associations between gene expression changes and 





Participants included in this chapter are drawn from the GENDEP sample, as described in detail 
in Chapter 2.2. Figure 6-1 shows the patients included in analyses presented in this chapter.  
 
6.2.2 Treatment response measures 
Treatment response was treated as a quantitative trait using percentage change in MADRS 
from week zero to week eight (when blood samples were taken), adjusting for age and centre 
(see Chapter 2.4.1 for further details).  
 
At week zero, MADRS scores amongst the subsample of GENDEP included in this analysis 
were Mean=29.28, SD=6.44, whilst at week eight of treatment, MADRS scores were 
Mean=15.22, SD=9.12. There was no significant association between baseline scores and 
adjusted percentage change in MADRS. 
 
6.2.3 Transcriptome-wide gene expression data 
Methods of sample processing and transcriptomic quality control steps are described fully in 
Chapter 2.7. Briefly, whole blood samples were obtained at week zero and week eight of 
treatment for 136 patients. After standard RNA extraction procedures, samples were analysed 
using HumanHT-12 v4 Expression BeadChip microarrays (Illumina, Inc., San Diego). After 
quality control measures were applied to the data, a total of 242 paired samples, from 121 




6.2.3.1 Cell type proportions 
As cell counts for blood samples were unavailable, a deconvolution method was used to 
estimate cell proportions in each sample. Using the R package CellMix (Gaujoux et al, 2013), 
previously identified cell-type specific gene expression profiles (Abbas et al, 2009) were used to 
estimate the proportion of neutrophils, monocytes and lymphocytes in each sample. Paired t-
tests were used to compare the estimated proportions of in samples taken at week zero 
compared to week eight. No significant differences were observed for the three cell types 
considered; lymphocytes t(120)=-0.6843, p=0.4951, neutrophils t(120)=1.3312, p=0.1856, or 
monocytes t(120)= -0.9833, p=0.3274. 
 
Additionally, there was no significant correlation between treatment response (as measured 
using adjusted percentage change in MADRS score from baseline to week 8) and change in cell 
Figure 6-1: Sample included in Chapter 6 
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Samples passing microarray quality control  
N=121 




proportions; lymphocytes, r(199)=-0.0960, p=0.2951, neutrophils, r(199)=0.0177, p=0.8469, 
monocytes, r(199)=0.0902, p=0.3250. 
 
6.2.4 Statistical Analysis 
In order to examine the association between gene expression changes and response to 
antidepressant treatment, two complementary approaches were used; first analysing individual 
genes and then analysing networks of coexpressed genes. 
 
6.2.4.1 Analysis of individual genes 
In the first approach, each measured gene expression level was considered independently as a 
potential correlate of therapeutic response. Changes in gene expression for each gene probe 
were correlated with antidepressant treatment response. We present the false discovery rates 
(FDR), as calculated within the limma package (Smyth, 2005), using the method of Benjamini 
and Hochberg (1995). To correct for multiple hypothesis testing, we considered only those 
associations with FDR (or q-value) <0.05 as significant, however all associations with p<0.001 
have been reported as suggestive.  
 
In order to annotate the functions of the genes associated with antidepressant treatment and 
response, additional pathway analysis was undertaken using IPA (Ingenuity® Systems), 
considering all gene probes where p<0.01. The IPA network displaying the closest overlap with 
the inputted gene probes is described, along with the IPA network score. The IPA network score 
is based on the –log (Fishers exact test) measuring the fit between the molecules identified 
within the data and the IPA network. Therefore higher IPA network scores indicate closer 
overlap between the IPA network and the inputted gene probes; see http://www.ingenuity.com/ 
for further details. Brief details on the IPA-defined functional categories referenced within this 
chapter are included in Appendix F.  
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6.2.4.2 Analysis of networks of coexpressed genes 
In the second methodological approach, a weighted co-expression approach (WGCNA; 
Langfelder et al, 2008) was applied, in order to identify coexpression modules (that is, clusters 
of gene probes with highly correlated gene expression levels). 
 
Modules of coexpression were built using the gene expression profiles obtained at week zero. 
Using the correlation strength of each gene probe to all other gene probes (as measured by the 
connectivity measure k), the top 10,000 most connected gene probes within this dataset were 
selected. This matrix was then transformed into a weighted adjacency matrix using soft 
thresholding (raising the absolute values of the correlation matrix to the power β).  
 
The topological overlap for all pairs of gene probes was then calculated (which describes the 
degree of dissimilarity between two gene probes in terms of their patterns of connectivity with all 
other gene probes), and hierarchical clustering was performed on the 1-topological overlap 
matrix. Each module was defined as a branch of this hierarchical clustering tree.  
 
To summarise the gene expression profile within each identified module, the module eigengene 
(or first principal component) was calculated for the gene probes belonging to the module. 
Using the modules identified in the week zero gene expression data, the module eigengene was 
calculated for each module in both the week zero and the week eight gene expression data. 
From this, the change in module eigengene (or change in gene expression profile during 
treatment) was obtained for each module, for each individual. The change in module eigengene 
for each individual was then correlated with antidepressant treatment response. To account for 
the number of modules tested, a threshold for significance of FDR<0.05 was used.  
 
In the modules showing the most significant correlation with treatment response, module 
membership and gene significance values were calculated for each gene probe included. In this 
dataset, we defined module membership as the correlation between gene expression and the 
130 
module eigengene at week zero, and can be used to identify those gene probes with greater 
connectivity within the module. Gene significance describes the correlation between the change 
in gene expression and treatment response.  
 
We explored the relationship between module membership and gene significance, then used 
these measures to define those gene probes within the top 50% for both gene significance and 
module membership as “hub genes”.  
 
These hub genes were used to annotate the modules of interest, using IPA (Ingenuity® 
Systems). The IPA networks displaying the strongest overlap with the inputted gene probes are 
described, along with the associated network scores (where higher scores indicate stronger 
overlap).  
 
6.2.4.3 Drug specific analyses 
The primary analysis used the entire sample available. However, the two antidepressants used 
in GENDEP (escitalopram and nortriptyline) have divergent mechanisms of action, and so we 
also conducted exploratory drug-specific analyses, in order to investigate any drug-specific 





6.3.1 Individual Gene Analysis 
6.3.1.1 Whole sample analysis 
No significant correlations were found between change in gene expression and treatment 
response, although suggestive associations (p<0.001) were observed for 58 probes; see 
Appendix F. All gene probes where correlation with treatment response was p<0.01 were 
entered into Ingenuity pathway analysis. The IPA network “Haematological Disease, 
Organismal Injury and Abnormalities, Developmental Disorder” showed greatest overlap with 
these gene probes (IPA score=46).  
 
 Table 6-1 shows the molecules identified within this IPA network. Each IPA network contains 
35 molecules; the “network eligible molecules” are those that were identified as suggestive in 
the GENDEP dataset, with “other molecules” being those identified as interacting molecules in 
the Ingenuity Knowledge Base. As described in the methods, the IPA network score is based on 
the –log (Fishers exact test) measuring the fit between the molecules identified within the 
GENDEP data and the IPA network. Therefore higher IPA network scores indicate closer 
overlap between the IPA network and the inputted gene probes. The “Top Functions” column 
describes the three most significant functions for each network. The connections between these 
molecules, as described using Ingenuity, are drawn in Figure 6-2. 
 
To set this network in context, the details of the top five networks identified are included in 
Appendix F.  
 
Confirmation of treatment adherence through analysis of antidepressant concentrations in 
plasma samples was available for 81 patients with gene expression data (this represents 67% 
of the sample analysed in this chapter). When analyses were restricted to these cases, the 
pattern of results was similar to that in the whole sample analyses; no gene probes reached 
significance (FDR<0.05), 93% of gene probes with suggestive association in the whole sample 
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showed nominal significance (p<0.05) in this subset, and all correlations were in the same 
direction.  
Table 6-1: Details of the IPA network identified within the individual gene analysis of the whole sample 


















































Figure 6-2: Connections between molecules identified in the IPA network identified in the individual gene 
analysis of the whole sample. Molecules in red show positive correlation with treatment response, whilst 
molecules in green show negative correlation. Molecules in white are those which are identified as 
interacting molecules in the Ingenuity Knowledge Base.   
 
6.3.1.2 Escitalopram-specific analysis 
For patients on escitalopram (n=82), again no gene probes displayed significant correlations 
between change in gene expression and treatment response (20 gene probes showed 
suggestive correlations, see Appendix F). Pathway analysis indicated the network showing 
greatest enrichment was “Infectious Disease, Organismal Development, Connective Tissue 
Disorders” (IPA score=37). The molecules within this network are shown in Table 6-2. The 
connections between these molecules are drawn in Figure 6-3. Brief details of the top five 
networks identified in the pathway analysis are shown in Appendix F.  
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Table 6-2: Details of the IPA network identified within the escitalopram-specific sample in the individual 
gene analysis 















































Figure 6-3: Connections between molecules identified in the IPA network identified within the 
escitalopram-specific sample in the individual gene analysis. Molecules in red show positive correlation 
with treatment response, whilst molecules in green show negative correlation. Molecules in white are those 
which are identified as interacting molecules in the Ingenuity Knowledge Base.   
 
 
6.3.1.3 Nortriptyline-specific analysis 
For patients taking nortriptyline (n=39), two gene probes showed gene expression change 
significantly correlated with treatment response; MMP28 (probe ILMN_1790951) and KXD1 
(probe ILMN_1790951), as shown in Table 6-3 and Figure 6-4.  
Table 6-3: Significant correlations between change in gene expression and treatment response amongst 
patients taking nortriptyline 
Gene ID Corr P Value Q Value Chromosome Location 
MMP28 ILMN_1752952 -0.683 1.662x10-6 0.031 17q12b 
KXD1 ILMN_1790951 0.678 2.103 x10-6 0.031 19p13.11c 
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Figure 6-4: Correlation between change in gene expression and percentage improvement in MADRS, for MMP28 and KXD1. (Nortriptyline-specific analysis) 

























































A Fisher’s exact test was used to compare overlap between gene probes nominally associated 
(p<0.05) with nortriptyline or escitalopram, but no significant overlap was observed (p=0.2251). 
 
An additional 59 gene probes showed suggestive associations (see Appendix F), with pathway 
analysis implicating the IPA network “Cellular Assembly and Organisation, Nervous System 
Development and Function, Cell Signalling” (IPA score=36). The molecules identified in this 
network are shown in Table 6-4, with the connections between molecules drawn in Figure 6-5. 
Brief details of the top five networks identified using IPA are shown in Appendix F.  
 
Table 6-4: Details of the IPA network identified within the nortripytline-specific sample in the individual 
gene analysis 
















































Figure 6-5: Connections between molecules identified in the IPA network identified within the nortripytline-
specific sample in the individual gene analysis.  Molecules in red show positive correlation with treatment 
response, whilst molecules in green show negative correlation. Molecules in white are those which are 
identified as interacting molecules in the Ingenuity Knowledge Base.   
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6.3.2 Analysis of networks of coexpressed genes 
6.3.2.1 Whole sample analysis 
Using the gene expression data available at week zero, ten modules of coexpression were 
identified within the WGCNA analysis framework.  
 
Correlating changes in the module eigengene from week zero to week eight with treatment 
response, a significant (FDR<0.05) correlation was observed for one module (cor=0.27, 
p=0.0029, FDR=0.0317), shown in Figure 6-6. This module (referred to as module A) does not 
show significant correlations with any baseline patient characteristics (see Figure 6-7).  
 
Module A contains a total of 146 genes, of which 141 could be annotated. We observed a 
substantial and significant  correlation (r=0.56, p=1.47x10-13) between module membership and 
gene significance within module A, showing gene probes with greater connectivity within the 




Figure 6-6: Correlation between change in the module eigengene and percentage improvement in MADRS, for module A. (Cor=0.27, p=0.0029)



























































































































































































Figure 6-8: Relationship between module membership and gene significance for each gene probe within module A









































Pathway analysis using “hub genes” (that is, those gene probes that were within the top 50% for 
both module membership and gene significance, n=50) revealed the top network for enrichment 
within module A to be “Cancer, organ development and organismal injury and abnormalities” 
(IPA score=59). Details of this network are shown in Table 6-5 and Figure 6-9, with further 
information on the top five networks included in Appendix F. There was no enrichment observed 
within the module for genes from annotated brain derived modules included in the BrainLists, 
within the WGCNA package. 
 
Table 6-5: Details of the IPA network identified using the hub genes in module A in the whole sample 















































Figure 6-9: Connections between molecules within the IPA network identified using the hub genes in 
module A in the whole sample. .  Molecules in grey are hub genes in the WCGNA module, molecules in 
white are identified as interacting molecules in the Ingenuity Knowledge Base 
 
6.3.2.2 Escitalopram-specific analysis 
Eleven co-expressed modules were identified when considering only those patients who were 
prescribed escitalopram. No modules showed significant correlation between change in module 
eigengene and treatment response after correction for the number of modules tested 
(FDR<0.05). The most significantly associated module (r=0.23, p=0.0416, FDR=0.4567) 
contained 92 gene probes, 90 of which could be annotated. The correlation between module 
membership and gene significance was r=0.32, p=0.0021). Pathway analysis using “hub genes” 
within this module (n=26) revealed the top network for enrichment to be “Cancer, organ 
development and organismal injury and abnormalities” (IPA score=37). The details of the 
molecules identified in this IPA network are shown in Table 6-6 and Figure 6-10, with additional 
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information on the top 5 networks identified in Appendix F. This is the same network annotation 
identified in the analysis of the whole sample.  Furthermore, of the 50 hub genes identified in 
the whole sample analysis, 25 were also identified as hub genes in the escitalopram-specific 
analysis.  
Table 6-6: Details of the IPA network identified using the hub genes in most significantly associated 
module in the escitalopram-specific sample 















































Figure 6-10: Connections between molecules within the IPA network identified using the hub genes in the 
most significant module in the escitalopram-specific WCNGA analysis.  Molecules in grey are hub genes in 
the WCGNA module, molecules in white are identified as interacting molecules in the Ingenuity Knowledge 
Base 
 
6.3.2.3 Nortriptyline-specific analysis 
When looking at the patients taking nortriptyline, 16 modules of coexpressed gene networks 
were identified. No significant correlations were observed between change in module eigengene 
and treatment response. The most significantly correlated module (r=0.36, p=0.0228, 
FDR=0.3873) contains 1,375 gene probes, 1,080 of which were annotated. The correlation 
between module membership and gene significance was highly significant (r=0.38, p= 6.80x10-
48). Pathway analysis of “hub genes” in this module (n=437) showed the best performing 
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network for enrichment within this module was “Cancer, organ development and organismal 
injury and abnormalities” (IPA score=48). The details of this IPA network as shown Table 6-7 
and Figure 6-11, with additional information of the top 5 networks identified in Appendix F. This 
is the same network identified in both the whole sample and in the escitalopram-specific 
sample. Of the 50 hub genes identified in the whole sample analysis, 42 were also identified as 
hub genes in the nortriptyline-specific analysis.  
 
In the nortriptyline subset of the sample, neither of the two genes identified as significant in the 
gene-by-gene were included in the WCGNA analysis, as they were not amongst the top 10,000 
most connected genes.  
 
Table 6-7: Molecules within the IPA network identified using the hub genes in most significantly associated 
module in the nortriptyline-specific sample 















































Figure 6-11: Connections between molecules within the IPA network identified using the hub genes in the 
most significant module in the nortriptyline-specific WCNGA analysis.  Molecules in grey are hub genes in 








6.4.1 Summary of results 
6.4.1.1 Individual gene analysis 
When employing a gene-by-gene approach, no significant correlations with response were 
observed for individual genes in either the whole sample or the escitalopram-specific sample. 
However, significant correlations were observed between changes in gene expression levels 
and treatment response for two genes, amongst patients taking nortriptyline. This was the 
smallest subsample to be analysed and should be considered exploratory. The two genes 
identified were MMP28 (matrix metalloproteinase 28, involved in extracellular matrix 
degradation) and KXD1 (KxDL motif-containing protein 1, involved in endosomal cargo sorting). 
Furthermore, pathway annotation of those genes reaching suggestive significance in the 
nortriptyline-specific analysis implicates the IPA network “Cellular Assembly and Organisation, 
Nervous System Development and Function, Cell Signalling”. These annotation terms appear to 
have direct relevance to previous work on neurotrophic theories of antidepressant action, where 
efficacy has been linked to second messenger signalling causing gene expression changes and 
so neurogenesis (Duman et al, 1997; Manji et al, 2003).  
 
6.4.1.2 Analysis of networks of coexpressed genes 
When analysing modules of coexpressed genes, we observed significant correlation between 
changes in gene expression and treatment response within one module of coexpressed genes 
in the whole sample analysis. Interestingly, whilst no modules reached significance in the drug-
specific analyses, the modules showing strongest association with treatment response in both 
sets of analyses annotated to the same IPA network terms as that identified in the whole 
sample analysis (that is “Cancer, organ development and organismal injury and abnormalities”). 
This shared annotation may indicate that on a systems level, the gene expression changes 
associated with treatment response are not drug-specific, but instead, affect common biological 
networks regardless of antidepressant mechanism of action. The link between the networks 
implicated in this analysis and what is known about antidepressant action is unclear, but it may 
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be of note that the IPA annotation term “organ development” includes neurogenesis amongst 
other terms (see Supplementary Materials). 
 
6.4.2 Comparison of methodologies 
Whilst the WGCNA-based coexpression approach gives evidence supporting a pattern of 
common biological pathways between the two drugs considered here, this is not seen when 
using the individual gene approach. This could indicate that response to different antidepressant 
medications is not the result of shared action on individual genes, but instead a common action 
upon genes within particular coexpression networks. However, in the context of the inherent 
noisiness of microarray data and a high multiple hypothesis testing burden, it may be that this 
study did not have sufficient statistical power to detect effects using a gene-by-gene approach.  
 
6.4.3 Statistical power 
Using G*Power (Faul et al, 2007), it is estimated that in the whole sample gene-by-gene 
analysis, using a threshold of p<5x10-6 (reflecting the 29,000 gene probes considered), the 
sample is large enough to detect correlations of r=0.417 or greater, with 80% power. Therefore, 
whilst this analysis represents the largest analysis of transcriptomic data from patients taking 
antidepressants to date, power calculations indicate that there is only sufficient statistical power 
to detect comparatively large effects using these data. The findings presented here appear to 
rule out the presence of such large correlations with treatment response for single genes, with 
the exception of some novel and potentially interesting candidates for the nortriptyline-specific 
group. 
 
Statistical power is increased using the network approaches of WGCNA. With a threshold of 
p<0.005 (reflecting the 10 identified coexpression modules), the sample is large enough to 




6.4.4 Comparison to previous literature 
The individual gene analysis presented here did not replicate the previous reported association 
with IRF7 from a transcriptomic analysis of treatment response of 63 patients with MDD 
(Mamdani et al, 2011). Furthermore those genes which have previously been identified within a 
smaller subset of GENDEP patients using a candidate gene approach (Cattaneo et al, 2013; 
Powell et al, 2013) did not achieve significance when considered within a gene-by-gene, 
transcriptomic framework. This may reflect the limitations in statistical power to detect smaller 
effect sizes.  
 
However, when using the more powerful network coexpression approach, the inclusion of 
neurogenesis in the annotation terms for the modules which are associated with treatment 
response does align with previous literature highlighting neurogenesis as an important 
mechanism of antidepressant action (Lee and Kim, 2010). Furthermore, candidate studies 
(including those in GENDEP) have linked expression changes in genes linked to neuroplasticity 
to treatment response in patients (Belzeaux et al, 2010; Cattaneo et al, 2013; Iga et al, 2007b). 
Still, there are other annotation terms within this category which do not appear to link to what is 
known about the action of antidepressants.  
 
Therefore, further replication is needed to establish the robustness of our findings, as well as 
extend this work to consider other treatments for depression beyond escitalopram and 
nortriptyline.  
 
6.4.5 Potential role of placebo effects 
In addition to addressing whether these results generalise across different treatments, the role 
of placebo effects should also be considered. The absence of a placebo arm within GENDEP 
was necessary in order to make the project more inclusive and open to a wider proportion of 
patients. Nevertheless, it means that in this analysis it is not possible to disentangle whether 
those gene expression changes that correlate with treatment response represent a signature of 




6.4.6 Tissue specificity 
The degree to which data from this study can be used to understand the relationship between 
gene expression and antidepressant response must, of course, be considered in the context of 
tissue specificity. Here, blood is being used as a proxy for the key tissue of interest in 
antidepressant research; the brain. Studies exploring the degree of gene coexpression in blood 
and brain in humans suggest moderate correlation (Cai et al, 2010; Liew et al, 2006; Lunnon et 
al, 2012; Sullivan et al, 2006), and so whilst blood does appear to be an accessible and useful 
tissue by which we can probe the transcriptome, the issue of tissue-specificity of gene 
expression (and indeed drug-induced changes to these gene expression patterns) does 
constrain the interpretability of our findings.  
 
Nevertheless, the use of blood samples in this study is critical, enabling samples to be taken 




Overall, we have shown that a relationship between changes in gene expression and treatment 
response can be observed in patients taking antidepressant medication. The pattern of results 
indicates these changes take the form of a number of smaller changes acting across a network 
of coexpressed genes, rather than single genes showing large changes in gene expression 
levels. Furthermore, even when considering two antidepressants with divergent mechanisms of 
action, the implicated coexpression networks share the same biological function indicating the 









Chapter 7 Examining the genetic control of gene expression to 





7.1.1 Understanding the mechanisms of genetic effects 
The work that I have presented in this thesis thus far focusses on identifying genetic biomarkers 
associated with antidepressant treatment. In this chapter, I will move to investigating the 
downstream consequences of genetic variation, in order to consider the molecular pathways 
through which genetics might ultimately impact on treatment outcomes.  
 
As noted in the introduction, there are a growing number of identified trait-associated genetic 
variants (Hindorff et al), but we are frequently unable to trace how these identified variants exert 
their effects. This is of particular interest given that the majority of trait-associated variants 
identified to date are neither non-synomymous nor missense mutations and so do not directly 
affect protein structure.  
 
One approach to understanding the mechanisms by which genetic variants act is to consider 
the impact of genotype on levels of gene expression, within an expression quantitative trait loci 
(eQTL) framework (see Introduction for further details).  
 
7.1.2 Using eQTLs to interpret genetic and transcriptomic associations 
 
eQTLs are widespread throughout the genome, and have already been shown to be a valuable 
starting point to unpick the path between genotype and disease, by demonstrating how genetic 
variation can alter the transcriptome. For example, eQTL analysis of the intronic variants within 
the FTO gene that have been linked to obesity phenotypes demonstrates that the SNPs affect 
IRX3 (but not FTO) transcript levels; follow-up experiments using knock-out models in mice 




7.1.3 Using eQTLs to identify genetic associations 
eQTLs are not only of value in understanding the mechanism by which previously identified 
genetic variants exert their effects, they can also be of value when trying to identify those 
variants.  
 
One of the primary challenges in conducting genome-wide association studies is the collection 
of sample sizes with sufficient statistical power to detect trait-associated variants, in the face of 
small genetic effect sizes and a high multiple hypothesis testing burden. Limitations in power, 
combined with a polygenic signal mean that within each genome-wide association study, there 
are likely to be a number of SNPs which are truly associated with the trait of interest, but yet fail 
to reach the threshold for statistical significance.  
 
This issue is particularly pertinent when considering the genetic predictors of antidepressant 
treatment outcomes. As previously noted, treatment response is under genetic influence 
(Tansey et al, 2013) but the largest mega-analysis to date (n=2,256) failed to identify any 
variants reaching genome-wide significance (GENDEP Investigators; MARS Investigators; 
STAR*D Investigators, 2013). The collection of larger sample sizes is needed to gain sufficient 
power to reach the threshold for genome-wide significance, but pharmacogenetic cohorts are 
very expensive to collect, given the need for clinical monitoring across the course of treatment.  
 
However, it may be possible to use eQTLs as an annotation tool to aid the extraction of 
information from those SNPs reaching only suggestive significance levels. There is an 
enrichment of eQTLs amongst identified trait-associated variants (Nicolae et al, 2010), and it 
has been demonstrated that this fact can be usefully exploited within a Bayesian framework by 
applying weightings to identified cis-eQTL SNPs, to increase discovery of trait-associated 
variants when performing a GWAS (Knight et al, 2011; Li et al, 2013). Therefore, using eQTL 
annotation with the SNPs showing suggestive association with treatment response may be a 





7.1.4 Using eQTLs to annotate transcriptomic findings 
EQTLs can also be used as an annotation tool to aid the interpretation of transcriptomic 
analyses, by identifying genotypes that may drive transcriptomic patterns. This has been 
demonstrated in the case of systemic lupus erythematosus, where the disease-linked 
transcriptomic profile of altered expression levels for C1QB and five interferon genes was 
shown to be controlled by a trans-acting eQTL SNP, which had also been previously linked to 
the disease (Westra et al, 2013).  
 
Analyses in GENDEP looking at the transcriptome prior to treatment has highlighted a number 
of suggestive predictors of treatment response (Tansey et al, in prep) and eQTLs can be used 
to determine if these transcriptomic markers are under genetic control.  
 
7.1.5 Context specificity of eQTLs 
Finally, the influence that the phenotype of antidepressant treatment response may have on the 
genetic control of gene expression can also be explored. As our understanding of the genetic 
regulation of gene expression develops, it becomes increasingly clear that eQTLs are variable 
dependent upon context; for example, as discussed in the Introduction, there is a growing body 
of research aimed at characterising how eQTLs vary between tissues (Grundberg et al, 2012; 
GTEx Consortium, 2013). There is also evidence that the genetic control of gene expression 
may also be phenotype-dependent. This has most robustly been indicated using the cellular 
phenotype of immune activation (Fairfax et al, 2014), but age- and sex-specific eQTLs have 
also been identified (Glass et al, 2013; Yao et al, 2014).  
 
In the same way that the presence of an eQTL may be dependent on levels of immune 
activation or age, they may also be dependent on treatment response. If this is shown to be the 
case, and gene expression levels are determined by an interaction between genotype and 
treatment response, this would indicate that the mechanism by which a genetic variant 
influences expression levels varies in a manner which is associated with treatment response. 
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This provides a window into the biological differences that might underlie the variability we 
observe in treatment outcomes.  
 
7.1.6 Aims of this study 
This study aims to explore the pattern of eQTLs observed in the GENDEP dataset, and how 
these can be used to understand the phenotype of antidepressant response. 
  
Firstly, the study will characterise the eQTLs observed in the GENDEP sample. Overlap with 
previously published blood eQTL datasets will be assessed, and the enrichment of trait-
associated genetic variants amongst eQTLs will be explored.  
 
Secondly, eQTLs identified here will be used to annotate those genetic variants reaching 
suggestive significance in a previously published GWAS of antidepressant treatment response 
in the GENDEP sample (Uher et al, 2010), in order to highlight variants which may be 
considered more likely to be causally associated with treatment response.  
 
Thirdly, the presence of eQTLs controlling the expression levels of transcripts that have been 
identified as possible predictors of treatment response (Tansey et al, in prep) will be explored, 
to identify whether the response-predictive differences in expression levels might be linked to 
genotypic variation.   
 
Finally, the presence of conditional eQTLs will be considered, whereby the genetic effect on 







Participants included in this chapter are drawn from the GENDEP sample, as described in detail 
in Chapter 2.2. Figure 7-1 shows the patients included in analyses presented in this chapter. 
 
7.2.2 Treatment response 
Response to antidepressant treatment was measured using percentage change in MADRS 
score from week zero to week twelve of the study. This measure was adjusted for age and 
recruitment centre (details in Chapter 2.4.1).  
 
7.2.3 Genomic data 
Genome-wide genotypic data was obtained for 796 patients within the GENDEP sample using 
the Illumina Human610-quad bead chip (Illumina Inc., San Diego). Standard quality control 
measures were applied, population stratification principal components calculated and imputation 
using 1000 Genomes data was undertaken, as described in Chapter 2.6.2. 
 
7.2.4 Transcriptomic data 
Gene expression data was collected at week zero (prior to antidepressant treatment) from blood 
samples, using Illumina HumanHT-12 v4 Expression BeadChip microarrays (Illumina Inc., San 
Diego). Standard quality control measures and batch correction were applied, as described in 
Chapter 2.7  
 
Aligning the genomic and transcriptomic data, information on 8,317,505 SNPs and 27,187 gene 




7.2.5 Statistical Analysis  
7.2.5.1 Identification of eQTLs 
eQTL analysis was performed using the R package Matrix eQTL (Shabalin, 2012). Prior to 
analysis, gene expression values were transformed to correct for outliers, using the protocol 
employed by the Genotype-Tissue expression (GTex) project (http://www.gtexportal.org/). For 
each gene, expression values were ranked across samples then mapped onto a standard 
normal distribution.  
 
Covariates entered into the model included the first four principal components calculated from 
the genotypic data (to account for population stratification), the first principal component 
calculated from the gene expression data, as surrogate measures of unwanted variation in gene 
expression data from non-genetic causes (Biswas et al, 2008; Leek and Storey, 2007), 




Transcriptomic data available at week zero  




Treatment response data available 
N=839 
 
Genomic data available  
(after quality control steps) 
N=796 
Figure 7-1: Sample included in Chapter 7 
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estimated proportions of cell type (as calculated using CellMix (Gaujoux et al, 2013), see 
Chapter 2.7 for details), age, sex and treatment response.  
 
An eQTL analysis involves performing a genome-wide association study for each of the 27,187 
probes. To correct for the number of tests performed, the threshold of genome-wide significance 
(p<5x10-8) was divided by the number of probes tested, to give a threshold of p<1.84x10-13. This 
represents a conservative Bonferroni adjustment, as the correlated structure of the 
transcriptomic data has not been considered. However, the stringent threshold was used, given 
the issue of limited replication within the eQTL literature (Breitling et al, 2008). Suggestive 
findings were defined as those where p<1x10-8. Results were then divided into cis and trans 
eQTLs; cis-eQTLs were defined as those within 500KB of the gene probe, all other associations 
were designated as trans-eQTLs. Any gene probes containing polymorphisms of a minor allele 
frequency greater than 0.01 (within the 1000 genomes sample of European ancestry) were 
removed from the analysis using BEDtools (Quinlan and Hall, 2010) and the protocol described 
by Ramasamy et al (2013). Probe locations were determined using the illuminaHumanv4.db 
Bioconductor package in R (Dunning et al), and any probes mapping to multiple locations were 
removed.  
 
To obtain the number of independent associations, for each gene probe with more than one 
SNP significantly associated, linkage disequilibrium clumping was performed using PLINKv1.07 
(http://pngu.mgh.harvard.edu/purcell/plink/) (Purcell et al, 2007).  
 
To consider how reliable the eQTLs in this analysis are, they were compared with those 
previously identified in peripheral blood samples taken from 5,311 individuals (Westra et al, 
2013). The authors of this large sample (referred to hereafter as the Westra dataset) made all 
cis and trans-eQTLs that reached an FDR<0.5 publicly available 
(http://genenetwork.nl/bloodeqtlbrowser/). It is of note that the Westra dataset used gene probes 
included on the Illumina Human HT12v3 array (these overlap but do not completely match those 
included on the v4 array used in this study), and that for the trans-eQTL analysis, only SNPs 
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that were included in the NHGRI catalogue of published genome-wide association studies 
(http://www.genome.gov/gwastudies/) were entered into the analysis. An eQTL was only 
considered to be replicated in the Westra dataset if the exact combination of SNP and probe 
was observed, with the same direction of effect.  
 
7.2.5.2 Assessing eQTL enrichment amongst genetic associations for any trait 
Using the NHGRI catalogue of published genome-wide association studies 
(http://www.genome.gov/gwastudies/; accessed 06/05/14), a list of all previously published 
genetic associations passing a threshold of p<5x10-8 was obtained, containing a total of 4,695 
SNPs. Using PLINK, additional tagging SNPs (with an r2 of 0.5 or greater and within 250kb of 
the index SNP) were also identified to create a list of trait-associated genetic variants (143,375 
SNPs). We then assessed overlap between these trait-associated SNPs and the cis-eQTL loci.  
 
To assess whether the number of trait-associated SNPs which were also cis-eQTLs is greater 
than would be expected by chance, permutation tests were run. A random sample of SNPs was 
selected, equal in size to the number of cis-eQTL loci observed. The overlap between this 
random sample of SNPs and the trait-associated variants (all GWAS hits plus tagging SNPs) 
was assessed. This was repeated 1,000 times to obtain a null distribution of the expected 
number of cis-eQTLs that would be observed by chance, and used to assess enrichment.  
 
7.2.5.3 Assessing eQTL enrichment amongst genetic associations with antidepressant 
response 
To then explore eQTLs amongst suggestive genetic associations with treatment response, a list 
of SNPs reaching suggestive levels in significance (60 SNPs p<0.0001) in the previously 
published GWAS in GENDEP (Uher et al, 2010) was obtained. Additional tagging SNPs were 
identified using PLINK (as described above), creating a total list of 1154 response-associated 




7.2.5.4 Using eQTLs to explore transcriptomic predictors of treatment response 
Using the results from the transcriptomic analysis of baseline predictors of treatment response 
in GENDEP (Tansey et al, in prep), we explored whether any of the genes showing suggestive 
association with response (p<0.001, n=53) were also identified here as eQTL genes.  
 
7.2.5.5 Identifying eQTLs conditional on treatment response 
Finally, a second eQTL analysis was performed to explore whether it was possible to identify 
eQTLs that are conditional on treatment response outcomes. In this analysis, rather than 
covarying for treatment response, the interaction between treatment response and genotype 






7.3.1.1 Identification of eQTLs 
After removing all eQTLs involving probes containing polymorphisms, a total of 25,269 
significant cis-eQTLs were observed. This represents 668 independent signals, affecting 444 
gene probes. The top 20 independent signals are shown in Table 7-1. The mean effect size of 
cis eQTLs was R2=0.375, with a maximum effect size of R2=0.769. Moving to a suggestive level 
of significance (p<1x10-8), an additional 32,845 cis-eQTLs were detected. A Manhattan plot 
showing all cis-eQTL signals is shown in Figure 7-2. 
 
Focussing on the trans-eQTLs, 5,898 significant SNP-gene probe associations were observed, 
representing 103 independent signals affecting 49 gene probes. The maximum number of gene 
probes associated with any single SNP was 12. The mean affect size of the trans-eQTLs was 
R2=0.403 (maximum effect size of R2=0.760). At a suggestive level of significance, an additional 
3,504 trans-eQTLs were observed.  
 
In line with previous studies (Dimas et al, 2009; Stranger et al, 2007; Veyrieras et al, 2008), we 
also noted that the effect sizes for cis-eQTLs are larger the closer they are to the gene probe 
(Figure 7-3).  
 
7.3.2 Replication of eQTL signals 
Of the 25,269 cis-eQTLs observed, 4,827 were also detected in the Westra dataset. No 
replications of the trans-eQTLs were detected, although it should be noted that whilst in the 
current study, all available variants were tested, Westra et al (2013) limited their trans-eQTL 




Table 7-1: The 20 most signficant cis-eQTLs  (SNP annotation from snp-nexus.org) 
SNP Gene Name Illumina Probe Chr P value Beta R2 




rs1131017 RPS26 ILMN_3299955 12 1.48E-63 1.26 0.77 - 5UTR 
rs1131017 RPS26 ILMN_1695585 12 8.80E-60 1.22 0.75 - 5UTR 
rs3813976 - ILMN_1818577 1 2.90E-59 1.13 0.74 - 5upstream 
rs10760117 PSMD5-AS1 ILMN_3236498 9 2.66E-58 1.23 0.74 - intronic 
rs1131017 RPS26 ILMN_3209193 12 1.01E-53 1.19 0.71 - 5UTR 
rs11717719 CHST13 ILMN_1734707 3 3.52E-51 -1.13 0.69 - intronic 
rs1131017 RPS26P31 ILMN_3285153 12 2.22E-49 1.18 0.68 - - 
rs10239340 IRF5 ILMN_2312606 7 5.67E-49 1.13 0.67 9.81E-198 5upstream 
rs9471975 PEX6 ILMN_1683279 6 9.77E-49 -1.18 0.67 - - 
rs9890200 SPATA20 ILMN_1687247 17 4.70E-47 -1.14 0.66 - 5UTR 
rs1131017 LOC641768 ILMN_3242288 12 5.86E-47 1.17 0.66 - - 
rs2431529 PAM ILMN_2313901 5 1.00E-46 1.18 0.66 9.81E-198 - 
rs61913527 CLEC12A ILMN_1663142 12 3.82E-45 1.20 0.64 - intronic 
rs12933746 LPCAT2 ILMN_1796335 16 1.06E-44 -1.05 0.64 - 3UTR 
rs7309256 CLEC12A ILMN_1711453 12 1.98E-44 1.24 0.64 9.81E-198 - 
rs4731533 IRF5 ILMN_1670576 7 2.63E-44 1.10 0.63 - 5upstream 
rs4766601 KCTD10 ILMN_1719064 12 1.88E-43 1.32 0.63 9.81E-198 intronic 
rs11191667 USMG5 ILMN_1773313 10 2.20E-43 1.14 0.63 - - 
rs1045599 ZSWIM7 ILMN_3298167 17 3.87E-43 -1.12 0.62 - 3UTR 





Figure 7-2: Manhattan plot of all cis-eQTLs.  





Figure 7-3: The distance between the cis-eQTL SNP and gene, in relation to the effect size of the eQTL 


























7.3.2.1 Enrichment of eQTL-SNPs amongst GWAS hits associated with any trait 
To assess whether the cis-eQTLs identified in this analysis were enriched amongst GWAS-
significant variants, a total of 143,375 trait associated SNPs (4,695 from the NHGRI GWAS 
catalogue plus tagging SNPs) were compared with the 668 cis-eQTL loci identified in this 
analysis. A total of 77 SNPs were present in both lists and permutation tests show this 
demonstrates significant enrichment (p<0.001, see Figure 7-4) 
 
Figure 7-4: Enrichment of cis-eQTLs amongst any trait-associated SNPs. Null distribution from 1,000 
permutations is shown, with a red line indicating the number of cis-eQTL loci observed amongst trait-
associated SNPs 
 
7.3.2.2 eQTL-SNPs amongst suggestive findings linked to antidepressant response 
Considering the suggestive response-associated SNPs (n=1145; 60 identified SNPs plus 
tagging variants) identified in the GWAS of treatment response in GENDEP (Uher et al, 2010), 1 
SNP (rs10747570) was located within a cis-eQTL locus. This locus was located on chromosome 
12, and associated with expression levels of the gene CERS5, which encodes Ceramide 
Synthase 5. The cis-eQTL locus contains 56 SNPs in high LD, 23 of these are replicated in the 
Westra dataset. Furthermore, this cis-eQTL locus is also reported in tibial nerve tissue in the 
GTex dataset (http://www.gtexportal.org/home/). 















The pattern of high LD in this locus (shown in Appendix G) means that it is difficult to identify the 
specific SNP involved, and so the potential mechanism underlying this eQTL. Nevertheless, 
Figure 7-5 shows the context of this eQTL locus, with the position of all implicated SNPs, the 
CERS5 gene and details from the ENCODE project on the regulation of transcription (see 
details of ENCODE Integrated Regulation Tracks on the UCSC Browser for further details, 
www.genome.ucsc.edu). Table 7-2 to Table 7-4 show annotations that have been identified for 
the 56 identified SNPs in the eQTL locus, using the HaploReg tool (www.broadinstitute 








Table 7-2: Annotations of 56 SNPs identified in CERS5 eQTL locus, as identified using Haploreg v2 (A)  















rs10747570 A/G 0.59 
      
COX14 intronic 
rs7967705 T/C 0.59 
     
AhR,  EBF,  Pax-5 COX14 intronic 




CDP,  Cdx COX14 
 
rs2178173 A/G 0.6 
      
COX14 
 
rs7297421 C/T 0.6 
 
GM12878 
   
Foxa,  Foxp3 COX14 
 
rs7301740 C/G 0.6 
     
AhR,  EBF COX14 
 
rs7967844 G/C 0.59 
     
4 altered motifs COX14 
 
rs7136570 A/G 0.6 
     
Bcl6b, Pax-4 COX14 intronic 
rs7532 T/C 0.6 
     
Ets, Hic1, Maf COX14 3'-UTR 
rs7279 A/G 0.6 
     
HDAC2, Irf, p300 COX14 3'-UTR 
rs836179 A/G 0.4 
 
GM12878,  K562,  
HepG2 
HUVEC, HeLa-S3, 
GM19238   4 altered motifs GPD1 intronic 
rs836180 C/T 0.41 
 
GM12878,  K562,  
HepG2 A549   5 altered motifs GPD1 synon. 
rs6580729 G/A 0.4 
     
5 altered motifs COX14 intronic 
rs11831413 A/T 0.4 
     
8 altered motifs COX14 intronic 
rs7294548 A/G 0.6 
 
Huvec 4 cell types 
  
AP-4, Ascl2, YY1 COX14 intronic 
rs12815871 G/A 0.4 
      
COX14 intronic 
rs7301649 T/C 0.6 
     
Hltf COX14 intronic 
rs35549836 C/T 0.4 
      
RP11-411N4.1 intronic 
rs12830386 G/A 0.4 
     
CEBPB, CEBPD, GR RP11-411N4.1 intronic 
rs12824125 A/G 0.4 
 
6 cell types 
   
5 altered motifs COX14 intronic 
rs34573394 C/A 0.4 
     




Table 7-3: Annotations of 56 SNPs identified in CERS5 eQTL locus, as identified using Haploreg v2 (B). 















rs35998534 A/G 0.4 
     
LF-A1, TATA, YY1 COX14 intronic 
rs7302981 A/G 0.6 
      
COX14 missense 
rs7308356 A/G 0.6 
     
NRSF COX14 intronic 
rs11169300 T/C 0.59 
     
4 altered motifs LIMA1 intronic 
rs12426261 A/G 0.6 
     
4 altered motifs LIMA1 intronic 
rs4883481 T/C 0.6 
     
GCNF, Hand1, Nr2f2 LIMA1 intronic 
rs1862043 G/C 0.59 
  
HRGEC, HRPEpiC, SK-
N-MC SMC3   LIMA1 intronic 
rs4883482 A/G 0.59 
     
7 altered motifs LIMA1 intronic 
rs11169294 A/G 0.4 HepG2 6 cell types pHTE 
  
Ets 709bp 5' of CERS5  
rs706790 A/G 0.43 HSMM K562,  Huvec,  NHEK 116 cell types 11 bound proteins  5 altered motifs ASIC1 intronic 
rs2272391 A/G 0.54 
     
6 altered motifs ASIC1 intronic 
rs706792 G/T 0.44 
     
10 altered motifs ASIC1 missense 
rs836172 C/G 0.44 
      
SMARCD1 intronic 




Zfp691 SMARCD1 intronic 
rs836174 G/A 0.44 
     
Brachyury, LUN-1, 
Nkx2 SMARCD1 intronic 
rs836173 C/T 0.44 
     
YY1 SMARCD1 intronic 
rs836176 C/T 0.44 
     
4 altered motifs SMARCD1 intronic 
rs706793 G/A 0.44 
     
4 altered motifs ASIC1 synon. 
rs646782 T/C 0.44 
 
4 cell types 
   
5 altered motifs SMARCD1 intronic 
rs706791 A/G 0.44 
 
K562 
   
Pax-4, Pax-5, Sin3Ak-
20 ASIC1 intronic 
rs1044370 T/C 0.44 
     




Table 7-4: Annotations of 56 SNPs identified in CERS5 eQTL locus, as identified using Haploreg v2 (C) 















rs66768395 G/T 0.44 
  
5 cell types 
  
Myf 1.3kb 3' of LIMA1 
 
rs56709084 T/C 0.44 
 




2.6kb 5' of 
CERS5  
rs7301566 T/C 0.55 
 
7 cell types HA-sp, Th2 CTCF, POL24H8  7 altered motifs RP3-405J10.3 intronic 
rs4459386 A/G 0.56 
 
4 cell types 37 cell types FOXA1, GATA3 
 
4 altered motifs LIMA1 5'-UTR 
rs10219559 T/C 0.55 
 
4 cell types 
   
5 altered motifs LIMA1 intronic 
rs8181679 T/C 0.56 GM12878 NHEK,  HMEC 
   
4 altered motifs LIMA1 intronic 
rs7967954 G/A 0.56 
  
GM19238, HRCEpiC, 
RPTEC   4 altered motifs LIMA1 intronic 
rs10783342 T/C 0.56 
 
4 cell types HeLa-S3 9 bound proteins   LIMA1 intronic 
rs6580732 T/G 0.56 
 
K562,  NHEK,  
GM12878     LIMA1 intronic 
rs7957659 T/C 0.56 
 
NHLF 
   
CEBPG LIMA1 intronic 
rs590460 T/C 0.66 7 cell types HMEC 105 cell types 10 bound proteins  4 altered motifs 1.4kb 5' of ASIC1  
rs3184122 A/G 0.34 
      
LIMA1 3'-UTR 
rs9364 G/A 0.65 
     
Lhx8 LIMA1 3'-UTR 
rs12424335 C/T 0.35 
     
4 altered motifs LIMA1 intronic 
173 
 
7.3.2.3 Annotation of suggestive transcriptomic signatures linked to antidepressant 
response 
Looking at gene expression levels that had been previously identified as suggestively 
associated with treatment outcomes in this dataset (Tansey et al, in prep), one of the 53 
identified gene probes was also a cis-eQTL gene in this analysis. The implicated gene was 
GSTM3, which encodes Glutathione S-transferase M3, a brain expressed enzyme linked to the 
uptake and detoxification of a range of toxins and drugs at the blood brain barrier. Expression 
levels of the gene were associated with one locus containing 18 cis-acting SNPs. Figure 7-6 
shows how gene expression levels change with genotype for the most significant SNP at this 
locus. The cis eQTL is not replicated in the Westra dataset, however is observed within the 
GTEx portal, for a range of tissues considered.  
 
Figure 7-6: Relationship between genotype and expression levels of GSTM3 
 
The high LD within this locus is shown In Appendix G, which makes the identification of the 
possible mechanism underlying this eQTL difficult to establish. Nevertheless, Figure 7-7 shows 
the context of the eQTL locus, and Table 7-5 shows the annotations available for the implicated 
SNPs at this eQTL locus in HaploReg. Interestingly, several of the SNPs have been identified 

























Figure 7-7: Position of SNPs within eQTL locus affecting GSTM3 expression.  Top track shows eQTL SNPs identified in eQTL locus controlling expression of GSTM3. SNPs are 
coloured by known function; blue = intronic, red = 3’UTR, magenta,=5’UTR, green = missense, cyan=synonymous, black=intergenic. 
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Table 7-5: Annotations of 18 SNPs identified in GSTM3 eQTL locus, as identified using Haploreg v2. eQTL tissues identified; CB= cerebellum, FC= frontal cortex, TC= temporal 
cortex. 











rs1332018 G/T 0.58 9 cell types 
 
98 cell types 12 bound proteins CB, FC, Pons, TC RXRA,SMC3 GSTM3 5'-UTR 
rs10735234 G/A 0.59 HSMM 4 cell types Osteobl 
 
CB, FC, Pons, TC 4 altered motifs GSTM3 intronic 
rs4970777 C/T 0.58 
 
Huvec, HepG2 HPAEC, HRGEC CTCF CB, FC, Pons, TC 4 altered motifs GSTM3 
 
rs4970736 C/T 0.59 
     
5 altered motifs RP4-735C1.4 
 
rs1109138 T/C 0.59 
    
CB, FC, Pons, TC HEN1 GSTM3 3'-UTR 
rs4970775 T/G 0.6 
     
4 altered motifs RP4-735C1.4 
 




4 altered motifs RP4-735C1.4 
 
rs4540683 T/G 0.59 
     
EWSR1-FLI1, HDAC2 RP4-735C1.4 
 




CB 5 altered motifs EPS8L3 intronic 




CB BATF, Pax-6, RFX5 EPS8L3 synon. 
rs6673976 C/T 0.61 
    
CB Zfp410 EPS8L3 intronic 
rs6684608 T/C 0.61 
    
CB 4 altered motifs EPS8L3 intronic 
rs6676743 C/T 0.61 
    
CB 8 altered motifs EPS8L3 intronic 
rs1537236 C/T 0.51 
    
CB, FT, TC Sox GSTM3 3'-UTR 
rs1360513 T/C 0.47 
     
Maf RP4-735C1.4 
 
rs4970774 A/C 0.47 
 
K562 4 cell types FOXA1 FC, TC 29 altered motifs RP4-735C1.4 
 
rs11101999 G/C 0.46 
     
6 altered motifs RP4-735C1.4 
 
rs1537234 C/A 0.43 
     






7.3.2.4 Conditional eQTLs 
Finally, we explored whether genetic control of gene expression varied with the phenotype of 
treatment response; that is whether any eQTLs were conditional on the phenotype of treatment 
response. No conditional eQTLs passed the threshold for significance. However, 801 trans-
eQTLs reached suggestive levels of significance (representing 154 independent signals 
affecting 143 probes), with a mean R2 of 0.165 (maximum R2=0.206). The top 20 trans-eQTL 
loci are shown in Table 7-6, with the most significant eQTL illustrated in Figure 7-8. It should be 
noted that for illustration purposes, in the boxplot, the sample has been divided into responders 
and non-responders, however the analysis used a quantitative phenotype of treatment 
response.   
 
Using WebGestalt to explore the implicated gene probes in this analysis, no GO categories 
showed enrichment with a p<0.05, except one relating to photoreceptor cell fate commitment 




Figure 7-8: Boxplot showing illustrative example of relationship between treatment response, genotype 
and gene expression levels for the most significant conditional trans-eQTL observed (rs9597258, RMST 










































Table 7-6: The 20 most significant conditional trans-eQTL loci 
SNP SNP C’some Genetic context of SNP Gene Name Illumina Probe Probe C’some P value Beta R2 
rs9597258 13 Intergenic RMST ILMN_3245464 12 3.21E-11 -0.03 0.20 
rs4742127 9 Intergenic ZSWIM4 ILMN_1735231 19 1.46E-10 -0.02 0.19 
rs34693904 4 COL25A1 (intronic) GSDMB ILMN_1666206 17 2.28E-10 -0.02 0.19 
rs11745163 5 SPOCK1 (intronic) TMPRSS11BNL ILMN_3243223 4 3.13E-10 -0.02 0.19 
rs78407051 1 Intergenic LOC100130133 ILMN_3231667 Y 4.45E-10 -0.02 0.18 
rs2446125 8 CNBD1 (intronic) - ILMN_1865268 16 5.78E-10 -0.02 0.18 
rs113338623 7 Intergenic SNORA22 ILMN_3246713 7 6.19E-10 -0.03 0.18 
rs1448903 2 ADAM23 (intronic) LOC388114 ILMN_1669777 15 6.53E-10 -0.03 0.18 
rs2021974 20 MACROD2 (intronic) LOC729154 ILMN_3297582 15 7.02E-10 -0.02 0.18 
rs27003 5 MCTP1 (intronic) LOC650154 ILMN_1773323 5 8.62E-10 -0.02 0.18 
rs2418402 9 Intergenic LOC402617 ILMN_1708542 7 9.90E-10 0.03 0.18 
rs7814809 8 Intergenic - ILMN_1854580 13 1.18E-09 -0.03 0.17 
rs1477874 4 PDGFRA (intronic) SDHALP1 ILMN_1734640 5 1.25E-09 -0.02 0.17 
rs12240135 1 Upstream to  AX747377 and NAV1 RAP1GDS1 ILMN_1687724 4 1.34E-09 0.02 0.17 
rs10207872 2 Intergenic NUSAP1 ILMN_1726720 15 1.52E-09 -0.02 0.17 
rs10873963 1 Upstream to GIPC2 STAC2 ILMN_1718295 17 1.55E-09 0.03 0.17 
rs12965167 18 Intergenic RNF214 ILMN_1800420 11 1.56E-09 -0.03 0.17 
rs2716930 17 Intergenic ZNF550 ILMN_1760102 19 1.69E-09 0.02 0.17 
rs4140768 12 ARHGDIB (intronic) LOC647942 ILMN_1705246 2 1.72E-09 -0.02 0.17 






7.4.1 Summary of results 
In this analysis 25,269 cis acting and 5,898 trans acting eQTLs were identified within whole 
blood samples of 207 individuals. 4,829 of the cis-eQTLs (19%) were replications of eQTLs 
previously observed in a large analysis of blood eQTLs (Westra et al, 2013). As has been noted 
previously, in this study effect sizes for cis-eQTLs were larger as the distance between the SNP 
and gene probes decreases. However, in contrast to much of the existing literature (Petretto et 
al, 2006), trans-eQTL effect sizes were not smaller than effect sizes for cis-eQTLs. Using the 
identified cis-eQTLs, we observed enrichment amongst GWAS hits associated with any trait. 
One cis-eQTL locus was identified, at the gene CERS5, amongst those genetic variants which 
have shown suggestive association with antidepressant treatment response in a previous 
GWAS in the GENDEP sample. Annotation of the suggestive transcriptomic signatures 
predicting treatment response also revealed one gene probe (for GSTM3) under cis-regulation. 
Finally, a number of suggestive conditional trans-eQTLs were identified, where the relationship 
between genotype and gene expression level at baseline was related to the outcome of 
antidepressant treatment response.  
 
7.4.2 Pattern of eQTLs 
Of the cis-eQTLs identified here, 19% are exact replications (with matching SNP, gene probe 
and direction of effect) of cis-eQTLs previously identified in an analysis of whole blood samples 
taken from over 5,000 individuals (Westra et al, 2013). Although we do not replicate any trans- 
eQTL signals, this is likely to be due to methodological differences; the Westra dataset only 
considers SNPs included in the NHGRI catalogue of genome-wide significant variants 
(n=4,542), in contrast to our whole genome approach.  
 
Indeed, much of the previous literature has focussed on cis-eQTLs with less research into the 
pattern of trans-eQTLs. This is in part due to the difficulties of the very large number of tests 
performed (in this analysis a total of 245,998,527,880 comparisons were performed). Trans- 
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eQTLs have not only been less frequently studied, but are also less reliably replicated between 
studies (Breitling et al, 2008). In light of this, we have used conservative corrections for multiple 
hypothesis testing; indeed many studies select thresholds separately for cis- and trans-eQTLs, 
whereas here we have corrected for all tests performed. But the lack of replication may also be 
due to both greater tissue- and context-specificity amongst trans-eQTLs (Fairfax et al, 2014; 
Price et al, 2011).  
 
Despite these difficulties in assessing trans-eQTLs, they are of biological importance and we felt 
it was important to characterise them within this dataset. The heritability estimates of gene 
expression indicate that trans-eQTLs are likely to have an important contribution to variance in 
gene expression (Grundberg et al, 2012), and it is also thought that master regulators of gene 
expression (such as transcription factors) will be identified through the analysis of trans-eQTL 
hotspots, where a single genetic locus will exert effects on the transcript of a wide range of 
genes (Breitling et al, 2008). We did not identify any hotspots in this relatively small sample; the 
maximum number of gene probes associated with a single SNP amongst the trans-eQTLs was 
12, and many of these genes were related ribosomal pseudogenes. Nevertheless, as more data 
become available, the presence of these potential hotspots can be better evaluated.  
 
7.4.3 Using eQTLs as an annotation tool in GWAS 
We observe significant enrichment of eQTL-SNPs amongst variants that have been previously 
linked to traits (consist with Nicolae et al, 2010), however the picture is less clear when 
focussing on those variants associated with antidepressant treatment response.  
 
Taking those SNPs reaching suggestive significance in the GWAS of antidepressant treatment 
response previously conducted in the GENDEP sample (Uher et al, 2010), only one variant is 
located within a cis-eQTL locus. Within this locus, there are a cluster of 52 SNPs in high LD 
which all have cis effects on expression levels of the gene CERS5. The protein encoded by this 
gene is ceramide synthase 5; ceramide is a lipid molecule found in cell membranes which is 
involved in cellular signalling, such as cell differentiation and apoptosis (Obeid et al, 1993).  
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There are a number of known pathways for ceramide production, but ceramide has been 
implicated in a number of complex traits, included neuronal growth and development, with the 
synthesis and accumulation of ceramide known to be induced by stress stimuli (Bikman and 
Summers, 2011). Given the links between depression and both neuronal growth and stress, this 
might be an interesting candidate for further follow-up, albeit with caution as not only is this 
association unreplicated, but also recent work has highlighted how colocalising a genetic 
association with an eQTL is not sufficient prove that the eQTL is causally linked to the 
phenotype of interest (Giambartolomei et al, 2014; Plagnol et al, 2009).   
 
As we have not found an enrichment of eQTLs amongst the suggestive genetic associations 
with response, it seems that using eQTL annotations to try to discriminate true signal from noise 
with antidepressant treatment response may be difficult to achieve given the current unreliability 
of eQTL annotation and the limited available sample sizes of antidepressant GWAS (where the 
signal to noise ratio may be too low). These problems have been also been highlighted as more 
general issues across a range of phenotypes when using cis-eQTL annotations to increase 
discovery for genome-wide analyses (Gagliano et al, 2014; Pickrell, 2014). This suggests that 
whilst eQTLs have potential as valuable annotation tools, further development is required to 
maximise their potential to gain insights into the biological pathways to disease.  
 
7.4.4 Annotation of transcriptomic signals 
When considering the potential transcriptomic predictors of treatment response, a cis-acting 
eQTL locus controlling expression levels of GSTM3 was identified. This gene appears to be of 
relevance to antidepressant response given its expression in the brain, and its role in oxidative 
stress, drug uptake and detoxification. Furthermore, in a chronic restraint model of depression, 
changes in expression levels of GSTM3, amongst other genes, were observed in rat brain, 
which were reversed with antidepressant treatment (Jungke et al, 2011). Whilst the association 
between gene expression levels prior to treatment and treatment response is only suggestive 
(p<0.0001), the link between gene expression differences and genotypic variability point to 




7.4.5 Treatment response conditional eQTLs  
Finally, exploring the relationship between genetic control of gene expression and the 
phenotype of antidepressant treatment response, no significant response-conditional eQTLs 
were observed. However, a number of suggestive trans-eQTLs were found. This links with 
previous indications that trans-eQTLs are more context-specific than cis-eQTLs (Fairfax et al, 
2014; van Nas et al, 2010), although as noted above, the pattern may be an artefact of poor 
reliability.  
 
The response conditional eQTLs may indicate that the genetic control of gene expression varies 
in a way which is predictive of later treatment response, and point to potential biological 
differences between those who are more or less likely to respond to antidepressant treatment. 
Therefore the SNPs and genes implicated in this analysis may point to the molecular pathways 
involved in antidepressant response. However, annotation within the suggestive conditional 
trans-eQTL probes identified here did not reveal any previously described pathways.  
 
7.4.6 Tissue-specificity of eQTLs 
All eQTL associations must be interpreted within the context of the observed tissue-specificity of 
eQTLs (as discussed in the Introduction). This analysis has been performed using peripheral 
blood samples and ease of collection means that this is usually the case. However, the primary 
tissue of interest for antidepressant response is the brain. It may be that there are phenotype-
relevant eQTLs that we are unable to detect in this analysis as they are only seen in brain tissue 
(or vice versa, some of the signals detected here may not be relevant as they are not present at 
the site of antidepressant action). Nevertheless, obtaining large samples of brain tissue for 
transcriptomic analysis is complex, with associated difficulties of post mortem changes in 
expression profiles and mRNA quality to be considered. Additionally, brain region-specific 
eQTLs have been reported (Hernandez et al, 2012), and the site of action for antidepressants is 
not known. Finally, to consider conditional eQTLs (where genotypic control of gene expression 
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prior to treatment is considered in the context of response after receiving treatment) would not 
be possible using brain tissue.  
 
7.4.7 Conclusions 
This chapter explores the pattern of eQTLs observed within the GENDEP dataset. Using these 
eQTLs, it has been possible to identify a cis-eQTL locus which controls expression levels of the 
gene CERS5 amongst the suggestive variants implicated in a previous GWAS on the GENDEP 
sample, as well as a cis-eQTL locus for the gene GSTM3 amongst the suggestive transcripts 
implicated in a previous transcriptomic analysis of the GENDEP sample.  
 
Both of these candidates show promise in terms of the relevance of their known functions to 
antidepressant treatment outcomes, and replication of the identified eQTLs are observed in 
other datasets. However, it should be remembered that evidence linking these genes to 
treatment response remains suggestive and unreplicated at this stage, and evidence causally 
linking the eQTL to the phenotype has not be found.  
 
Nonetheless, the analysis presented here demonstrates how understanding the genetic effects 
on gene expression levels may be useful for identifying trait-associated genetic variants, and 
understanding how they exert their effects. Furthermore, the approach highlights that if 
phenotype-dependent eQTLs can be identified, they may give insight into the biological 
differences underlying that phenotype. The potential value of eQTLs for dissecting molecular 
consequences of genetic variability will only increase in the future, as our understanding and 













8.1 Summary of principal findings 
In this thesis I aimed to identify genetic biomarkers of antidepressant outcomes, within the 
GENDEP dataset. I have used a number of different approaches, including candidate gene, 
transcriptomic and eQTL-based methodologies to explore biomarkers that predict treatment 
outcomes (both wanted and unwanted) and index the biological mechanisms that underpin 
therapeutic efficacy.  
 
8.1.1 Predicting treatment outcomes 
8.1.1.1 Genetic predictors of antidepressant side effects 
After grouping the many different antidepressant side effects using knowledge about their 
pharmacological basis, candidate gene analysis revealed that risk of serotonergic side effects 
was associated with variation in the HTR2C gene. However, when attempting replication of 
these findings in GenPod (a pharmacogenetic study of antidepressants with similar design 
features to GENDEP), this association was not observed. Nevertheless, this approach 
demonstrates that the rational grouping of side effects based on their known pharmacological 
causes may be a useful method to condense the large number of different side effects reported 
with antidepressant treatment.  
 
As Kato and Serretti (2010) highlight, the large number of different possible outcomes has been 
a key limitation in the current literature regarding the genetic predictors of these ADRs. 
Therefore the work presented in Chapter 3 offers a novel method which may enable 
researchers to gain traction on this issue, condensing the large number of reported outcomes 
into a smaller number of variables, without losing the detail necessary to capture the important 
mechanistic differences between side effects. This is the key message of the analysis; 
nonetheless we have been able to highlight genetic associations with antidepressant side 
effects which align with existing literature on the role of HTR2C in side effects associated with 
antipsychotic treatment (Reynolds et al, 2005), although the failure to replicate this association 





Whilst the candidate gene approach used in Chapter 3 has the limitation of not surveying the 
entire genome, there is strong pharmacological evidence of the mechanisms underlying side 
effects which justifies the selection of the candidates used. Further, given the profiles of ADRS 
across the course of the 12 week study, a longitudinal model is an important strength of the 
approach which could not be easily employed within a genome-wide approach. Nevertheless, 
the limitations of candidate gene studies are discussed within the introduction, and the 
important of replication and validation of these analyses is key.  
 
8.1.1.2 Drug metabolism variables in treatment outcomes 
When exploring the pharmacokinetics of antidepressant response, genotypic variability in the 
cytochrome P450 enzymes was found to be unrelated to treatment response, side effects or 
study discontinuation. Furthermore, serum concentrations of antidepressants were not 
predictive of either response or the majority of side effects measured. Associations between 
serum drug concentration and dry mouth were observed for patients taking nortriptyline, and for 
patients taking escitalopram, drug concentration was linked to the rarer side effects of diarrhoea 
and dizziness. Nevertheless, beyond these specific ADRs, the findings here show that the 
observed variability in treatment outcomes is not due to pharmacokinetic factors.  
 
The data presented in Chapter 4 builds on previous work linking CYP450 genotypes to serum 
levels of antidepressant (for example, Rudberg et al, 2006; Rudberg et al, 2008; Kirchheiner et 
al, 2004), giving further information on the relationship within a large, well-phenotyped patient 
sample receiving  escitalopram or nortriptyline.  
 
When addressing the key clinical question of whether these effects on rates of drug metabolism 
have an impact on treatment outcomes, the previously published, extensive review from 
Matchar et al highlighted the limitations in the available evidence in 2007, with a paucity of 
studies examining the link between CP450 genotype and treatment outcomes. The evidence 
presenting in this thesis, together with other publications published since 2007 (including Peters 
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et al 2008; Mrazek et al 2011; Serretti et al 2009) all represent important efforts to tackle this 
issue. Generally, our findings align with these other reports, even in papers where associations 
are reported (for example Mrazek et al 2011) these effects are generally small in size, and do 
not survive correction for multiple hypothesis testing, suggesting that they lack the robustness 
required to be translationally valuable.  
 
The absence of association between CYP450 genotype and treatment outcomes in clinical 
cohorts is not surprising, given the therapeutic windows of antidepressants. Unlike drugs such 
as warfarin, where the therapeutic window is very small due to the severe and lethal side effects 
associated with high levels of drug, many antidepressants (in particular SSRIs) have relatively 
large therapeutic windows, with low risk of severe adverse drug reactions when higher doses 
are prescribed. Therefore, clinicians are able to adjust the prescribed dose in response to poor 
efficacy or side effects.  
It is important to remember that the design of GENDEP means that it is only possible to 
conclude the extent to which CYP450 genotypes are linked to treatment outcomes in patients 
under clinical observation, where doses can be adjusted in response to side effects or lack of 
efficacy. Nevertheless, the fixed-dosage study published by Steimer et al (2005) looking at 
patients taking amitriptyline also failed to find an association with treatment response. Putting 
the evidence presented within this thesis together with the other literature published in the area, 
it would seem that the potential value of CYP450 genotyping of patients who are to be 
prescribed antidepressants is far from being established, and should not be recommended to 
clinicians without substantial further evidence, and clear demonstration that treatment guided by 
CYP450 genotyping can improve patient outcomes. 
 
8.1.2 Understanding the biological mechanisms underpinning response 
8.1.2.1 Gene expression correlates of treatment response 
Analysis of transcriptomic changes associated with antidepressant treatment indicated that 
response-correlated changes in gene expression levels occur at a network level. One module of 
coexpressed genes showed significant correlation with treatment response, and this relationship 
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appeared to be general rather than drug-specific. Annotation of the implicated module highlights 
pathways related to “Cellular Assembly and Organisation, Nervous System Development and 
Function, Cell Signalling”, which is consistent with existing neurotrophic theories of 
antidepressant action. Therefore, the results indicate that systems-level investigations into 
neurotrophic processes may prove fruitful in unveiling the mechanisms of antidepressant action.  
 
As the largest analysis of transcriptomic changes associated with antidepressant treatment to 
date, these findings are useful for placing previous research looking at expression changes 
within individual candidate genes in context. The findings presented here indicate that there are 
no single genes which show large changes in expression level, instead complex network-level 
changes are seen to be associated with treatment response. This evidence is consistent not 
only with what is known about the effects of antidepressants on neurobiology but also with the 
accumulating literature demonstrating that DNA variation in single genes do not have a 
predictive effect on treatment outcomes (Tansey et al, 2013), in that it indicates that 
antidepressant treatment response is a complex phenotype with multiple factors interacting in a 
complex system. Nevertheless, the data presented here is still from a limited sample size; to 
identify which genes are involved in these networks underlying treatment response, larger 
samples are needed, and replication of these findings is required. In particular, it is important 
that these findings are replicated with reference to treatment response outcomes (as opposed 
to simply taking antidepressant medications), as these will be the most informative with respect 
to understanding the mechanisms of effective antidepressant treatment.  
 
8.1.2.2 Identification and exploration of eQTLs 
Moving to more generally consider the mechanism through which genetic differences might 
influence gene expression, the pattern of eQTLs within this dataset was established, with 
25,269 cis- and 5,898 trans-eQTLs observed. Exploring the value of this data as a potential 
bioinformatics tool, eQTL annotations could be made for two previously identified genetic 
(CERS5) and transcriptomic (GSTM3) predictors of treatment response, highlighting them as 




Whilst the work presented here has been conducted on a sample size that is much smaller than 
many other studies exploring eQTLs (for example, Westra et al (2013) included data from 5,311 
individuals in their meta-analysis with an additional 2,775 in a replication set), it is encouraging 
to note that within GENDEP it is possible to replicate many of the eQTLs that have previously 
been identified.  
 
The key purpose of Chapter 7 was to demonstrate how the identification of eQTLs can be 
exploited to identify important candidates within suggestive findings for further follow up and to 
begin to build a pathway between genotype and phenotype. To this end, the results are 
intriguing. Whilst the evidence linking CERS5 and GSTM3 to treatment response in GENDEP is 
only suggestive, the annotation of these candidates as eQTLs in the analysis presented here is 
also observed within other datasets. Furthermore, the known action of these genes links very 
well with what is known about the pathways underpinning antidepressant efficacy. CERS5 
encodes ceramide synthase 5; ceramide is not only linked to neuronal development but its 
synthesis is linked to stress-related stimuli (Bikman and Summer 2011). Similarly, GSTM3 
encodes glutathione S-transferase, which is expressed in the brain, plays a key role in drug 
uptake and has previously been linked to depression and antidepressant phenotypes in animal 
models (Jungke et al 2011). Nevertheless, the important question of the tissue specificity of 
these eQTLs is yet to be addressed, and identification of an eQTL at a gene of interest does not 
prove that this eQTL is causally linked to the phenotype of interest.  
 
Finally, the evidence within this chapter also includes a preliminary investigation of how the 
context-specificity of eQTLs demonstrated by Fairfax et al (2014) might also be observed when 
considering clinical phenotypes. Whilst no antidepressant-response conditional eQTLs reached 
significance, a number of suggestive conditional trans-eQTLs were observed. Further 






Whilst the limitations specific to each analysis have been outlined within the relevant chapters, 
there are some overarching limitations that are important to bear in mind when interpreting the 
evidence presented here.  
 
One issue which is recurrent throughout this thesis is that of statistical power. GENDEP is 
amongst the largest studies considering the genetics of antidepressant treatment response, 
alongside STAR*D (Rush et al, 2004), GenPod (Thomas et al, 2008) and MARS (Hennings et 
al, 2009). But whilst these datasets have been critical in establishing the genetic architecture of 
treatment response as a complex polygenic trait, even larger samples will be required to identify 
genetic biomarkers of treatment outcomes.  
 
In order to obtain a sample of 868 patients, GENDEP incorporated several pragmatic design 
features to broaden recruitment potential. These included non-random allocation to treatment in 
cases where patients had existing contra-indications to one of the study medications, the 
absence of a placebo arm, and a flexible dosing protocol rather than a fixed dosage design. 
Each of these features may add confounds to the design, but as March et al. (2005) have 
highlighted, the inclusion of more patients through these pragmatic features increases the 
generalizability of findings. Nevertheless, the requirement that all patients were Caucasian (to 
limit population stratification in genetic analyses), as well as the weekly clinical contact (either 
via telephone or face-to-face interview), may be of importance when considering translation into 
the clinic.  
 
A further consideration is that GENDEP focusses on only two of the many antidepressants 
currently available. The selection of escitalopram and nortriptyline as study medications was 
designed to give maximum value, as these drugs have similar efficacy but differentially affect 
two of the key neurotransmitter systems targeted by antidepressants. Nevertheless, the 
relevance of findings within this sample to patients taking other medications must be 
established. This is particularly the case with antidepressants which have mechanisms of action 
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involving different neurotransmitter systems (for example, agomelatine which targets melatonin 
and serotonin 2C receptors). 
 
Finally, a key issue to consider in any research effort exploring antidepressant treatment is the 
intense debate surrounding the issue of antidepressant efficacy relative to placebo (Horder et 
al, 2011; Kirsch et al, 2008), the impact of publication bias in the literature (Turner et al, 2008) 
and the relative efficacy of different medications (Cipriani et al, 2009; Gartlehner et al, 2011). 
This debate is not limited to the use of medications for the treatment of MDD, but also applies to 
the evidence regarding psychotherapy (for example, discussed by Nutt and Sharpe, 2008). 
Nonetheless, the only way to tackle the debate about the benefits of these medications is 
through further research, to better understand how they exert their effects, and why outcomes 
are so variable between patients.  
 
8.3 Implications of findings 
8.3.1 Clinical implications 
Given the absence of any replicated genetic biomarkers of treatment outcomes, the research 
presented here is not at a stage where findings can be translated into the clinic. Nevertheless, 
given the interest regarding the potential for pharmacogenetics in guiding treatment, effective 
communication of findings to clinicians is important. This is particularly relevant for the null 
findings regarding the role of pharmacokinetics on variability in outcomes (presented in Chapter 
4 & 5), given the hype surrounding the potential of CYP450 genotyping (as discussed by 
Matchar et al, 2007a). Whilst the study design of GENDEP means that it is not possible to draw 
conclusions regarding the value of genotyping prior to treatment, on reviewing the literature in 
this field, there is also a scarcity of well-powered studies to address this question. To ensure 
that clinicians can base their treatment recommendations on the best available evidence, it is 




8.3.2 Research implications 
Whilst the findings presented here cannot yet be used to guide treatment or the development of 
novel medications, they do have broader implications for further research efforts. Both within 
this thesis and more broadly across pharmacogenetics of antidepressant response, findings 
indicate that treatment response is a complex phenotype almost certainly involving many genes 
of small effect (GENDEP Investigators; MARS Investigators; STAR*D Investigators, 2013; 
Tansey et al, 2013; Tansey et al, 2012). This is counter to the early hopes that 
pharmacogenetic phenotypes might prove simpler than common familial disease phenotypes, 
but fits with the complexity and redundancy that we know exists within the brain. Furthermore, 
given that depression is a complex phenotype likely to involve many different molecular 
components, then it is fitting that effective treatment mirrors this complexity.  
 
The evidence regarding antidepressant-linked side effects suggests a similar complex genetic 
basis, but in light of the importance of ADRs for treatment outcomes, similar efforts to 
empirically establish the role of genetics in ADRs using a genome-wide complex trait analysis 
(GCTA) approach would be valuable. However, the additional complexity of many different 
outcomes has limited research to date. 
 
In the context of this complex polygenic phenotype, “omic” approaches are needed, where the 
entire genome or transcriptome is considered. This is clearly demonstrated by the 
transcriptomic analysis in Chapter 6, where correlates of treatment response were only 
identified using system level analyses. This was the case because the signal of changes in 
gene expression levels was distributed across many genes within the same network.  
 
Furthermore, in the face of this phenotypic complexity, this thesis has demonstrated the value of 
layering together different levels of information to dissect the molecular mechanisms involved in 
antidepressant action. This involves not only using pharmacological information (as in Chapters 
3, 4 and 5), but also the use of different layers of genetic data (as shown in Chapter 7). Further 
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approaches considering methylomic, proteomic and metabolomic data may also prove fruitful in 
tracing the molecular pathway of antidepressant action. 
 
8.4 Future directions 
Looking ahead to how research in this field may progress, there are two complementary 
approaches that will be valuable in driving forward our understanding of the genetic 
underpinnings of antidepressant action.  
 
The first approach is to continue with the development of more sophisticated methodological 
approaches to genome-wide analysis. This may include using bioinformatic data, such as the 
application of functional annotations (explored with the eQTL analysis presented in Chapter 7). 
It has been shown that within a Bayesian framework, it is possible to extract more signal from 
genomic analyses (Gagliano et al, 2014), and with improved annotation data, the success of the 
approach should increase further. Additionally, given the polygenic nature of the phenotype, 
multivariate methods which allow exploration of how effects might be distributed across many 
genetic predictors are likely to be of value. For example, machine learning techniques can be 
used to capture a signal which is diffusely spread across a large number of predictor variables, 
and are increasingly being considered within the field of genetics, exploring both genomic 
(Bureau et al, 2005) and transcriptomic (Pirooznia et al, 2008) data.  
 
The second approach is to gain more statistical power for genome-wide analyses by increasing 
sample sizes, using strategies that will enable easier and cheaper collection of genetic and 
treatment response data from patients.  One potential avenue by which this could be achieved 
is through the use of electronic medical records. Schemes such as the NIHR Bioresource 
(http://bioresource.nihr.ac.uk/), involve large scale collection of biological samples for genomic 
analyses, which are then linked to the information that is contained within patient records. 
These datasets can then be mined for patients with relevant phenotypic features. Given the high 
prescription rates for antidepressants, these methods could potentially collect information on 
very large numbers of patients, albeit at the cost of increased sample heterogeneity, and the 
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non-random allocation of patients to treatment. Furthermore, developments in mobile 
technology and online assessment tools allow the easy administration of questionnaires to rate 
symptoms and side effects. If data from these sources could be integrated into medical records, 
then in-depth, longitudinal data on treatment outcomes would be available without the need for 
researchers to undertake face-to-face or telephone assessments for all study participants.  
 
8.5 Conclusions 
Major depressive disorder is a huge public health issue, and is projected to be the number one 
cause of disease burden across the globe by 2030 (World Health Organisation, 2008). But 
currently, our ability to treat the illness is limited, with only 30% of patients achieving remission 
with their first treatment medication (Trivedi et al, 2006). However, the variability that is seen in 
treatment outcomes is known to be determined, in part, by genetics (Tansey et al, 2013). It is 
not yet possible to identify the specific genes that are involved in treatment efficacy, but 
examples of genetic research in other traits such as diabetes (Morris et al, 2012) or 
schizophrenia (Schizophrenia Working Group of the Psychiatric Genomics, 2014) indicate that 
continued efforts to collect larger samples will be successful. Once genetic biomarkers have 
been identified, they have huge potential in improving treatment options for MDD. The 
identification of response-linked genes gives an important window into the biology of 
antidepressant action, which may enable the development of novel treatments. Furthermore, if 
these markers can be used to predict outcomes prior to treatment, they have the potential to 
shorten treatment times, improve response rates and reduce side effects, with only a simple 
and relatively low cost genetic test required. Therefore, the continued research effort into 
identifying genetic predictors of antidepressant outcomes has the potential to have a real impact 
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Appendix C. Modified Toronto Side Effects Scale 
Your symptoms 
 
The following questions ask you about symptoms you may have experienced during the past 
week.  Please tick only one answer for each question. 
 
On how many days have you had…… None 1-3 days 4-7 days 
  1. Back pain 
1 2 3 
  2. Chest pain 
1 2 3 
  3. Stiffness in your arms or legs 
1 2 3 
  4. Headaches 
1 2 3 
  5. Sore throat 
1 2 3 
  6. Tenderness of the glands in your neck 
1 2 3 
  7. A rapid heart beat 
1 2 3 
  8. Tremor 
1 2 3 
  9. Agitation  
1 2 3 
10. Dry mouth 
1 2 3 
11. Excessive sweating 
1 2 3 
12. Tingling in your limbs, fingers or toes 
1 2 3 
13. Stomach pains 
1 2 3 
14. Constipation 
1 2 3 
15. Diarrhoea 
1 2 3 
16. Felt sick or nauseous 
1 2 3 
17. Noticed changes in the way your food tastes 
1 2 3 
18. Daytime drowsiness 
1 2 3 
19. Light headedness or dizziness 
1 2 3 
20. Shortness of breath at rest 









On how many days have you had…… None 1-3 days 4-7 days 
21. Ringing in the ears 
1 2 3 
22. Increased sensitivity to light or noise 
1 2 3 
23. Difficulty or pain passing urine 
1 2 3 
24. Passed urine more often 
1 2 3 
25. Swelling of your breasts 
1 2 3 
26. Skin rash or irritation 
1 2 3 
27. Hot flushes 
1 2 3 
28. Difficulty sleeping 
1 2 3 
If you have had any OTHER PHYSICAL SYMPTOMS during the past week that are not 
included in the above list, please specify below
 
29. 
1 2 3 
30. 
1 2 3 
 
FOR MEN ONLY 
In the past week, have you had any…… Yes No Not applicable 
31. Difficulty ejaculating 
1 2 3 
32. Impotence (difficulty getting/maintaining an erection) 
1 2 3 
 
FOR WOMEN ONLY 
In the past month, have you had any…… Yes No Not applicable 
33. Problems with your periods 
1 2 3 














Appendix D. Supplementary results for Chapter 3.  
One of the differences between the GENDEP and GenPod samples is the frequency with which ADRs were measured throughout the st
were measured on a weekly basis, whilst in GenPod, they were measured at week six and week twelve of the study. In order to test whether this difference might 
contribute to the discrepant findings between the two studies, the GENDEP analysis was repeated using only the ADR data colle
The significant association between genetic variation in HTR2C and the occurrence of serotonergic ADRs was still observed (see 
difference in the frequency with which ADRs were measured is not responsible for the divergent results in the two samples.
Table 10-1: Genetic association with serotonergic adverse drug reactions in GENDEP using only week six and week twelve data (whole sample
MAF= minor allele frequency, n=number of individuals, Obs=total number of observations across 2 timepoints. Odds Ratios are per minor allele. SNPs shown are those that reach 
significance, when correcting for the number of SNPs testing within the HTR2C gene (p<0.00520) 
Gene C’some SNP Location Allele MAF n Obs 
HTR2C X 
rs6644093 114064023 T/G 0.15 300 503 0.0001
rs12846241 113854086 G/T 0.18 300 503 0.0036
rs2428700 114010664 A/G 0.14 299 502 0.0041
rs4332303 114047867 T/C 0.14 300 503 0.0040
rs5946005 114082535 G/A 0.14 300 503 0.0040
rs5988087 113934856 T/C 0.16 300 503 0.0014
rs11167436 113944060 A/C 0.16 300 503 0.0014
rs556677 113822902 A/G 0.16 300 503 0.0025
rs543229 113820986 C/T 0.17 300 503 0.0031
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10.1.1 Supplementary analysis of expanded gene region 
To consider whether more distant variants were involved in determining individual risk to 
antidepressant side effects, the region surrounding each candidate gene was expanded to 
cover 50KB up and downstream. This expanded approach was only possible within the 
GENDEP sample.  
 
An additional 360 SNPs were identified (the number of new and old SNPs per gene are shown 
in Table 10-2. Using SNPSpD, the addition of these extra variants was assessed to give a new 
threshold of significance of p<7.59x10-5. These additional variants enabled assessment of 
variation in the candidate genes HTR1B, HTR1D, HTR1F and CHRM4, which was not possible 
in the primary analysis.   
 
Repeating the analysis in the framework of the primary analysis, each variant was tested for 
association with cholinergic, serotonergic, adrenergic and histaminergic side effects, using 
logistic regressions as detailed in the Methods section of Chapter 3. The analyses were 
conducted in the whole sample, and then in escitalopram and nortriptyline subsets.  
 
The association of rs6644093 with serotonergic ADRs remained significant, exceeding the more 
stringent significance threshold set for this expanded analysis. Only one of the additional 
variants showed significant association with any of the four phenotypes (serotonergic, 
cholinergic, adrenergic and histaminergic ADRs) tested, when performing whole sample and 
drug-specific analyses. This variant (rs6467694) is 7318bp downstream from the UTR of the 
CHRM2 gene, and showed significant association with cholinergic outcomes in the whole 
sample analysis (OR=3.09, 95% CI=1.81-5.29, p=3.75 x 10-5). The function of the variant is 
unknown, with a minor allele frequency of 9.3% in the GENDEP sample.  
 
Figure 10-1 shows the pattern of association with cholinergic side effects across the CHRM2 
gene. The gene-wide significance threshold for CHRM2, when additional variants are included 
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is p<0.00107; but no other SNPs within the gene reached this threshold. Furthermore, 
rs6467694 failed to reach gene-wide significance in either of the drug-specific analyses.  
 
The occurrence of cholinergic side effects for each genotype at rs6467694, for the whole 
sample is shown in Figure 10-2. It should be noted that the prevalence of cholinergic symptoms 
at baseline (prior to receiving an antidepressant) differs between genotypic categories.  
 
Table 10-2: Additional markers included by extending analysis to encompass 50KB up and downstream of 
the gene. 
Candidate gene 




in extended analysis 
(50KB) 
Total markers per 
gene 
SLC6A2 47 14 61 
ADRA1A 53 36 89 
ADRA1B 14 20 34 
ADRA1D 7 27 34 
SCL6A4 21 7 28 
HTR1A 3 9 12 
HTR1B 0 29 29 
HTR1D 0 13 13 
HTR1E 9 20 29 
HTR1F 0 14 14 
HTR2A 51 35 86 
HTR2B 2 7 9 
HTR2C 14 9 23 
HTR3A 9 15 24 
HTR3B 5 10 15 
HTR3C 2 4 6 
HTR3D 5 25 30 
HTR3E 2 10 12 
CHRM1 3 11 14 
CHMR2 32 23 55 
CHRM3 119 10 129 
CHRM4 0 4 4 
CHRM5 16 6 22 
HRH1 22 2 24 





Figure 10-1: Regional association plot showing SNPs within CHRM2 and association with cholinergic side 
















































Appendix E. Supplementary results for Chapter 5.  
Table 10-3: Association between specific ADRs and CYP450 genotype or serum levels of antidepressant, 
for patients taking nortriptyline 
Dry mouth n obs p OR SE 
CYP2D6 genotype 251 2182 0.111 0.710 0.153 
nortriptyline 184 1888 0.002 1.826 0.362 
10-hydroxynortriptyline 180 1845 1.20E-04 2.100 0.405 
ratio (10-hydroxynortriptyline: nortriptyline) 178 1830 0.041 1.406 0.234 
total (nortriptyline + 10-hydroxynortriptyline) 187 1830 4.97E-05 2.284 0.465 
Drowsiness n obs p OR SE 
CYP2D6 genotype 251 2178 0.844 1.032 0.164 
nortriptyline 184 1884 0.695 1.054 0.142 
10-hydroxynortriptyline 180 1841 0.996 0.999 0.123 
ratio (10-hydroxynortriptyline: nortriptyline) 178 1826 0.277 1.172 0.171 
total (nortriptyline + 10-hydroxynortriptyline) 178 1826 0.794 1.033 0.129 
Insomnia n obs p OR SE 
CYP2D6 genotype 251 2160 0.395 0.838 0.174 
nortriptyline 182 1866 0.486 0.908 0.126 
10-hydroxynortriptyline 179 1835 0.655 1.087 0.202 
ratio (10-hydroxynortriptyline: nortriptyline) 177 1820 0.086 1.264 0.172 
total (nortriptyline + 10-hydroxynortriptyline) 177 1820 0.921 0.985 0.153 
Blurred vision n obs p OR SE 
CYP2D6 genotype 250 2172 0.681 1.125 0.323 
nortriptyline 183 1878 0.849 0.972 0.145 
10-hydroxynortriptyline 179 1835 0.514 0.916 0.123 
ratio (10-hydroxynortriptyline: nortriptyline) 177 1820 0.775 1.040 0.142 
total (nortriptyline + 10-hydroxynortriptyline) 177 1820 0.697 0.953 0.119 
Headache n obs p OR SE 
CYP2D6 genotype 251 2176 0.127 1.320 0.241 
nortriptyline 183 1874 0.023 0.678 0.115 
10-hydroxynortriptyline 179 1831 0.325 0.857 0.134 
ratio (10-hydroxynortriptyline: nortriptyline) 177 1816 0.220 1.165 0.145 
total (nortriptyline + 10-hydroxynortriptyline) 177 1816 0.052 0.713 0.124 
Constipation n obs p OR SE 
CYP2D6 genotype 251 2181 0.075 0.687 0.145 
nortriptyline 184 1887 0.175 1.224 0.183 
10-hydroxynortriptyline 180 1845 0.658 0.944 0.122 
ratio (10-hydroxynortriptyline: nortriptyline) 178 1830 0.487 0.893 0.146 
total (nortriptyline + 10-hydroxynortriptyline) 178 1830 0.472 1.097 0.141 
Diarrhoea n obs p OR SE 
CYP2D6 genotype 251 2181 0.125 1.898 0.793 
nortriptyline 184 1888 0.654 1.113 0.266 
10-hydroxynortriptyline 180 1845 0.016 0.652 0.116 
ratio (10-hydroxynortriptyline: nortriptyline) 178 1830 0.077 0.624 0.166 
total (nortriptyline + 10-hydroxynortriptyline) 178 1830 0.579 0.879 0.204 
Increased Appetite n obs p OR SE 
CYP2D6 genotype 251 2182 0.978 0.994 0.224 
nortriptyline 184 1888 0.191 1.212 0.178 
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10-hydroxynortriptyline 180 1845 0.768 1.044 0.151 
ratio (10-hydroxynortriptyline: nortriptyline) 178 1830 0.751 0.953 0.145 
total (nortriptyline + 10-hydroxynortriptyline) 178 1830 0.248 1.174 0.163 
Decreased Appetite n obs p OR SE 
CYP2D6 genotype 251 2180 0.696 0.923 0.189 
nortriptyline 184 1888 0.254 0.828 0.137 
10-hydroxynortriptyline 180 1845 0.451 0.871 0.160 
ratio (10-hydroxynortriptyline: nortriptyline) 178 1830 0.662 1.086 0.204 
total (nortriptyline + 10-hydroxynortriptyline) 178 1830 0.219 0.818 0.134 
Nausea/vomiting n obs p OR SE 
CYP2D6 genotype 251 2176 0.740 0.911 0.257 
nortriptyline 184 1885 0.420 0.849 0.172 
10-hydroxynortriptyline 180 1842 0.122 0.763 0.133 
ratio (10-hydroxynortriptyline: nortriptyline) 178 1827 0.577 1.090 0.169 
total (nortriptyline + 10-hydroxynortriptyline) 178 1827 0.196 0.767 0.157 
Problems with urination n obs p OR SE 
CYP2D6 genotype 251 2178 0.111 1.591 0.464 
nortriptyline 184 1885 0.318 0.704 0.248 
10-hydroxynortriptyline 180 1842 0.637 0.923 0.157 
ratio (10-hydroxynortriptyline: nortriptyline) 178 1827 0.242 1.233 0.220 
total (nortriptyline + 10-hydroxynortriptyline) 178 1827 0.477 0.846 0.199 
Problems with sexual function n obs p OR SE 
CYP2D6 genotype 247 2087 0.814 0.960 0.166 
nortriptyline 181 1812 0.867 0.978 0.130 
10-hydroxynortriptyline 177 1769 0.969 0.994 0.150 
ratio (10-hydroxynortriptyline: nortriptyline) 175 1754 0.760 0.954 0.148 
total (nortriptyline + 10-hydroxynortriptyline) 175 1754 0.958 1.008 0.142 
Palpitations n obs p OR SE 
CYP2D6 genotype 251 2178 0.933 0.985 0.182 
nortriptyline 184 1888 0.775 0.964 0.124 
10-hydroxynortriptyline 180 1845 0.567 1.069 0.125 
ratio (10-hydroxynortriptyline: nortriptyline) 178 1830 0.096 1.249 0.167 
total (nortriptyline + 10-hydroxynortriptyline) 178 1830 0.803 1.031 0.126 
Feeling light-headed on standing n obs p OR SE 
CYP2D6 genotype 251 2180 0.867 1.033 0.199 
nortriptyline 184 1888 0.679 1.055 0.137 
10-hydroxynortriptyline 180 1845 0.178 1.187 0.151 
ratio (10-hydroxynortriptyline: nortriptyline) 178 1830 0.425 1.106 0.139 
total (nortriptyline + 10-hydroxynortriptyline) 178 1830 0.275 1.157 0.155 
Feeling like the room is spinning n obs p OR SE 
CYP2D6 genotype 250 2167 0.184 1.343 0.298 
nortriptyline 183 1873 0.382 0.886 0.122 
10-hydroxynortriptyline 179 1830 0.848 1.030 0.159 
ratio (10-hydroxynortriptyline: nortriptyline) 177 1815 0.533 1.105 0.177 
total (nortriptyline + 10-hydroxynortriptyline) 177 1815 0.622 0.930 0.137 
Sweating n obs p OR SE 
CYP2D6 genotype 251 2181 0.573 1.128 0.242 
nortriptyline 184 1887 0.028 0.720 0.108 
10-hydroxynortriptyline 180 1844 0.846 0.974 0.131 
ratio (10-hydroxynortriptyline: nortriptyline) 178 1829 0.015 1.424 0.207 
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total (nortriptyline + 10-hydroxynortriptyline) 178 1829 0.130 0.812 0.112 
Increased body temperature n obs p OR SE 
CYP2D6 genotype 248 2158 0.367 1.358 0.461 
nortriptyline 182 1867 0.007 0.399 0.136 
10-hydroxynortriptyline 178 1824 0.403 0.794 0.219 
ratio (10-hydroxynortriptyline: nortriptyline) 176 1809 0.098 1.460 0.334 
total (nortriptyline + 10-hydroxynortriptyline) 176 1809 0.021 0.514 0.148 
Tremor n obs p OR SE 
CYP2D6 genotype 251 2181 0.022 0.641 0.124 
nortriptyline 184 1886 0.117 1.223 0.157 
10-hydroxynortriptyline 180 1843 0.627 1.061 0.130 
ratio (10-hydroxynortriptyline: nortriptyline) 178 1828 0.660 1.065 0.154 
total (nortriptyline + 10-hydroxynortriptyline) 178 1828 0.146 1.195 0.147 
Disorientation n obs p OR SE 
CYP2D6 genotype 239 2070 0.643 1.139 0.321 
nortriptyline 183 1877 0.879 1.029 0.191 
10-hydroxynortriptyline 179 1834 0.604 0.923 0.143 
ratio (10-hydroxynortriptyline: nortriptyline) 177 1819 0.837 0.965 0.166 
total (nortriptyline + 10-hydroxynortriptyline) 177 1819 0.926 1.018 0.194 
Yawning n obs p OR SE 
CYP2D6 genotype 251 2181 0.402 0.814 0.200 
nortriptyline 184 1887 0.642 0.922 0.161 
10-hydroxynortriptyline 180 1844 0.977 0.994 0.205 
ratio (10-hydroxynortriptyline: nortriptyline) 178 1829 0.501 1.117 0.184 
total (nortriptyline + 10-hydroxynortriptyline) 178 1829 0.708 0.930 0.181 
Weight gain n obs p OR SE 
CYP2D6 genotype 251 2171 0.563 0.911 0.146 
nortriptyline 184 1876 0.361 1.123 0.143 
10-hydroxynortriptyline 180 1833 0.464 0.913 0.113 
ratio (10-hydroxynortriptyline: nortriptyline) 178 1818 0.454 0.907 0.118 





Table 10-4: Association between specific ADRs and CYP450 genotype or serum levels of antidepressant, 
for patients taking escitalopram 
Dry mouth n obs p OR SE 
CYP2C19 genotype 340 3323 0.964 1.004 0.091 
escitalopram 275 2969 6.85E-04 1.480 0.170 
desmethylcitalopram 205 2233 0.002 1.420 0.159 
ratio (desmethylcitalopram: escitalopram) 204 2221 0.616 0.931 0.133 
total (escitalopram + desmethylcitalopram) 204 2221 1.20E-03 1.496 0.186 
Drowsiness n obs p OR SE 
CYP2C19 genotype 336 3274 0.766 0.978 0.074 
escitalopram 272 2930 0.005 1.335 0.137 
desmethylcitalopram 203 2206 0.003 1.314 0.122 
ratio (desmethylcitalopram: escitalopram) 202 2194 0.293 0.872 0.114 
total (escitalopram + desmethylcitalopram) 202 2194 0.007 1.357 0.153 
Insomnia n obs p OR SE 
CYP2C19 genotype 340 3323 0.936 1.006 0.071 
escitalopram 275 2968 0.434 0.919 0.099 
desmethylcitalopram 205 2234 9.01E-01 1.014 0.117 
ratio (desmethylcitalopram: escitalopram) 204 2222 0.499 1.081 0.125 
total (escitalopram + desmethylcitalopram) 204 2222 0.497 0.922 0.110 
Blurred vision n obs p OR SE 
CYP2C19 genotype 339 3307 0.200 1.123 0.102 
escitalopram 275 2963 0.301 1.142 0.147 
desmethylcitalopram 205 2227 0.077 1.230 0.144 
ratio (desmethylcitalopram: escitalopram) 204 2215 0.381 1.125 0.152 
total (escitalopram + desmethylcitalopram) 204 2215 0.237 1.193 0.179 
Headache n obs p OR SE 
CYP2C19 genotype 339 3311 0.770 0.979 0.070 
escitalopram 275 2966 0.983 1.002 0.096 
desmethylcitalopram 205 2230 0.669 0.958 0.097 
ratio (desmethylcitalopram: escitalopram) 204 2218 0.459 1.085 0.120 
total (escitalopram + desmethylcitalopram) 204 2218 0.869 0.982 0.109 
Constipation n obs p OR SE 
CYP2C19 genotype 340 3322 0.214 0.868 0.099 
escitalopram 275 2967 0.477 1.107 0.159 
desmethylcitalopram 205 2231 0.131 1.200 0.145 
ratio (desmethylcitalopram: escitalopram) 204 2219 0.397 0.865 0.148 
total (escitalopram + desmethylcitalopram) 204 2219 0.237 1.196 0.181 
Diarrhoea n obs p OR SE 
CYP2C19 genotype 339 3311 0.153 0.870 0.085 
escitalopram 274 2958 0.032 1.269 0.141 
desmethylcitalopram 204 2222 0.608 1.066 0.133 
ratio (desmethylcitalopram: escitalopram) 203 2210 4.96E-04 0.597 0.088 
total (escitalopram + desmethylcitalopram) 203 2210 0.010 1.368 0.167 
Increased Appetite n obs p OR SE 
CYP2C19 genotype 338 3299 0.199 0.892 0.080 
escitalopram 272 2934 0.815 1.028 0.122 
desmethylcitalopram 202 2199 0.522 0.886 0.168 
ratio (desmethylcitalopram: escitalopram) 201 2187 0.316 0.835 0.150 
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total (escitalopram + desmethylcitalopram) 201 2187 0.537 0.905 0.147 
Decreased Appetite n obs p OR SE 
CYP2C19 genotype 340 3324 0.856 1.016 0.089 
escitalopram 274 2960 0.522 0.924 0.113 
desmethylcitalopram 204 2224 0.949 0.990 0.151 
ratio (desmethylcitalopram: escitalopram) 203 2212 0.544 1.083 0.143 
total (escitalopram + desmethylcitalopram) 203 2212 0.940 0.989 0.141 
Nausea/vomiting n obs p OR SE 
CYP2C19 genotype 336 3276 0.637 1.041 0.089 
escitalopram 272 2932 0.452 1.100 0.140 
desmethylcitalopram 202 2196 0.174 0.856 0.098 
ratio (desmethylcitalopram: escitalopram) 201 2184 0.104 0.806 0.107 
total (escitalopram + desmethylcitalopram) 201 2184 0.445 1.104 0.143 
Problems with urination n obs p OR SE 
CYP2C19 genotype 339 3304 0.977 1.004 0.130 
escitalopram 274 2949 0.697 1.078 0.208 
desmethylcitalopram 204 2214 0.313 1.221 0.242 
ratio (desmethylcitalopram: escitalopram) 203 2202 0.979 0.994 0.225 
total (escitalopram + desmethylcitalopram) 203 2202 0.631 1.115 0.253 
Problems with sexual function n obs p OR SE 
CYP2C19 genotype 337 3220 0.664 1.035 0.082 
escitalopram 271 2866 0.200 1.176 0.149 
desmethylcitalopram 202 2175 0.468 1.094 0.135 
ratio (desmethylcitalopram: escitalopram) 201 2163 0.264 0.859 0.117 
total (escitalopram + desmethylcitalopram) 201 2163 0.240 1.167 0.153 
Palpitations n obs p OR SE 
CYP2C19 genotype 339 3307 0.155 1.116 0.086 
escitalopram 274 2953 0.281 1.118 0.116 
desmethylcitalopram 204 2217 0.008 1.311 0.133 
ratio (desmethylcitalopram: escitalopram) 203 2205 0.278 1.129 0.126 
total (escitalopram + desmethylcitalopram) 203 2205 0.298 1.137 0.140 
Feeling light-headed on standing n obs p OR SE 
CYP2C19 genotype 338 3298 0.120 1.193 0.135 
escitalopram 274 2957 0.978 1.004 0.145 
desmethylcitalopram 204 2221 0.026 1.276 0.140 
ratio (desmethylcitalopram: escitalopram) 203 2209 0.138 1.243 0.182 
total (escitalopram + desmethylcitalopram) 203 2209 0.457 1.122 0.173 
Feeling like the room is spinning n obs p OR SE 
CYP2C19 genotype 338 3297 0.987 1.002 0.096 
escitalopram 272 2933 0.160 1.263 0.210 
desmethylcitalopram 202 2197 3.28E-05 1.564 0.168 
ratio (desmethylcitalopram: escitalopram) 201 2185 0.306 1.225 0.243 
total (escitalopram + desmethylcitalopram) 201 2185 0.020 1.523 0.275 
Sweating n obs p OR SE 
CYP2C19 genotype 339 3311 0.553 1.047 0.082 
escitalopram 274 2957 0.474 1.069 0.100 
desmethylcitalopram 204 2221 0.658 1.056 0.131 
ratio (desmethylcitalopram: escitalopram) 203 2209 0.360 0.901 0.102 
total (escitalopram + desmethylcitalopram) 203 2209 0.994 1.001 0.112 
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Increased body temperature n obs p OR SE 
CYP2C19 genotype 339 3308 0.808 1.032 0.134 
escitalopram 273 2942 0.905 0.983 0.143 
desmethylcitalopram 203 2206 0.106 0.723 0.146 
ratio (desmethylcitalopram: escitalopram) 202 2194 0.136 0.744 0.147 
total (escitalopram + desmethylcitalopram) 202 2194 0.131 0.805 0.116 
Tremor n obs p OR SE 
CYP2C19 genotype 338 3296 0.812 1.024 0.100 
escitalopram 273 2942 0.370 1.138 0.164 
desmethylcitalopram 204 2219 0.146 1.215 0.163 
ratio (desmethylcitalopram: escitalopram) 203 2207 0.971 1.005 0.143 
total (escitalopram + desmethylcitalopram) 203 2207 0.180 1.234 0.194 
Disorientation n obs p OR SE 
CYP2C19 genotype 337 3286 0.893 0.984 0.115 
escitalopram 271 2919 0.540 1.088 0.150 
desmethylcitalopram 202 2195 0.253 0.857 0.116 
ratio (desmethylcitalopram: escitalopram) 201 2183 0.475 1.199 0.305 
total (escitalopram + desmethylcitalopram) 201 2183 0.919 0.981 0.185 
Yawning n obs p OR SE 
CYP2C19 genotype 338 3300 0.366 1.088 0.101 
escitalopram 272 2935 0.154 1.163 0.123 
desmethylcitalopram 202 2199 0.205 0.824 0.126 
ratio (desmethylcitalopram: escitalopram) 201 2187 0.112 0.804 0.111 
total (escitalopram + desmethylcitalopram) 201 2187 0.977 0.997 0.112 
Weight gain n obs p OR SE 
CYP2C19 genotype 338 3295 0.407 0.923 0.090 
escitalopram 273 2941 0.296 0.888 0.101 
desmethylcitalopram 203 2206 0.364 0.878 0.126 
ratio (desmethylcitalopram: escitalopram) 202 2194 0.571 0.921 0.134 





Appendix F. Supplementary results for Chapter 6.  
Table 10-5: IPA definitions of functional categories referenced in Chapter 6 
IPA functional category Definition 
Haematological Disease Describes haematological diseases.  Some examples include anaemia, leukaemia, haemolysis and thrombosis. 
Organismal Injury and 
Abnormalities 
Describes functions associated with injuries and 
abnormalities of multicellular organisms, primarily humans, 
mice and rats.  This includes abnormal functions such as 
bleeding, oedema, and haemorrhage of any tissue or organ, 
as well as functions associated with abnormal tissues such 
as lesions, ulcers, scars and wounds. 
Developmental Disorder 
Describes developmental disorders or abnormalities.  Some 
examples include agenesis of organ, hypertrophy of tissue 
and scoliosis. 
Infectious Disease 
Describes diseases that result from infection of a 
multicellular organism, primarily humans, mice and rats, by a 
pathogenic bacteria, fungus, virus or prion.  Some examples 
include HIV infection, malaria and scrapie. 
Organismal Development 
Describes functions associated with the normal 
development of multicellular organisms, primarily humans, 
mice and rats.  This includes those functions directly 
involved with organismal development, such as the growth 
and development of organisms, organismal response to 
stimuli and birth of organisms as well as functions indirectly 
involved in development such as learning and flow of blood. 
Connective Tissue Disorders 
Describes diseases of the connective tissue.  Some 
examples include arthritis, rheumatic disease, and 
developmental disorders of bone. 
Cellular Assembly and 
Organisation 
Describes functions associated with subcellular components 
that are involved in cellular organisation and assembly of 
cellular substructures.  Examples of functions in this 
category include alignment of actin filaments and 
aggregation of liposomes. 
Nervous System Development 
and Function 
Describes functions associated with the normal 
development and function of the cells, tissues and organs 
that make up the nervous system as well as functions 
specific to the nervous system.  Examples include activation 
of astrocytes and cognition. 
Cell Signalling 
Describes functions that are involved in intracellular 
signalling pathways.  Specifically it describes functions 
associated with signalling molecules such as cyclic AMP, 
nitric oxide, and calcium, signalling functions such as 
tyrosine phosphorylation and guanine nucleotide exchange, 
as well as receptor-mediated signalling interactions. 
Cancer 
Describes functions associated with cancer.  This includes 
any process associated with a tumor, cancer cell or 
cancerous tissue, as well as any object associated with a 
cancer process such as transformation and 
metastasis.  This category also includes all cancerous 
diseases such as lymphoma and neuroblastoma. 
Organ Development 
Describes functions associated with the normal 
development, differentiation, and formation of 
organs.  Some examples of these functions include 






Table 10-6: Gene probes showing suggestive associations with treatment response in whole sample 
analysis  (p<0.001) 
Gene Probe ID Corr P Value Q Value Cytoband 
HS.242159 ILMN_1822368 0.387 1.159E-05 0.179  
OR52B4 ILMN_1776846 -0.382 1.496E-05 0.179 11p15.4d 
PMS2CL ILMN_2262198 -0.375 2.303E-05 0.179 7p22.1a 
CHAF1B ILMN_1674231 -0.374 2.409E-05 0.179 21q22.12b-q22.13a 
KCNH2 ILMN_1739987 0.359 5.210E-05 0.310 7q36.1c 
TTC18 ILMN_1784516 -0.354 6.778E-05 0.336 10q22.2a 
IQCG ILMN_1802377 -0.343 1.171E-04 0.455 3q29i 
NTRK2 ILMN_2357855 0.331 2.098E-04 0.455 9q21.33a 
TRIM69 ILMN_1813430 -0.327 2.493E-04 0.455 15q21.1a 
LOC728002 ILMN_3296519 -0.327 2.570E-04 0.455 12p13.31b 
MARCH8 ILMN_2341626 0.326 2.596E-04 0.455 10q11.21d 
LOC100130451 ILMN_3176545 0.326 2.687E-04 0.455 2q34e 
LOC100130624 ILMN_3272476 -0.324 2.852E-04 0.455 22q12.1b 
APC ILMN_1662668 -0.322 3.191E-04 0.455 5q22.2a 
ZFP36L1 ILMN_1675448 0.321 3.298E-04 0.455 14q24.1c 
CHRFAM7A ILMN_1791501 -0.321 3.337E-04 0.455 15q13.2a 
TMCC2 ILMN_1659024 0.321 3.383E-04 0.455 1q32.1g 
ICAM4 ILMN_1681296 0.319 3.585E-04 0.455 19p13.2c 
MRPS9 ILMN_1813207 -0.317 3.930E-04 0.455 2q12.1d 
LOC650909 ILMN_1657348 -0.316 4.124E-04 0.455  
MIR580 ILMN_3309734 0.313 4.806E-04 0.455 5p13.2c 
FAM149A ILMN_1786278 -0.312 5.045E-04 0.455 4q35.2a 
HS.582536 ILMN_1887823 0.310 5.291E-04 0.455  
C3ORF34 ILMN_2288483 0.309 5.571E-04 0.455 3q29g 
LOC85390 ILMN_1689294 -0.307 6.057E-04 0.455 11q24.1b 
CTLA4 ILMN_2348905 -0.307 6.061E-04 0.455 2q33.2a 
STK11 ILMN_1751871 0.307 6.176E-04 0.455 19p13.3i 
MKRN1 ILMN_1671583 0.306 6.283E-04 0.455 7q34c 
RTN4 ILMN_1693598 0.306 6.314E-04 0.455 2p16.1d 
LOC644391 ILMN_1815495 -0.306 6.320E-04 0.455  
CD8B ILMN_1748601 -0.304 6.895E-04 0.455 2p11.2e 
LOC100133435 ILMN_3238148 -0.304 6.972E-04 0.455  
DUSP15 ILMN_1689000 0.304 6.990E-04 0.455 20q11.21b 
LOC100132011 ILMN_3248157 0.304 7.034E-04 0.455 17q25.1c 
MOXD1 ILMN_1687501 -0.304 7.043E-04 0.455 6q23.2b 
OPALIN ILMN_1666090 0.304 7.086E-04 0.455 10q24.1a 
PPP2R2B ILMN_2298365 0.304 7.141E-04 0.455 5q32d-q32e 
DRD5 ILMN_1689043 0.303 7.196E-04 0.455 4p16.1b 
RBM38 ILMN_1704079 0.303 7.354E-04 0.455 20q13.31a 
KLHL28 ILMN_3251605 0.303 7.396E-04 0.455 14q21.3a-q21.3b 
ROGDI ILMN_1722738 0.302 7.678E-04 0.455 16p13.3b 
POFUT1 ILMN_2276758 0.302 7.764E-04 0.455 20q11.21b 
CHODL ILMN_1726575 -0.301 7.920E-04 0.455 21q21.1d 
CDCA7 ILMN_1737184 -0.300 8.194E-04 0.455 2q31.1e 
HS.133410 ILMN_1819304 -0.300 8.279E-04 0.455  
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LIG3 ILMN_2373335 0.300 8.309E-04 0.455 17q12a 
LOC100132346 ILMN_3238735 -0.299 8.472E-04 0.455 16q22.3c 
ZNF208 ILMN_1662777 0.299 8.567E-04 0.455 19p12c 
PTPRM ILMN_1744937 -0.299 8.595E-04 0.455 18p11.23b-p11.23a 
MEF2A ILMN_3249825 -0.299 8.759E-04 0.455 15q26.3b 
RPL6 ILMN_1717490 -0.299 8.782E-04 0.455 12q24.13a 
FCAR ILMN_2279367 0.299 8.794E-04 0.455 19q13.42b 
PSMG3 ILMN_1802627 -0.299 8.814E-04 0.455 7p22.3b-p22.3a 
FKBP7 ILMN_1717737 -0.297 9.291E-04 0.455 2q31.2b 
HS.519298 ILMN_1861556 0.297 9.314E-04 0.455  
FEN1 ILMN_2160929 -0.297 9.422E-04 0.455 11q12.2b 
C9ORF37 ILMN_1799320 -0.297 9.430E-04 0.455 9q34.3f 





Table 10-7: Gene probes showing suggestive associations with treatment response in escitalopram-
specific analysis  (p<0.001) 
Gene Probe ID Corr P Value Q Value Cytoband 
IQCG ILMN_1802377 -0.455 1.721E-05 0.512 3q29i 
LOC728905 ILMN_3237395 -0.424 7.193E-05 0.934 1q21.1d 
HS.582536 ILMN_1887823 0.414 1.111E-04 0.934  
VWA1 ILMN_1660554 0.403 1.708E-04 0.934 1p36.33a 
DRD5 ILMN_1689043 0.398 2.102E-04 0.934 4p16.1b 
GNB3 ILMN_2115336 -0.395 2.433E-04 0.934 12p13.31d 
PMS2CL ILMN_2262198 -0.391 2.769E-04 0.934 7p22.1a 
SDC1 ILMN_1768953 0.389 3.060E-04 0.934 2p24.1d 
ULK4 ILMN_3236866 -0.385 3.559E-04 0.934 3p22.1b 
LOC100133435 ILMN_3238148 -0.384 3.626E-04 0.934  
BAG5 ILMN_1728514 -0.384 3.661E-04 0.934 14q32.33a 
PSMG3 ILMN_1802627 -0.383 3.765E-04 0.934 7p22.3b-p22.3a 
RBMS3 ILMN_1665040 -0.377 4.874E-04 0.999 3p24.1b-p24.1a 
LOC100130348 ILMN_3259120 -0.374 5.450E-04 0.999 11q13.1c 
LOC100131655 ILMN_3217577 -0.372 5.786E-04 0.999  
OPALIN ILMN_1666090 0.365 7.571E-04 0.999 10q24.1a 
SELS ILMN_1803744 -0.363 8.023E-04 0.999 15q26.3d 
MOXD1 ILMN_1687501 -0.363 8.126E-04 0.999 6q23.2b 
RPS6KA2 ILMN_1790801 -0.359 9.346E-04 0.999 6q27c 





Table 10-8: Gene probes showing suggestive associations with treatment response in nortriptyline-specific 
analysis  (p<0.001) 
Gene Probe ID Corr P Value Q Value Cytoband 
MMP28 ILMN_1752952 -0.683 1.662E-06 0.031 17q12b 
KXD1 ILMN_1790951 0.678 2.103E-06 0.031 19p13.11c 
SAMD6 ILMN_1691716 0.655 6.065E-06 0.060 9q22.33c 
POFUT2 ILMN_2376667 0.606 4.402E-05 0.328 21q22.3e 
FLJ41200 ILMN_1694458 0.590 7.662E-05 0.381 9p23a 
OR8J3 ILMN_1795000 -0.587 8.596E-05 0.381 11q11c 
LOC100133172 ILMN_3286235 0.583 9.676E-05 0.381 8p23.1a 
SPTBN2 ILMN_1667079 0.576 1.243E-04 0.381 11q13.1e 
LOC644634 ILMN_1776524 0.574 1.311E-04 0.381 1q21.1e 
CDIPT ILMN_1770425 0.571 1.451E-04 0.381 16p11.2d 
NVL ILMN_1712636 -0.570 1.522E-04 0.381 1q42.11b 
HS.389313 ILMN_1846771 0.570 1.536E-04 0.381  
DDX19-DDX19L ILMN_1728069 0.564 1.870E-04 0.428 16q22.1f 
CHST2 ILMN_1794011 0.561 2.025E-04 0.431 3q23d 
LOC100131735 ILMN_3208233 -0.558 2.226E-04 0.437  
LOC727825 ILMN_1681325 0.549 2.994E-04 0.437  
CTDSP1 ILMN_1728163 0.546 3.222E-04 0.437 2q35e 
KLF2 ILMN_1735930 0.544 3.440E-04 0.437 19p13.11f 
PLIN2 ILMN_2138765 -0.543 3.542E-04 0.437 9p22.1b 
HS.569921 ILMN_1839217 0.543 3.587E-04 0.437  
GMPS ILMN_3242205 -0.540 3.911E-04 0.437 3q25.31a 
HS.242159 ILMN_1822368 0.539 3.944E-04 0.437  
HS.147346 ILMN_1864989 0.539 4.034E-04 0.437  
LOC100130413 ILMN_3265391 0.538 4.057E-04 0.437  
CHAF1B ILMN_1674231 -0.538 4.117E-04 0.437 21q22.12b-q22.13a 
HS.543219 ILMN_1862873 0.537 4.249E-04 0.437  
AKR1A1 ILMN_1774938 0.537 4.253E-04 0.437 1p34.1b 
HSFYP1 ILMN_3239912 0.536 4.386E-04 0.437 22q11.1d 
LOC390466 ILMN_1665781 -0.533 4.750E-04 0.437  
CLDN6 ILMN_1804531 0.533 4.777E-04 0.437 16p13.3d 
CAPN2 ILMN_1716057 -0.533 4.830E-04 0.437 1q41e 
UBAC1 ILMN_1807044 0.531 4.984E-04 0.437 9q34.3c 
C1ORF120 ILMN_1755835 0.531 5.080E-04 0.437 1q25.3c 
MIMT1 ILMN_3237745 -0.528 5.494E-04 0.437  
SNORD50B ILMN_3247444 -0.525 6.068E-04 0.437 6q14.3c 
LOC100128859 ILMN_3258657 -0.524 6.143E-04 0.437 6q13c 
PM20D1 ILMN_2293067 0.524 6.256E-04 0.437 1q32.1g 
SUV39H2 ILMN_1789351 0.523 6.297E-04 0.437 10p13c 
ZNF238 ILMN_1663155 0.522 6.572E-04 0.437 1q44a 
LOC100131744 ILMN_3293244 0.522 6.588E-04 0.437 17q12a 
KIAA1245 ILMN_1676829 0.520 6.927E-04 0.437  
C4ORF23 ILMN_1704637 -0.520 6.989E-04 0.437 4p16.1c 
ETV3 ILMN_1703180 0.519 7.015E-04 0.437 1q23.1b 
IGHMBP2 ILMN_1801909 0.518 7.227E-04 0.437 11q13.2b 
C2ORF55 ILMN_3243366 0.516 7.775E-04 0.437 2q11.2c 
MTRF1L ILMN_1786684 0.516 7.830E-04 0.437 6q25.2a 
CRYBA4 ILMN_1686362 -0.515 7.969E-04 0.437 22q12.1a 
PPM1G ILMN_1806867 -0.515 7.977E-04 0.437 2p23.3a 
LOC646786 ILMN_1654915 0.514 8.144E-04 0.437  
C3ORF60 ILMN_1691557 0.514 8.222E-04 0.437 3p21.31d 
LOC643993 ILMN_1660393 0.513 8.314E-04 0.437  
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CCNY ILMN_1708991 0.513 8.343E-04 0.437 10p11.21c 
LOC642350 ILMN_1762995 0.513 8.427E-04 0.437 9p24.3b 
UBE2I ILMN_1662934 0.513 8.484E-04 0.437 16p13.3e 
CHRNA10 ILMN_1776314 0.513 8.492E-04 0.437 11p15.4d 
ECHDC1 ILMN_1762134 -0.512 8.667E-04 0.437 6q22.33a 
HS.349049 ILMN_1849285 -0.511 8.828E-04 0.437  
RTN2 ILMN_1749115 0.511 8.858E-04 0.437 19q13.32a 





Table 10-9: Table showing top 5 IPA networks identified in each individual variant analysis 
Network Score Network eligible 
molecules 
Top diseases and functions 
Whole sample analysis, individual variants 
1 46 28 Hematological Disease, Organismal Injury 
and Abnormalities, Developmental 
Disorder 
2 38 24 Cellular Compromise, Cell Death and 
Survival, Cellular Development 
3 37 25 Cell Cycle, Cellular Assembly and 
Organization, Cancer 
4 36 23 Skeletal and Muscular Disorders, Cell 
Signaling, Post-Translational Modification 
5 33 22 Cell Death and Survival, Cell Cycle, DNA 
Replication, Recombination, and Repair 
Escitalopram-specific analysis, individual variants 
1 37 19 Infectious Disease, Organismal 
Development, Connective Tissue Disorders 
2 35 21 Cellular Assembly and Organization, 
Cellular Function and Maintenance, Cell 
Cycle 
3 30 17 Carbohydrate Metabolism, Lipid 
Metabolism, Small Molecule Biochemistry 
4 26 16 Metabolic Disease, Organismal Injury and 
Abnormalities, Renal and Urological 
Disease 
5 26 15 Connective Tissue Disorders, 
Developmental Disorder, Hereditary 
Disorder 
Nortriptyline-specific analysis, individual variants 
1 36 15 Cellular Assembly and Organization, 
Nervous System Development and 
Function, Cell Signaling 
2 22 10 Digestive System Development and 
Function, Organ Morphology, Organismal 
Development 
3 21 10 Lipid Metabolism, Small Molecule 






Table 10-10: Table showing top 5 IPA networks identified using hub genes in the WGCNA analysis 
Network Score Network eligible 
molecules 
Top diseases and functions 
Whole sample analysis, WGCNA 
1 59 23 Cancer, Organ Development, Organismal 
Injury and Abnormalities 
2 33 14 Nervous System Development and 
Function, Cardiovascular Disease, 
Organismal Injury and Abnormalities 
3 9 5 Cell Signaling, Metabolic Disease, 
Neurological Disease 
4 3 1 Cellular Function and Maintenance, Cell-
To-Cell Signaling and Interaction, 
Hematological System Development and 
Function 
5 2 1 Cellular Development, Cellular Growth and 
Proliferation, Developmental Disorder 
Escitalopram-specific analysis, WGCNA 
1 37 14 Cancer, Organ Development, Organismal 
Injury and Abnormalities 
2 16 7 Antimicrobial Response, Inflammatory 
Response, Infectious Disease 
Nortriptyline-specific analysis, WGCNA 
1 48 20 Cancer, Organ Development, Organismal 
Injury and Abnormalities 
2 44 17 Post-Translational Modification, Hereditary 
Disorder, Neurological Disease 
3 37 19 Lipid Metabolism, Molecular Transport, 
Small Molecule Biochemistry 
4 32 17 Protein Synthesis, Cardiovascular System 
Development and Function, Connective 
Tissue Development and Function 





Appendix G. Supplementary results for Chapter 7. 
 




Figure 10-4: Plot showing pattern of LD (as measured using R2) between SNPs implicated in the GSTM3 eQTL locus (drawn using Haploview, Barrett et al, 2005) 
